,SYMBOL,COMPANY NAME,SUBJECT,DETAILS,BROADCAST DATE/TIME,RECEIPT,DISSEMINATION,DIFFERENCE,ATTACHMENT,Date,Open,High,Low,Close,Adj Close,Volume,Dividends,Stock Splits,Next_Date,Sentiment
0,CIPLA,Cipla Limited,updates," regarding 'update on acquisition of actor pharma (pty) ltd., south africa'.",07-Feb-2024 23:13:11,2024-02-07 23:13:11,07-Feb-2024 23:13:17,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_07022024231311_Cipla_CMSA_Actor_closing_SE_07022024.pdf,07-02-2024,1436.0,1444.5,1420.8499755859375,1438.75,1438.75,890299,0.0,0.0,14-02-2024,0
1,CIPLA,Cipla Limited,updates, regarding 'update on acquisition of additional stake in goapptiv private limited'.,02-Feb-2024 21:16:48,2024-02-02 21:16:48,02-Feb-2024 21:16:55,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_02022024211648_CiplaGoApptivclosingSEIntimation02022024singed.pdf,02-02-2024,1387.0,1404.699951171875,1385.0,1392.6500244140625,1392.6500244140625,1161705,0.0,0.0,09-02-2024,0
2,CIPLA,Cipla Limited,updates," regarding 'intimation under regulation 30 of sebi (listing obligations and disclosure requirements) regulations, 2015'.",31-Jan-2024 23:54:06,2024-01-31 23:54:06,31-Jan-2024 23:54:11,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_31012024235406_SEIntimationGSTPenalty31012024.pdf,31-01-2024,1317.0999755859375,1352.9000244140625,1312.0,1351.0,1351.0,1723379,0.0,0.0,07-02-2024,1
3,CIPLA,Cipla Limited,change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent, about change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent,25-Jan-2024 17:29:42,2024-01-25 17:29:42,25-Jan-2024 17:29:49,00:00:07,https://nsearchives.nseindia.com/corporate/xbrl/CIPLA_25012024172942_CIM_17255_1036253_25012024052941_WEB.xml,25-01-2024,1413.3499755859375,1413.449951171875,1353.5,1369.6500244140625,1369.6500244140625,1801468,0.0,0.0,02-02-2024,0
4,CIPLA,Cipla Limited,appointment," regarding appointment of mr balram bhargava as non- executive independent director of the company w.e.f. april 01, 2024.",25-Jan-2024 14:46:13,2024-01-25 14:46:13,25-Jan-2024 14:46:19,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_25012024144613_AppointmentrelatedmattersSEIntimationsigned.pdf,25-01-2024,1413.3499755859375,1413.449951171875,1353.5,1369.6500244140625,1369.6500244140625,1801468,0.0,0.0,02-02-2024,0
5,CIPLA,Cipla Limited,acquisition," about intimation under regulation 30 read with schedule iii of sebi (listing obligations and disclosure requirements) regulations, 2015.",23-Jan-2024 14:43:50,2024-01-23 14:43:50,23-Jan-2024 14:43:55,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_23012024144350_StockExchangeIntimation_Mexico19012024.pdf,23-01-2024,1385.0,1425.0,1368.699951171875,1409.0,1409.0,7556815,0.0,0.0,31-01-2024,0
6,CIPLA,Cipla Limited,press release," regarding a press release dated january 08, 2024, titled ""cipla announces joint venture in the united states with kemwell biopharma and manipal education & medical group for global development and commercialisation of innovative cell therapy products "".",08-Jan-2024 17:39:49,2024-01-08 17:39:49,08-Jan-2024 17:39:55,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_08012024173949_Pressrelease.pdf,08-01-2024,1296.6500244140625,1297.0,1266.199951171875,1271.75,1271.75,740848,0.0,0.0,15-01-2024,0
7,CIPLA,Cipla Limited,board meeting intimation, about board meeting to be held on 25-jan-2024 to consider and approve the quarterly unaudited financial results of the company for the period ended december 2023 and other business.,03-Jan-2024 19:05:17,2024-01-03 19:05:17,03-Jan-2024 19:05:23,00:00:06,https://nsearchives.nseindia.com/corporate/xbrl/CIPLA_03012024190517_PRIOR_INTIMATION_15761_1007428_03012024070516_WEB.xml,03-01-2024,1291.0,1307.0,1274.050048828125,1300.1500244140625,1300.1500244140625,2357093,0.0,0.0,10-01-2024,0
8,CIPLA,Cipla Limited,updates," regarding 'intimation under regulation 30 of sebi (listing obligations and disclosure requirements) regulations, 2015'.",02-Jan-2024 19:35:10,2024-01-02 19:35:10,02-Jan-2024 19:35:16,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_02012024193510_SEIntimationGSTPenalty31122023.pdf,02-01-2024,1255.0999755859375,1285.0,1252.0999755859375,1281.550048828125,1281.550048828125,2589484,0.0,0.0,09-01-2024,0
9,CIPLA,Cipla Limited,updates," regarding 'intimation under regulation 30 of sebi (listing obligations and disclosure requirements) regulations, 2015.'",29-Dec-2023 13:00:54,2023-12-29 13:00:54,29-Dec-2023 13:00:59,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_29122023130054_SEIntimationGSTPenalty28122023.pdf,29-12-2023,1264.0,1267.5999755859375,1242.050048828125,1246.300048828125,1246.300048828125,1794218,0.0,0.0,05-01-2024,0
10,CIPLA,Cipla Limited,updates," regarding ''.intimation under reg 30 of  sebi (listing obligations and disclosure requirements) regulations, 2015",22-Dec-2023 18:34:48,2023-12-22 18:34:48,22-Dec-2023 18:34:54,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_22122023183448_SEIntimationGSTPenalty22122023.pdf,22-12-2023,1230.050048828125,1242.5,1221.6500244140625,1235.5999755859375,1235.5999755859375,1969524,0.0,0.0,01-01-2024,0
11,CIPLA,Cipla Limited,press release (revised)," regarding a revised press release dated december 15, 2023, titled ""revised press release - this is further to the press release submitted by the company on 10th december 2023. it was brought to our attention by us fda that there was information in our risk assessment that was not pertinent to this product. as a result we are reissuing a revised press release on the said matter.",15-Dec-2023 23:45:49,2023-12-15 23:45:49,15-Dec-2023 23:45:55,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_15122023234549_RevisedPressrelease_Productrecall.pdf,15-12-2023,1215.0,1217.5999755859375,1202.8499755859375,1207.0999755859375,1207.0999755859375,1976112,0.0,0.0,22-12-2023,0
12,CIPLA,Cipla Limited,press release," regarding a press release dated december 14, 2023, titled ""acquisition of additional stake in goapptiv private limited"".",14-Dec-2023 22:27:31,2023-12-14 22:27:31,14-Dec-2023 22:27:35,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_14122023222731_PressReleaseAcquisitionGoApptiv.pdf,14-12-2023,1219.050048828125,1222.550048828125,1201.0999755859375,1204.6500244140625,1204.6500244140625,1809248,0.0,0.0,21-12-2023,0
13,CIPLA,Cipla Limited,updates," regarding 'cessation of facility demand guarantee issued in favor of first rand bank, south africa'.",13-Dec-2023 19:27:08,2023-12-13 19:27:08,13-Dec-2023 19:27:15,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_13122023192708_SEIntimationGuaranteecessation.pdf,13-12-2023,1198.6500244140625,1217.949951171875,1195.199951171875,1216.5,1216.5,1809563,0.0,0.0,20-12-2023,0
14,CIPLA,Cipla Limited,updates," regarding 'intimation under regulation 30 of sebi (listing obligations and disclosure requirements) regulations, 2015 '.",07-Dec-2023 15:59:40,2023-12-07 15:59:40,07-Dec-2023 15:59:45,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_07122023155941_SEIntimationGSTPenalty.pdf,07-12-2023,1206.0,1225.0,1197.0,1222.800048828125,1222.800048828125,1269290,0.0,0.0,14-12-2023,0
15,CIPLA,Cipla Limited,news verification,the exchange has sought clarification from cipla limited with respect to recent news item captioned cipla shares top nifty 50 losers after biggest fall in nine months; cnbc-tv18 accesses pithampur warning letter.  the response from the company is attached.,23-Nov-2023 18:07:49,2023-11-23 18:07:49,23-Nov-2023 18:07:57,00:00:08,https://nsearchives.nseindia.com/corporate/CIPLA_23112023180749_ClarificationUSFDAWL.pdf,23-11-2023,1270.0,1270.0,1164.550048828125,1170.6500244140625,1170.6500244140625,7643376,0.0,0.0,01-12-2023,0
16,CIPLA,Cipla Limited,updates," regarding 'disclosure pursuant to regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015 '.",17-Nov-2023 19:00:13,2023-11-17 19:00:13,17-Nov-2023 19:00:19,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_17112023190013_CMSAGuaranteeSEintimationsigned.pdf,17-11-2023,1236.0,1256.0999755859375,1235.5,1249.4000244140625,1249.4000244140625,992848,0.0,0.0,24-11-2023,0
17,CIPLA,Cipla Limited,updates, regarding 'update on sale of stake held in cipla quality chemical industries limited (cqcil)'.,15-Nov-2023 13:21:10,2023-11-15 13:21:10,15-Nov-2023 13:21:20,00:00:10,https://nsearchives.nseindia.com/corporate/CIPLA_15112023132110_CQCILclosing.pdf,15-11-2023,1260.0,1260.0,1237.699951171875,1241.75,1241.75,1323010,0.0,0.0,22-11-2023,0
18,CIPLA,Cipla Limited,updates," regarding 'intimation pursuant to regulation 30 of sebi (lodr) regulations, 2015 regarding slump sale of business undertaking'.",06-Nov-2023 16:54:40,2023-11-06 16:54:40,06-Nov-2023 16:54:50,00:00:10,https://nsearchives.nseindia.com/corporate/CIPLA_06112023165440_GXbusinesstransferSEIntimation06112023signed.pdf,06-11-2023,1211.949951171875,1217.0,1197.25,1204.0999755859375,1204.0999755859375,1262938,0.0,0.0,13-11-2023,0
19,CIPLA,Cipla Limited,press release," regarding a press release dated october 27, 2023, titled ""q2 fy24 results"".",27-Oct-2023 14:26:56,2023-10-27 14:26:56,27-Oct-2023 14:27:02,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_27102023142656_PressReleaseQ2FY24Signed.pdf,27-10-2023,1152.0,1197.9000244140625,1149.25,1174.25,1174.25,1775011,0.0,0.0,03-11-2023,0
20,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended september 30, 2023.",27-Oct-2023 13:46:47,2023-10-27 13:46:47,27-Oct-2023 13:46:51,00:00:04,https://nsearchives.nseindia.com/corporate/FINANCIALRESULTWITHOUTCOMESIGNED_27102023134647.pdf,27-10-2023,1152.0,1197.9000244140625,1149.25,1174.25,1174.25,1775011,0.0,0.0,03-11-2023,0
21,CIPLA,Cipla Limited,updates," regarding 'usfda inspection at invagen manufacturing facility in hauppauge, long island, new york, usa'.",26-Oct-2023 14:22:12,2023-10-26 14:22:12,26-Oct-2023 14:22:29,00:00:17,https://nsearchives.nseindia.com/corporate/CIPLA_26102023142212_Intimation.pdf,26-10-2023,1154.800048828125,1155.0,1132.0,1150.8499755859375,1150.8499755859375,2016469,0.0,0.0,02-11-2023,1
22,CIPLA,Cipla Limited,updates," regarding 'update on usfda inspection at invagen manufacturing facility in central islip, long island, ny, usa'.",11-Oct-2023 17:43:03,2023-10-11 17:43:03,11-Oct-2023 17:43:09,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_11102023174303_Disclosure.pdf,11-10-2023,1151.0,1175.0,1146.5,1171.949951171875,1171.949951171875,1465239,0.0,0.0,18-10-2023,0
23,CIPLA,Cipla Limited,board meeting intimation, about board meeting to be held on 27-oct-2023 to consider and approve the quarterly unaudited financial results of the company for the period ended september 2023 and other business.,04-Oct-2023 19:28:23,2023-10-04 19:28:23,04-Oct-2023 19:28:31,00:00:08,https://nsearchives.nseindia.com/corporate/xbrl/CIPLA_04102023192823_PRIOR_INTIMATION_11202_940319_04102023072822_WEB.xml,04-10-2023,1178.0999755859375,1185.0,1161.300048828125,1167.050048828125,1167.050048828125,999123,0.0,0.0,11-10-2023,0
24,CIPLA,Cipla Limited,updates," regarding 'update on sale of stake held in saba investment limited, uae'.",29-Sep-2023 22:15:10,2023-09-29 22:15:10,29-Sep-2023 22:15:13,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_29092023221510_SabaUpdateSEIntimation.pdf,29-09-2023,1169.9000244140625,1199.199951171875,1165.0,1186.1500244140625,1186.1500244140625,1878381,0.0,0.0,09-10-2023,0
25,CIPLA,Cipla Limited,updates," regarding 'usfda inspection at invagen manufacturing facility in central islip, long island, ny, usa'.",20-Sep-2023 19:41:55,2023-09-20 19:41:55,20-Sep-2023 19:42:00,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_20092023194155_SEIntimationInvaGenSigned20092023.pdf,20-09-2023,1243.25,1252.5999755859375,1236.0,1239.699951171875,1239.699951171875,1701959,0.0,0.0,27-09-2023,0
26,CIPLA,Cipla Limited,press release," regarding a press release dated september 04, 2023, titled ""cipla medpro south africa (pty) ltd., a wholly owned subsidiary of the companyin south africa to acquire actor pharma (pty) ltd., south africa"".",04-Sep-2023 19:52:59,2023-09-04 19:52:59,04-Sep-2023 19:53:05,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_04092023195259_PressRelease.pdf,04-09-2023,1250.300048828125,1255.4000244140625,1232.550048828125,1238.8499755859375,1238.8499755859375,1126182,0.0,0.0,11-09-2023,0
27,CIPLA,Cipla Limited,updates," regarding 'disclosure under regulation 30 of the sebi (listing obligations and disclosure requirements)regulations, 2015'.",16-Aug-2023 20:07:02,2023-08-16 20:07:02,16-Aug-2023 20:07:18,00:00:16,https://nsearchives.nseindia.com/corporate/CIPLA_16082023200702_StockExchangeIntimationOrderPatalgangaSigned.pdf,16-08-2023,1231.550048828125,1246.0,1226.050048828125,1243.550048828125,1243.550048828125,1665083,0.0,0.0,23-08-2023,0
28,CIPLA,Cipla Limited,updates," regarding 'disclosure of material continuing events under regulation 30(4) of the sebi (listing obligations anddisclosure requirements) regulations, 2015'.",14-Aug-2023 23:37:09,2023-08-14 23:37:09,14-Aug-2023 23:37:20,00:00:11,https://nsearchives.nseindia.com/corporate/CIPLA_14082023233709_SEIntimationpendinglitigation14082023signed.pdf,14-08-2023,1250.199951171875,1252.0,1231.6500244140625,1235.5999755859375,1235.5999755859375,830936,0.0,0.0,22-08-2023,0
29,CIPLA,Cipla Limited,shareholders meeting,"cipla limited has submitted the exchange a copy srutinizers report of  annual general meeting held on august 10, 2023. further, the company has informed the exchange regarding voting results.",10-Aug-2023 22:23:30,2023-08-10 22:23:30,10-Aug-2023 22:23:42,00:00:12,https://nsearchives.nseindia.com/corporate/CIPLA_10082023222330_SEIntimationvotingresultssigned.pdf,10-08-2023,1266.0,1277.9000244140625,1248.0999755859375,1258.949951171875,1258.949951171875,2102129,0.0,0.0,18-08-2023,0
30,CIPLA,Cipla Limited,shareholders meeting," regarding proceedings of annual general meeting held on august 10, 2023",10-Aug-2023 20:23:51,2023-08-10 20:23:51,10-Aug-2023 20:24:07,00:00:16,https://nsearchives.nseindia.com/corporate/CIPLA_10082023202351_SEintimationAGMProceedings2023signed.pdf,10-08-2023,1266.0,1277.9000244140625,1248.0999755859375,1258.949951171875,1258.949951171875,2102129,0.0,0.0,18-08-2023,0
31,CIPLA,Cipla Limited,updates," regarding 'intimation under regulation 30(5) of the sebi (listing obligations and disclosure requirements) regulations, 2015 ( listing regulations )'.",27-Jul-2023 13:35:24,2023-07-27 13:35:24,27-Jul-2023 13:35:31,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_27072023133524_final.pdf,27-07-2023,1115.0,1219.4000244140625,1108.550048828125,1171.449951171875,1171.449951171875,14590950,0.0,0.0,03-08-2023,0
32,CIPLA,Cipla Limited,copy of newspaper publication,"pursuant to regulation 47 of the sebi (listing obligations and disclosure requirements) regulations 2015, we are enclosing herewith extracts of the consolidated unaudited financial results for the quarter ended 30th june 2023 to be published in newspaper.",26-Jul-2023 15:40:05,2023-07-26 15:40:05,26-Jul-2023 15:40:15,00:00:10,https://nsearchives.nseindia.com/corporate/CIPLA_26072023154005_NewspaperintimationJuly2023signed.pdf,26-07-2023,1060.0,1082.050048828125,1042.1500244140625,1068.5,1068.5,1854416,0.0,0.0,02-08-2023,1
33,CIPLA,Cipla Limited,change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent, about change in directors/ key managerial personnel/ auditor/ compliance officer/ share transfer agent,26-Jul-2023 15:37:40,2023-07-26 15:37:40,26-Jul-2023 15:37:59,00:00:19,https://nsearchives.nseindia.com/corporate/xbrl/CIPLA_26072023153740_CIM_7701_900447_26072023033740_WEB.xml,26-07-2023,1060.0,1082.050048828125,1042.1500244140625,1068.5,1068.5,1854416,0.0,0.0,02-08-2023,1
34,CIPLA,Cipla Limited,change in management, about change in senior management personnel due to change in reporting structure,26-Jul-2023 15:35:30,2023-07-26 15:35:30,26-Jul-2023 15:35:38,00:00:08,https://nsearchives.nseindia.com/corporate/CIPLA_26072023153530_ChangeinSMPSharadJain26July2023signed.pdf,26-07-2023,1060.0,1082.050048828125,1042.1500244140625,1068.5,1068.5,1854416,0.0,0.0,02-08-2023,1
35,CIPLA,Cipla Limited,outcome of board meeting,"in furtherance to our intimation dated 26th july 2023 under pursuant to regulation 30 and 33 of the sebi (listing obligations and disclosure requirements) regulations, 2015, we hereby notify that the meeting of the board of directors which commenced today at 12:30 p.m. (ist) has concluded at 3: 30 p.m. (ist).",26-Jul-2023 15:32:03,2023-07-26 15:32:03,26-Jul-2023 15:32:12,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_26072023153203_Boardmeetingoutcomeclosure26072023signed.pdf,26-07-2023,1060.0,1082.050048828125,1042.1500244140625,1068.5,1068.5,1854416,0.0,0.0,02-08-2023,1
36,CIPLA,Cipla Limited,press release,"pursuant to regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015, we are enclosing the press release dated 26th july 2023. "".",26-Jul-2023 15:20:54,2023-07-26 15:20:54,26-Jul-2023 15:21:04,00:00:10,https://nsearchives.nseindia.com/corporate/CIPLA_26072023152054_CiplaQ1FY24PressReleasev2signed.pdf,26-07-2023,1060.0,1082.050048828125,1042.1500244140625,1068.5,1068.5,1854416,0.0,0.0,02-08-2023,1
37,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended june 30, 2023.",26-Jul-2023 15:11:38,2023-07-26 15:11:38,26-Jul-2023 15:11:44,00:00:06,https://nsearchives.nseindia.com/corporate/FinancialresultsQ1FY24signed_26072023151138.pdf,26-07-2023,1060.0,1082.050048828125,1042.1500244140625,1068.5,1068.5,1854416,0.0,0.0,02-08-2023,1
38,CIPLA,Cipla Limited,shareholders meeting," regarding notice of annual general meeting to be held on august 10, 2023",18-Jul-2023 23:36:52,2023-07-18 23:36:52,18-Jul-2023 23:37:01,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_18072023233652_IRandAGMnoticeFY202223Signed.pdf,18-07-2023,1032.6500244140625,1035.199951171875,1019.5,1030.800048828125,1022.5072021484376,780402,0.0,0.0,25-07-2023,0
39,CIPLA,Cipla Limited,notice of shareholders meetings-xbrl, about notice of shareholders meeting for annual general meeting to be held on 10-aug-2023,18-Jul-2023 23:16:17,2023-07-18 23:16:17,18-Jul-2023 23:16:24,00:00:07,https://nsearchives.nseindia.com/corporate/xbrl/CIPLA_18072023231617_NOTICE_OF_SHAREHOLDERS_MEETINGS_891337_18072023111616_WEB.xml,18-07-2023,1032.6500244140625,1035.199951171875,1019.5,1030.800048828125,1022.5072021484376,780402,0.0,0.0,25-07-2023,0
40,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"dr. y. k. hamied and mr. m. k. hamied has submitted to the exchange a copy of disclosure under regulation 31(4) of the securities and exchange board of india (substantial acquisition of shares and takeovers) regulations, 2011.",12-Jul-2023 18:28:26,2023-07-12 18:28:26,12-Jul-2023 18:28:34,00:00:08,https://nsearchives.nseindia.com/corporate/CIPLA_12072023182826_Cipla.pdf,12-07-2023,1025.0,1032.9000244140625,1019.9500122070312,1022.2000122070312,1013.976318359375,1163653,0.0,0.0,19-07-2023,0
41,CIPLA,Cipla Limited,copy of newspaper publication," about copy of newspaper publication published in business standard (english) and sakal (marathi) on 11th july, 2023 intimating the shareholders about the annual general meeting, e-voting, manner of registering email address, mobile number & bank account mandate, record date and dividend.",11-Jul-2023 22:40:54,2023-07-11 22:40:54,11-Jul-2023 22:41:02,00:00:08,https://nsearchives.nseindia.com/corporate/CIPLA_11072023224054_SEIntimation_signed.pdf,11-07-2023,1018.9500122070312,1033.5,1018.0,1027.800048828125,1019.5313110351562,814514,0.0,0.0,18-07-2023,0
42,CIPLA,Cipla Limited,press release," regarding a press release dated july 07, 2023, titled ""press release &#8208; voluntary nationwide recall of six batches of albuterol sulfate inhalation aerosol, 90 mcg (200 metered inhalation) due to container defect by cipla usa inc., wholly owned step down subsidiary of the company in usa"".",07-Jul-2023 09:13:06,2023-07-07 09:13:06,07-Jul-2023 09:13:15,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_07072023091306_Pressrelease_Productrecall.pdf,07-07-2023,1009.4500122070312,1028.75,998.0499877929688,1020.6500244140624,1012.4388427734376,1914093,0.0,0.0,14-07-2023,0
43,CIPLA,Cipla Limited,board meeting intimation, about board meeting to be held on 26-jul-2023 to consider and approve the quarterly unaudited financial results of the company for the period ended june 2023 and other business.,04-Jul-2023 12:37:30,2023-07-04 12:37:30,04-Jul-2023 12:37:39,00:00:09,https://nsearchives.nseindia.com/corporate/xbrl/CIPLA_04072023123730_PRIOR_INTIMATION_6651_873356_04072023123729_WEB.xml,04-07-2023,1007.9500122070312,1016.0,996.5,1011.8499755859376,1003.7095947265624,1112255,0.0,0.0,11-07-2023,0
44,CIPLA,Cipla Limited,updates, regarding 'update on sale of stake held in cipla quality chemical industries limited ( cqcil )'.,31-May-2023 21:29:29,2023-05-31 21:29:29,31-May-2023 21:29:31,00:00:02,https://nsearchives.nseindia.com/corporate/CIPLA_31052023212929_SEIntimationCQCILstakesale.pdf,31-05-2023,960.2000122070312,965.0,942.2999877929688,953.0499877929688,945.3826293945312,3561991,0.0,0.0,07-06-2023,0
45,CIPLA,Cipla Limited,annual secretarial compliance report,"pursuant to regulation 24a of the securities and exchange board of india (listing obligation and disclosure requirement) regulations 2015, please find enclosed the annual secretarial compliance report for the financial year 2022-23 issued by bnp & associates, practising company secretaries",30-May-2023 19:40:57,2023-05-30 19:40:57,30-May-2023 19:41:06,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_30052023194057_signed.pdf,30-05-2023,957.5999755859376,961.5,951.0,959.8499755859376,952.1279296875,1337311,0.0,0.0,06-06-2023,0
46,CIPLA,Cipla Limited,diversification/disinvestment,"in compliance with the provisions of regulation 30 of the sebi listing regulations, we hereby notify that the company has entered into a binding term sheet to sell its entire stake of 51% held in saba investment limited, uae ( saba ) to shibam group holding limited, uae. consequent to the sale, upon execution of the transaction, saba and its subsidiaries viz cipla middle east pharmaceuticals fz llc, uae ( cme ) and cipla medica pharmaceutical and chemical industries limited, yemen ( cipla medica ), will cease to be subsidiaries of the company.",15-May-2023 23:52:33,2023-05-15 23:52:33,15-May-2023 23:52:38,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_15052023235233_SEIntimationSaba.pdf,15-05-2023,940.0,940.0,896.8499755859375,922.7999877929688,915.3759765625,5487301,0.0,0.0,22-05-2023,0
47,CIPLA,Cipla Limited,updates, regarding 'machine-readable version of audited financial results for the quarter and year ended 31st march 2023'.,15-May-2023 17:54:59,2023-05-15 17:54:59,15-May-2023 17:55:04,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_15052023175459_FINANCIALRESULTsigned.pdf,15-05-2023,940.0,940.0,896.8499755859375,922.7999877929688,915.3759765625,5487301,0.0,0.0,22-05-2023,0
48,CIPLA,Cipla Limited,resignation," regarding resignation of mr peter mugyenyi as independent director of the company w.e.f. may 13, 2023.",12-May-2023 19:55:41,2023-05-12 19:55:41,12-May-2023 19:55:44,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_12052023195541_Resignationletterofdrpetermugyenyisigned.pdf,12-05-2023,948.8499755859376,953.0,913.0,937.4500122070312,929.9081420898438,3850078,0.0,0.0,19-05-2023,0
49,CIPLA,Cipla Limited,esop/esos/esps, regarding grant of 464657 employee stock appreciation rights under the cipla employee stock appreciation rights scheme,12-May-2023 18:58:31,2023-05-12 18:58:31,12-May-2023 18:58:35,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_12052023185831_SEintimationESOPGrantMay2023signed.pdf,12-05-2023,948.8499755859376,953.0,913.0,937.4500122070312,929.9081420898438,3850078,0.0,0.0,19-05-2023,0
50,CIPLA,Cipla Limited,esop/esos/esps, regarding grant of 161629  stock options under the employees stock option scheme 2013-a,12-May-2023 18:54:26,2023-05-12 18:54:26,12-May-2023 18:54:36,00:00:10,https://nsearchives.nseindia.com/corporate/CIPLA_12052023185426_SEintimationESOPGrantMay2023signed.pdf,12-05-2023,948.8499755859376,953.0,913.0,937.4500122070312,929.9081420898438,3850078,0.0,0.0,19-05-2023,0
51,CIPLA,Cipla Limited,dividend," that board of directors at its meeting held on may 12, 2023, recommended final dividend of 8.50 per equity share.",12-May-2023 15:27:55,2023-05-12 15:27:55,12-May-2023 15:28:06,00:00:11,https://nsearchives.nseindia.com/corporate/CIPLA_12052023152755_Boardmeetingoutcome12052023signed.pdf,12-05-2023,948.8499755859376,953.0,913.0,937.4500122070312,929.9081420898438,3850078,0.0,0.0,19-05-2023,0
52,CIPLA,Cipla Limited,press release," regarding a press release dated may 12, 2023, titled ""cipla announces q4 and fy23 results"".",12-May-2023 15:10:15,2023-05-12 15:10:15,12-May-2023 15:10:19,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_12052023151015_PressreleaseMay2023signed.pdf,12-05-2023,948.8499755859376,953.0,913.0,937.4500122070312,929.9081420898438,3850078,0.0,0.0,19-05-2023,0
53,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended march 31, 2023.",12-May-2023 14:59:14,2023-05-12 14:59:14,12-May-2023 14:59:20,00:00:06,https://nsearchives.nseindia.com/corporate/FinancialresultsMarch2023signed_12052023145914.pdf,12-05-2023,948.8499755859376,953.0,913.0,937.4500122070312,929.9081420898438,3850078,0.0,0.0,19-05-2023,0
54,CIPLA,Cipla Limited,updates," regarding 'usfda inspection at invagen manufacturing facility in fall river, usa'.",02-May-2023 22:20:10,2023-05-02 22:20:10,02-May-2023 22:20:15,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_02052023222010_SEIntimation02052023signed.pdf,02-05-2023,910.4000244140624,921.0,906.0999755859376,917.7000122070312,910.3170166015624,1857324,0.0,0.0,09-05-2023,0
55,CIPLA,Cipla Limited,alteration of capital and fund raising-xbrl, regarding board meeting of the company held on allotment of securities for allotment of securities,20-Apr-2023 18:45:25,2023-04-20 18:45:25,20-Apr-2023 18:45:33,00:00:08,https://nsearchives.nseindia.com/corporate/xbrl/CIPLA_20042023184526_ALTERATION_OF_CAPITAL_AND_FUND_RAISING_828894_20042023064525_WEB.xml,20-04-2023,912.0,913.7000122070312,898.9500122070312,904.0,896.7272338867188,4446158,0.0,0.0,27-04-2023,0
56,CIPLA,Cipla Limited,board meeting intimation," about board meeting to be held on 12-may-2023 to consider financial statements for the period ended march 2023, financial results/dividend.",19-Apr-2023 20:09:13,2023-04-19 20:09:13,19-Apr-2023 20:09:15,00:00:02,https://nsearchives.nseindia.com/corporate/xbrl/CIPLA_19042023200913_PRIOR_INTIMATION_2952_826875_19042023080912_WEB.xml,19-04-2023,925.9500122070312,925.9500122070312,909.0,911.9000244140624,904.563720703125,1538261,0.0,0.0,26-04-2023,0
57,CIPLA,Cipla Limited,updates," regarding 'certificate under regulation 74(5) of the sebi (depositories and participants) regulations, 2018'.",12-Apr-2023 16:10:49,2023-04-12 16:10:49,12-Apr-2023 16:10:51,00:00:02,https://nsearchives.nseindia.com/corporate/CIPLA_12042023161049_Disclosure.pdf,12-04-2023,909.0,920.9000244140624,908.2000122070312,917.9500122070312,910.5650634765624,3449942,0.0,0.0,20-04-2023,0
58,CIPLA,Cipla Limited,updates, regarding 'perpetual licensing agreement with novartis pharma ag for galvusￂﾮ range for diabetes therapy in india'.,10-Apr-2023 11:58:37,2023-04-10 11:58:37,10-Apr-2023 11:58:44,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_10042023115837_SEIntimation.pdf,10-04-2023,896.9500122070312,904.5,894.2000122070312,901.8499755859376,894.5945434570312,919722,0.0,0.0,18-04-2023,0
59,CIPLA,Cipla Limited,diversification/disinvestment,"cipla limited and its wholly owned subsidiaries, cipla (eu) limited, uk and meditab holdings limited, mauritius, have entered into a share purchase agreement with africa capitalworks ssa 3 on 14th march 2023 for sale of 51.18% stake held in cipla quality chemical industries limited (cqcil), uganda. subsequent to the sale, cqcil will cease to be a subsidiary of the company.",14-Mar-2023 18:29:09,2023-03-14 18:29:09,14-Mar-2023 18:29:35,00:00:26,https://nsearchives.nseindia.com/corporate/CIPLA_14032023182909_SEIntimation.pdf,14-03-2023,873.0,883.7000122070312,853.8499755859375,872.0499877929688,865.0343017578125,2444217,0.0,0.0,21-03-2023,0
60,CIPLA,Cipla Limited,updates," regarding 'intimation under regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015'.",06-Feb-2023 18:34:14,2023-02-06 18:34:14,06-Feb-2023 18:34:19,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_06022023183414_update0602.pdf,06-02-2023,1020.0,1033.5999755859375,1010.1500244140624,1029.800048828125,1021.5151977539062,979035,0.0,0.0,13-02-2023,0
61,CIPLA,Cipla Limited,press release," regarding a press release dated january 25, 2023, titled ""q3fy23 results"".",25-Jan-2023 14:49:42,2023-01-25 14:49:42,25-Jan-2023 14:49:51,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_25012023144942_PressReleasesigned.pdf,25-01-2023,1064.9000244140625,1068.25,1020.0,1035.25,1026.92138671875,2226483,0.0,0.0,02-02-2023,0
62,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended december 31, 2022.",25-Jan-2023 14:09:02,2023-01-25 14:09:02,25-Jan-2023 14:09:06,00:00:04,https://nsearchives.nseindia.com/corporate/Resultsigned_25012023140902.pdf,25-01-2023,1064.9000244140625,1068.25,1020.0,1035.25,1026.92138671875,2226483,0.0,0.0,02-02-2023,0
63,CIPLA,Cipla Limited,press release," regarding a press release dated january 18, 2023, titled ""cipla launches cippoint   a point-of-care device for non-communicable diseases,infectious diseases, and other health conditions"".",18-Jan-2023 09:48:37,2023-01-18 09:48:37,18-Jan-2023 09:48:44,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_18012023094837_PressReleaseCiplalaunchesCippoint.pdf,18-01-2023,1068.9000244140625,1072.0,1059.3499755859375,1063.4000244140625,1054.8448486328125,1299797,0.0,0.0,25-01-2023,0
64,CIPLA,Cipla Limited,press release," regarding a press release dated december 29, 2022, titled ""cipla eu to invest eur 15 million in ethris, initiating a strategic collaboration"".",30-Dec-2022 09:23:10,2022-12-30 09:23:10,30-Dec-2022 09:23:15,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_30122022092310_PressRelease.pdf,30-12-2022,1094.949951171875,1095.0,1073.5,1075.949951171875,1067.2938232421875,1185711,0.0,0.0,06-01-2023,0
65,CIPLA,Cipla Limited,press release, about press release dated 29-nov-2022 titled cipla announces launch of leuprolide acetate injection depot (22.5mg),29-Nov-2022 08:40:39,2022-11-29 08:40:39,29-Nov-2022 08:40:42,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_29112022084039_Pressrelease_Leuprolidelaunch.pdf.pdf,29-11-2022,1106.0,1125.8499755859375,1105.0,1121.1500244140625,1112.1302490234375,1899345,0.0,0.0,06-12-2022,0
66,CIPLA,Cipla Limited,general updates,"pursuant to regulation 30 of sebi (listing obligations and disclosure requirements) regulations, 2015 and in furtherance to intimation dated 26th august, 2022 for united states food and drug administration (usfda) inspection of our goa manufacturing facility, we wish to inform you that the company has received a communication from the usfda that the classification of company￢ﾀﾙs said facility continues to be as official action indicated (￢ﾀﾜoai￢ﾀﾝ). usfda may continue to withhold product approvals from this facility till the outstanding observations are resolved. the company has an ongoing derisking plan in place for new product approvals. the company will work closely with the usfda and is committed to address these within the stipulated time",24-Nov-2022 10:56:48,2022-11-24 10:56:48,24-Nov-2022 10:57:02,00:00:14,https://nsearchives.nseindia.com/corporate/CIPLA_24112022105648_SEIntimationUSFDAGoa.pdf,24-11-2022,1113.550048828125,1117.6500244140625,1092.4000244140625,1095.3499755859375,1086.537841796875,2933085,0.0,0.0,01-12-2022,0
67,CIPLA,Cipla Limited,esop/esps/sbeb scheme," about allotment of 23,935 equity shares under esos 2013-a scheme and cipla esar scheme 2021 of the company",21-Nov-2022 18:40:54,2022-11-21 18:40:54,21-Nov-2022 18:40:56,00:00:02,https://nsearchives.nseindia.com/corporate/CIPLA_21112022184054_SE_Intimation_signed.pdf,21-11-2022,1104.949951171875,1108.199951171875,1093.75,1104.449951171875,1095.5645751953125,1488424,0.0,0.0,28-11-2022,0
68,CIPLA,Cipla Limited,general updates," about update on intimation dated 25th january 2022 under regulation 30 of the securities and exchange board of india (listing obligation and disclosure requirements), regulations 2015",04-Nov-2022 16:01:45,2022-11-04 16:01:45,04-Nov-2022 16:01:49,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_04112022160145_SignedClapSEintimation04112022.pdf,04-11-2022,1167.8499755859375,1175.25,1141.0,1146.0999755859375,1136.8795166015625,1712836,0.0,0.0,14-11-2022,0
69,CIPLA,Cipla Limited,outcome of board meeting,"in furtherance to our intimation dated 4th november 2022 under regulation 30 and 33 of the sebi (listing obligations and disclosure requirements) regulations, 2015, we hereby notify the meeting of the board of directors which commenced today at 10.30 a.m. (ist) has concluded at 3.30 p.m. (ist).",04-Nov-2022 15:54:18,2022-11-04 15:54:18,04-Nov-2022 15:54:22,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_04112022155418_signedOutcome04112022.pdf,04-11-2022,1167.8499755859375,1175.25,1141.0,1146.0999755859375,1136.8795166015625,1712836,0.0,0.0,14-11-2022,0
70,CIPLA,Cipla Limited,outcome of board meeting,cipla limited  has informed the exchange about board meeting held on 04-nov-2022 to consider financial statements for the period ended september 2022,04-Nov-2022 13:55:57,2022-11-04 13:55:57,04-Nov-2022 13:56:01,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_04112022135557_FinancialResultSeptember2022signed.pdf,04-11-2022,1167.8499755859375,1175.25,1141.0,1146.0999755859375,1136.8795166015625,1712836,0.0,0.0,14-11-2022,0
71,CIPLA,Cipla Limited,esop/esps/sbeb scheme," about allotment of 47,894 equity shares under esos 2013-a scheme and cipla esar scheme 2021 of the company",19-Oct-2022 15:36:18,2022-10-19 15:36:18,19-Oct-2022 15:36:21,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_19102022153618_SEIntimationOctober2022.pdf,19-10-2022,1131.5,1145.0,1119.0999755859375,1122.0,1112.973388671875,1300144,0.0,0.0,27-10-2022,0
72,CIPLA,Cipla Limited,press release, about press release dated 11-oct-2022 titled cipla￢ﾀﾙs indore plant joins the world economic forum￢ﾀﾙs (wef) prestigious lighthouse network,11-Oct-2022 14:35:57,2022-10-11 14:35:57,11-Oct-2022 14:36:00,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_11102022143557_Pressreleasefinalsigned.pdf,11-10-2022,1121.800048828125,1127.1500244140625,1103.800048828125,1110.0999755859375,1101.169189453125,1538943,0.0,0.0,18-10-2022,0
73,CIPLA,Cipla Limited,loss of share certificate,"pursuant to regulation 39(3) of the sebi lodr regulations and in terms of sebi circular no. sebi/ho/mirsd/mirsd_rtamb/p/cir/2022/8 dated 25th january, 2022, the company has approved the issuance of ￢ﾀﾜletter ofconfirmation￢ﾀﾝ on 27th september, 2022 in lieu of share certificate(s), which were reported as lost by the shareholder.",27-Sep-2022 14:25:33,2022-09-27 14:25:33,27-Sep-2022 14:25:37,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_27092022142533_SEintimationIssuanceofLOCsigned.pdf,27-09-2022,1070.949951171875,1104.9000244140625,1069.0,1098.699951171875,1089.86083984375,2343041,0.0,0.0,04-10-2022,0
74,CIPLA,Cipla Limited,esop/esps/sbeb scheme," about allotment of 5,683 equity shares under esos 2013-a scheme and cipla esar scheme 2021 of the company",14-Sep-2022 11:28:00,2022-09-14 11:28:00,14-Sep-2022 11:28:15,00:00:15,https://nsearchives.nseindia.com/corporate/CIPLA_14092022112800_SE_Intimation_F.pdf,14-09-2022,1040.0,1068.0,1040.0,1059.949951171875,1051.422607421875,998799,0.0,0.0,21-09-2022,0
75,CIPLA,Cipla Limited,press release, about press release dated 07-sep-2022 titled cipla receives usfda approval for the generic version of revlimidￂﾮ (lenalidomide capsules),07-Sep-2022 14:07:24,2022-09-07 14:07:24,07-Sep-2022 14:07:28,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_07092022140724_PressReleaseCIPLARECEIVESUSFDAAPPROVALFORGENERICVERSIONOFREVLIMIDLENALIDOMIDECAPSULES.pdf,07-09-2022,1033.8499755859375,1061.8499755859375,1033.0,1051.5,1043.0406494140625,2471263,0.0,0.0,14-09-2022,0
76,CIPLA,Cipla Limited,schedule of analysts/institutional investor meet/con. call,"pursuant to regulation 30 of the securities and exchange board of india (listing obligations and disclosure requirements) regulations, 2015, please find attached schedule of analyst / institutional investor meetings with the company.",06-Sep-2022 14:55:42,2022-09-06 14:55:42,06-Sep-2022 14:55:50,00:00:08,https://nsearchives.nseindia.com/corporate/CIPLA_06092022145542_InvestorMeetingSigned.pdf,06-09-2022,1025.0,1042.0,1024.9000244140625,1040.8499755859375,1032.4761962890625,1369910,0.0,0.0,13-09-2022,0
77,CIPLA,Cipla Limited,acquisition," that cipla (eu) limited, (""cipla eu""), wholly owned subsidiary of the company in uk has agreed to acquire an additional 13.10% stake in cipla (jiangsu) pharmaceutical co. ltd., a subsidiary of cipla eu in china",30-Aug-2022 20:56:45,2022-08-30 20:56:45,30-Aug-2022 20:56:48,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_30082022205645_StockExchangeIntimation_ChinaJV30082022_F.pdf,30-08-2022,1018.5,1042.199951171875,1016.0999755859376,1038.449951171875,1030.0955810546875,1571042,0.0,0.0,07-09-2022,0
78,CIPLA,Cipla Limited,general updates," about update on agreement with kemwell biopharma private limited (""kemwell india"") for incorporation of a joint venture company",30-Aug-2022 19:12:00,2022-08-30 19:12:00,30-Aug-2022 19:12:06,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_30082022191200_KemwellSEintimation25082022signedFinal.pdf,30-08-2022,1018.5,1042.199951171875,1016.0999755859376,1038.449951171875,1030.0955810546875,1571042,0.0,0.0,07-09-2022,0
79,CIPLA,Cipla Limited,general updates,"pursuant to regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015, this is to inform you that further to united states food and drug administration (usfda) inspection at the company￢ﾀﾙs goa manufacturing facility in september 2019 and the warning letter received in february 2020, the goa plant recently underwent a usfda inspection from 16th ￢ﾀﾓ 26th august 2022.on conclusion of the inspection, the company has now received 6 observations with some referencing to the observations made during the september 2019 inspection. there are no data integrity (di) observations. the company will work closely with the usfda and is committed to address these within the stipulated time.kindly take the above information on record.",26-Aug-2022 22:52:03,2022-08-26 22:52:03,26-Aug-2022 22:52:08,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_26082022225203_SEIntimationUSFDAFinal.pdf,26-08-2022,1030.9000244140625,1035.699951171875,1018.5,1020.7999877929688,1012.5875854492188,1264070,0.0,0.0,05-09-2022,0
80,CIPLA,Cipla Limited,annual general meeting,"pursuant to regulation 44(3) of the securities and exchange board of india (listing obligations and disclosure requirements) regulations, 2015 we are enclosing the voting results of the 86th annual general meeting of the company held on friday, 26th august, 2022 at 3.00 p.m. (ist) in the prescribed format together with scrutiniser￢ﾀﾙs report.",26-Aug-2022 22:22:15,2022-08-26 22:22:15,26-Aug-2022 22:22:18,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_26082022222215_SE_Intimation_VotingResults.pdf,26-08-2022,1030.9000244140625,1035.699951171875,1018.5,1020.7999877929688,1012.5875854492188,1264070,0.0,0.0,05-09-2022,0
81,CIPLA,Cipla Limited,annual general meeting,"we hereby notify that the 86th annual general meeting (agm) of the company was held on friday, 26th august 2022 at 3.00 pm through video conferencing / other audio-visual means (oavm).pursuant to the provisions of regulation 30 of the securities and exchange board of india (listing obligations and disclosure requirements) regulations, 2015 we are enclosing the following:1.    speech by dr y k hamied ￢ﾀﾓ chairman2.    presentation by mr umang vohra ￢ﾀﾓ managing director and global chief executive officer3.    proceedings of the agm.kindly take the above on record.",26-Aug-2022 22:19:12,2022-08-26 22:19:12,26-Aug-2022 22:19:14,00:00:02,https://nsearchives.nseindia.com/corporate/CIPLA_26082022221912_SE_Intimation_AGM_Proceedings.pdf,26-08-2022,1030.9000244140625,1035.699951171875,1018.5,1020.7999877929688,1012.5875854492188,1264070,0.0,0.0,05-09-2022,0
82,CIPLA,Cipla Limited,general updates,"we wish to inform that, the board of directors ofthe company at its meeting held on 16th august, 2022 has approvedthe changes in the key managerial personnel (kmps) authorised under regulation 30(5) of the listing regulations witheffect from 16th august, 2022.",16-Aug-2022 19:52:42,2022-08-16 19:52:42,16-Aug-2022 19:52:45,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_16082022195242_Intimationunder305.pdf,16-08-2022,1027.1500244140625,1036.0,1025.25,1034.550048828125,1026.22705078125,776409,0.0,0.0,23-08-2022,0
83,CIPLA,Cipla Limited,appointment,"the board of directors at its meeting held today i.e. 16th august, 2022, has approved the appointment of mr. ashish adukia as the global chief financial officer and key managerial personnel of the company",16-Aug-2022 17:32:57,2022-08-16 17:32:57,16-Aug-2022 17:33:00,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_16082022173257_CFOAppointmentSEIntimation.pdf,16-08-2022,1027.1500244140625,1036.0,1025.25,1034.550048828125,1026.22705078125,776409,0.0,0.0,23-08-2022,0
84,CIPLA,Cipla Limited,resignation,cipla limited  has informed the exchange about relieving mr. dinesh jain from the additional responsibility of interim chief financial officer of the company w.e.f. 16-aug-2022. mr. dinesh jain will continue as senior vice-president & head-corporate finance. the board places on record its appreciation towards his valuable contribution for the period as the interim chief financial officer ,16-Aug-2022 17:27:39,2022-08-16 17:27:39,16-Aug-2022 17:27:42,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_16082022172739_CFOAppointmentSEIntimation.pdf,16-08-2022,1027.1500244140625,1036.0,1025.25,1034.550048828125,1026.22705078125,776409,0.0,0.0,23-08-2022,0
85,CIPLA,Cipla Limited,acquisition,"cipla (eu) limited, (""cipla eu""), wholly owned subsidiary of the company in uk, has agreed to acquire an additional 19.16% stake in cipla maroc sa, joint venture and subsidiary of cipla eu in morocco.",04-Aug-2022 23:15:33,2022-08-04 23:15:33,04-Aug-2022 23:15:39,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_04082022231533_Acqusition.pdf,04-08-2022,1017.7999877929688,1046.9000244140625,1015.0,1044.5,1031.0877685546875,2865077,0.0,0.0,12-08-2022,0
86,CIPLA,Cipla Limited,loss of share certificate,"pursuant to regulation 39(3) and other applicable regulations of sebi (listing obligations and disclosurerequirements) regulations, 2015, we would like to inform you that registrar and transfer agent of companym/s. kfin technologies limited has received intimation for loss of share certificate and request for issuance ofduplicate share certificate from the shareholder.",04-Aug-2022 18:50:21,2022-08-04 18:50:21,04-Aug-2022 18:50:25,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_04082022185021_LossofShareCertificate.pdf,04-08-2022,1017.7999877929688,1046.9000244140625,1015.0,1044.5,1031.0877685546875,2865077,0.0,0.0,12-08-2022,0
87,CIPLA,Cipla Limited,newspaper advertisements,"pursuant to regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015, we are enclosing herewith copies of newspaper advertisements published in business standard (english) and sakal (marathi) today i.e. 3rd august, 2022 which includes the following information:1. intimation of 86th annual general meeting (agm) of our company to be held on friday, 26th august, 2022, at 3.00 p.m. ist through video conferencing (vc) / other audio-visual means (oavm).2. completion of email dissemination on tuesday, 2nd august, 2022 of the notice of the 86th agm and the integrated annual report for fy 2021-22 to the members whose email ids are registered with the company/ depositories.3. details of remote e-voting facility provided to the shareholders of the company, to enable them to casttheir votes on the resolutions proposed to be passed at the agm.",03-Aug-2022 19:42:42,2022-08-03 19:42:42,03-Aug-2022 19:42:45,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_03082022194242_NEWSPAPERPUBLICATION.pdf,03-08-2022,1010.0,1028.75,1004.5,1011.8499755859376,998.85693359375,4052763,0.0,0.0,11-08-2022,0
88,CIPLA,Cipla Limited,loss of share certificate,"pursuant to regulation 39(3) and other applicable regulations of sebi (listing obligations and disclosure requirements) regulations, 2015, we would like to inform you that registrar and transfer agent of company m/s. kfin technologies limited has received intimation for loss of share certificate and request for issuance of duplicate share certificate from the shareholder.",03-Aug-2022 16:39:12,2022-08-03 16:39:12,03-Aug-2022 16:39:16,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_03082022163912_LOSSOFSHARECERTIFICATE.pdf,03-08-2022,1010.0,1028.75,1004.5,1011.8499755859376,998.85693359375,4052763,0.0,0.0,11-08-2022,0
89,CIPLA,Cipla Limited,business responsibility & sustainability report (brsr), about business responsibility & sustainability report (brsr) for the period ended 31st march 2022,02-Aug-2022 23:36:33,2022-08-02 23:36:33,02-Aug-2022 23:36:37,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_02082022233633_BusinessResponsibilitySustainabilityReportFY202122.pdf,02-08-2022,1003.6500244140624,1006.0999755859376,992.0,1004.2000122070312,991.3052368164062,1184696,0.0,0.0,10-08-2022,0
90,CIPLA,Cipla Limited,annual general meeting, about notice of annual general meeting to be held on 26-aug-2022 and integrated annual report fy 2021-22,02-Aug-2022 23:30:34,2022-08-02 23:30:34,02-Aug-2022 23:30:39,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_02082022233033_CiplaLimitedAnnualReportandAGMnoticeFY202122.pdf,02-08-2022,1003.6500244140624,1006.0999755859376,992.0,1004.2000122070312,991.3052368164062,1184696,0.0,0.0,10-08-2022,0
91,CIPLA,Cipla Limited,loss of share certificate,"pursuant to regulation 39(3) and other applicable regulations of sebi (listing obligations and disclosurerequirements) regulations, 2015, we would like to inform you that registrar and transfer agent of companym/s. kfin technologies limited has received intimation for loss of share certificate and request for issuance ofduplicate share certificates from the following shareholder.",02-Aug-2022 19:41:57,2022-08-02 19:41:57,02-Aug-2022 19:42:00,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_02082022194157_LossofShareCertificate.pdf,02-08-2022,1003.6500244140624,1006.0999755859376,992.0,1004.2000122070312,991.3052368164062,1184696,0.0,0.0,10-08-2022,0
92,CIPLA,Cipla Limited,transcript of analysts/institutional investor meet/con. call,"we are enclosing herewith copy of the transcript of the company's q1 fy23 earnings conference call dated 29th july, 2022. the transcript is also available on the company's website i.e., www.cipla.com under the investors section.",02-Aug-2022 17:10:21,2022-08-02 17:10:21,02-Aug-2022 17:10:26,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_02082022171021_Transcript.pdf,02-08-2022,1003.6500244140624,1006.0999755859376,992.0,1004.2000122070312,991.3052368164062,1184696,0.0,0.0,10-08-2022,0
93,CIPLA,Cipla Limited,investor presentation,"we refer the investor presentation submitted through letter dated 29th july 2022. please note that there was a minor error in the graphical presentation of the information in slide 11 (titled north america: respiratory, complex generics & peptide pipeline). in the slide the status of progress of complex inhalation asset was erroneously shown as 'approved' instead of the actual status as 'filed'. we are enclosing the updated presentation.",29-Jul-2022 21:10:09,2022-07-29 21:10:09,29-Jul-2022 21:10:12,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_29072022211009_CorrigendumInvestorPresentation.pdf,29-07-2022,973.7000122070312,983.9500122070312,953.0,977.4000244140624,964.849365234375,2941566,0.0,0.0,05-08-2022,1
94,CIPLA,Cipla Limited,appointment,cipla limited  has informed the exchange about appointment of mandar purushottam vaidya as independent director of the company w.e.f. 29-jul-2022,29-Jul-2022 20:35:39,2022-07-29 20:35:39,29-Jul-2022 20:35:41,00:00:02,https://nsearchives.nseindia.com/corporate/CIPLA_29072022203539_AppointmentofDrMandarVaidya.pdf,29-07-2022,973.7000122070312,983.9500122070312,953.0,977.4000244140624,964.849365234375,2941566,0.0,0.0,05-08-2022,1
95,CIPLA,Cipla Limited,outcome of board meeting,"in furtherance to our intimation dated 29th july, 2022 under regulation 30 and 33 of the sebi (listing obligations and disclosure requirements) regulations, 2015, the meeting of the board of directors which commenced today at 12.15 p.m. (ist) has concluded at 5.10 p.m. (ist).",29-Jul-2022 17:27:12,2022-07-29 17:27:12,29-Jul-2022 17:27:17,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_29072022172712_SEOutcomejuly2022.pdf,29-07-2022,973.7000122070312,983.9500122070312,953.0,977.4000244140624,964.849365234375,2941566,0.0,0.0,05-08-2022,1
96,CIPLA,Cipla Limited,outcome of board meeting,cipla limited  has informed the exchange about board meeting held on 29-jul-2022 to consider financial statements for the period ended june 2022,29-Jul-2022 15:44:45,2022-07-29 15:44:45,29-Jul-2022 15:44:50,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_29072022154445_Financialresults30062022signed.pdf,29-07-2022,973.7000122070312,983.9500122070312,953.0,977.4000244140624,964.849365234375,2941566,0.0,0.0,05-08-2022,1
97,CIPLA,Cipla Limited,newspaper advertisements,"pursuant to regulation 30 of the sebi (listing obligation and disclosure requirements) regulations, 2015 and in compliance with various circulars issued by the ministry of corporate affairs, we hereby enclose copies of newspaper advertisement published in business standard (english) and sakal (marathi) on 28th july, 2022 intimating the shareholders about the annual general meeting, e-voting, manner of registering email address, mobile number & bank account mandate, record date and dividend.",28-Jul-2022 21:32:00,2022-07-28 21:32:00,28-Jul-2022 21:32:08,00:00:08,https://nsearchives.nseindia.com/corporate/CIPLA_28072022213200_recorddateintimation.pdf,28-07-2022,977.0,978.9500122070312,964.2000122070312,967.4500122070312,955.027099609375,1043837,0.0,0.0,04-08-2022,1
98,CIPLA,Cipla Limited,loss of share certificate,"pursuant to regulation 39(3) and other applicable regulations of sebi (listing obligations and disclosurerequirements) regulations, 2015, we would like to inform you that registrar and transfer agent of companym/s. kfin technologies limited has received intimation for loss of share certificate and request for issuance ofduplicate share certificate from the shareholder.",27-Jul-2022 18:45:57,2022-07-27 18:45:57,27-Jul-2022 18:46:09,00:00:12,https://nsearchives.nseindia.com/corporate/CIPLA_27072022184557_LOSSOFSHARECERTIFICATE.pdf,27-07-2022,956.9000244140624,976.25,951.7999877929688,974.0499877929688,961.5424194335938,904733,0.0,0.0,03-08-2022,0
99,CIPLA,Cipla Limited,record date,"this is further to our letter dated 10th may, 2022, wherein it was informed that the board of directors of the company have inter-alia recommended final dividend of rs. 5/- per equity share (face value rs. 2 /- per equity share) for fy 2021-22, subject to the approval of the shareholders at the ensuing 86th  annual general meeting to be held on 26th august, 2022.pursuant to regulation 42 of sebi lodr regulations, the company has fixed the 'record date' for determining the member eligible for payment of final dividend.",27-Jul-2022 18:36:30,2022-07-27 18:36:30,27-Jul-2022 18:36:34,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_27072022183630_RecorddateStockintimation.pdf,27-07-2022,956.9000244140624,976.25,951.7999877929688,974.0499877929688,961.5424194335938,904733,0.0,0.0,03-08-2022,0
100,CIPLA,Cipla Limited,general updates," that lnvagen pharmaceuticals inc., wholly owned step-down subsidiary in usa has entered into a share repurchase agreement  for sale of equity stake held in avenue therapeutics, inc. ",26-Jul-2022 23:45:21,2022-07-26 23:45:21,26-Jul-2022 23:45:24,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_26072022234521_StockexchangeIntimation_Avenue_Final1.pdf,26-07-2022,959.9500122070312,962.0,944.5,955.7000122070312,943.4280395507812,988405,0.0,0.0,02-08-2022,1
101,CIPLA,Cipla Limited,loss of share certificate,"pursuant to regulation 39(3) of the sebi lodr regulations and in terms of sebi circular no. sebi/ho/mirsd/mirsd_rtamb/p/cir/2022/8 dated 25th january, 2022, the company has approved issuance of ""letter ofconfirmation"" on 19th july, 2022 in lieu of share certificate(s), which were reported as lost by the shareholder.",20-Jul-2022 19:15:00,2022-07-20 19:15:00,20-Jul-2022 19:15:05,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_20072022191500_issuanceofloc.pdf,20-07-2022,965.7000122070312,982.9500122070312,958.8499755859376,981.5,968.8966674804688,1627220,0.0,0.0,27-07-2022,0
102,CIPLA,Cipla Limited,press release, about press release dated 14-jul-2022 titled cipla health signs agreement to acquire endura mass,14-Jul-2022 19:32:06,2022-07-14 19:32:06,14-Jul-2022 19:32:10,00:00:04,"https://nsearchives.nseindia.com/corporate/CIPLA_14072022193206_PressRelease_Projecthulk_Final_July14,2022.pdf",14-07-2022,953.4000244140624,968.6500244140624,945.1500244140624,951.1500244140624,938.9365234375,1713101,0.0,0.0,21-07-2022,0
103,CIPLA,Cipla Limited,loss of share certificate,"pursuant to regulation 39(3) and other applicable regulations of sebi (listing obligations and disclosure requirements) regulations, 2015, we would like to inform you that registrar and transfer agent of company m/s. kfin technologies limited has received intimation for loss of share certificate and request for issuance of duplicate share certificates from the shareholder.",13-Jul-2022 20:29:27,2022-07-13 20:29:27,13-Jul-2022 20:29:30,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_13072022202927_LossofSharesCertificate.pdf,13-07-2022,940.4500122070312,958.9000244140624,932.1500244140624,953.3499755859376,941.108154296875,1511059,0.0,0.0,20-07-2022,0
104,CIPLA,Cipla Limited,loss of share certificate,"pursuant to regulation 39(3) and other applicable regulations of sebi (listing obligations and disclosurerequirements) regulations, 2015, we would like to inform you that our registrar and transfer agent ofcompany m/s. kfin technologies limited has received intimation for loss of share certificate and request forissuance of duplicate share certificate.",05-Jul-2022 17:53:39,2022-07-05 17:53:39,05-Jul-2022 17:53:44,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_05072022175339_SEINTIMATION.pdf,05-07-2022,935.0,949.6500244140624,930.25,937.4000244140624,925.363037109375,1532205,0.0,0.0,12-07-2022,0
105,CIPLA,Cipla Limited,press release, about press release dated 27-jun-2022 titled - cipla to further invest in digital tech company goapptiv; to hold 22.02% stake post completion of proposed transaction.,27-Jun-2022 19:55:57,2022-06-27 19:55:57,27-Jun-2022 19:55:59,00:00:02,https://nsearchives.nseindia.com/corporate/CIPLA_27062022195557_PressRelease.pdf,27-06-2022,936.0,946.4000244140624,930.5499877929688,932.3499755859376,920.3778686523438,846797,0.0,0.0,04-07-2022,0
106,CIPLA,Cipla Limited,acquisition,cipla limited has entered into definitive agreements on 27th june 2022 for further investment of rs. 25.90 crores (approx.) in goapptiv private limited.,27-Jun-2022 19:51:57,2022-06-27 19:51:57,27-Jun-2022 19:52:03,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_27062022195157_Acquistion.pdf,27-06-2022,936.0,946.4000244140624,930.5499877929688,932.3499755859376,920.3778686523438,846797,0.0,0.0,04-07-2022,0
107,CIPLA,Cipla Limited,newspaper advertisements," about newspaper advertisements of notice to shareholders whose shares are liable to be transferred to investor education and protection fund (""iepf"") published in business standard (english) and sakal (marathi) on 24th june 2022.",24-Jun-2022 16:54:48,2022-06-24 16:54:48,24-Jun-2022 16:54:52,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_24062022165448_SEINTIMATION.pdf,24-06-2022,933.0,943.5,930.0,933.7000122070312,921.7105102539062,722838,0.0,0.0,01-07-2022,0
108,CIPLA,Cipla Limited,press release," about press release dated 17-jun-2022 titled cipla signs agreement for acquisition of 21.05% stake in achira labs to develop affordable, innovative medical kits in india",17-Jun-2022 19:45:51,2022-06-17 19:45:51,17-Jun-2022 19:45:53,00:00:02,"https://nsearchives.nseindia.com/corporate/CIPLA_17062022194550_PressRelease_Achira_June17,2022.pdf",17-06-2022,932.2000122070312,944.5499877929688,910.7999877929688,914.75,903.0038452148438,2715476,0.0,0.0,24-06-2022,0
109,CIPLA,Cipla Limited,acquisition,cipla has entered into definitive agreements on 17th june 2022 for the acquisition of 21.05% stake (on a fully diluted basis) in achira labs private limited.,17-Jun-2022 19:34:15,2022-06-17 19:34:15,17-Jun-2022 19:34:18,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_17062022193415_StockExchangeIntimationAchiraLabs.pdf,17-06-2022,932.2000122070312,944.5499877929688,910.7999877929688,914.75,903.0038452148438,2715476,0.0,0.0,24-06-2022,0
110,CIPLA,Cipla Limited,press release, about press release dated 14-jun-2022 titled cipla and dndi launch child-friendly 4-in-1 antiretroviral treatment for young children living with hiv in south africa,14-Jun-2022 15:46:29,2022-06-14 15:46:29,14-Jun-2022 15:46:32,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_14062022154628_PressRelease_14062022rc.pdf,14-06-2022,955.0,970.7999877929688,950.7999877929688,964.7000122070312,952.3124389648438,1570434,0.0,0.0,21-06-2022,0
111,CIPLA,Cipla Limited,loss of share certificate," about loss of share certificate - pursuant to regulation 39(3) and other applicable regulations of the sebi (listing obligations and disclosure requirements) regulations, 2015, we hereby notify that the registrar and transfer agent of the company m/s. kfin technologies limited has received an intimation for loss of share certificate and request for issuance of duplicate share certificate from the shareholder.",02-Jun-2022 23:12:32,2022-06-02 23:12:32,02-Jun-2022 23:12:36,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_02062022231232_SEintimationARVIND.pdf,02-06-2022,977.5,1006.8499755859376,977.5,987.0999755859376,974.4248046875,2639988,0.0,0.0,09-06-2022,0
112,CIPLA,Cipla Limited,loss of share certificate," about  - issuance of ""letter of confirmation"" in lieu of physical duplicate share certificate upon loss of old share certificate by shareholder.",02-Jun-2022 23:10:11,2022-06-02 23:10:11,02-Jun-2022 23:10:14,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_02062022231011_SEintimationPAI.pdf,02-06-2022,977.5,1006.8499755859376,977.5,987.0999755859376,974.4248046875,2639988,0.0,0.0,09-06-2022,0
113,CIPLA,Cipla Limited,press release, about press release dated 02-jun-2022 titled cipla adds capacity of captive renewable energy power plant in maharashtra & karnataka,02-Jun-2022 08:12:46,2022-06-02 08:12:46,02-Jun-2022 08:12:50,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_02062022081246_Intimation.pdf,02-06-2022,977.5,1006.8499755859376,977.5,987.0999755859376,974.4248046875,2639988,0.0,0.0,09-06-2022,0
114,CIPLA,Cipla Limited,press release, about press release dated 25-may-2022 titled cipla scored highest among pharma companies in crisil￢ﾀﾙs sustainability rating 2022,25-May-2022 08:16:57,2022-05-25 08:16:57,25-May-2022 08:17:02,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_25052022081657_PressRelease_rc.pdf,25-05-2022,972.4000244140624,985.9000244140624,969.4500122070312,971.8499755859376,959.37060546875,1950710,0.0,0.0,01-06-2022,0
115,CIPLA,Cipla Limited,general updates,"pursuant to regulation 24a of the securities and exchange board of india (listing obligation and disclosurerequirement) regulations 2015, please find enclosed the annual secretarial compliance report for the financialyear 2021-22 issued by bnp & associates, practising company secretaries.",24-May-2022 14:38:31,2022-05-24 14:38:31,24-May-2022 14:38:36,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_24052022143829_AnnualSecretarialComplianceReportSigned.pdf,24-05-2022,977.0,977.7000122070312,961.75,970.4000244140624,957.9392700195312,1622192,0.0,0.0,31-05-2022,0
116,CIPLA,Cipla Limited,general updates," about intimation under regulation 30(5) of the sebi (listing obligations and disclosure requirements) regulations, 2015",10-May-2022 20:07:37,2022-05-10 20:07:37,10-May-2022 20:07:41,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_10052022200737_Reg305_signed.pdf,10-05-2022,930.0,939.5999755859376,918.5499877929688,926.1500244140624,914.2575073242188,1662201,0.0,0.0,17-05-2022,0
117,CIPLA,Cipla Limited,outcome of board meeting,"in furtherance to our intimation dated 10th may, 2022 under regulation 30 and 33 of the sebi (listing obligations requirements) regulations, 2015, the meeting of the board of directors which commenced today at 2.30 p.m. (ist) has concluded at 6.40 p.m. (ist). ",10-May-2022 19:09:08,2022-05-10 19:09:08,10-May-2022 19:09:13,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_10052022190905_SEOutcomeMay2022finalsigned.pdf,10-05-2022,930.0,939.5999755859376,918.5499877929688,926.1500244140624,914.2575073242188,1662201,0.0,0.0,17-05-2022,0
118,CIPLA,Cipla Limited,press release, about press release dated 10-may-2022 titled cipla announces q4 and fy22 results,10-May-2022 18:40:38,2022-05-10 18:40:38,10-May-2022 18:40:41,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_10052022184033_IntimationofPressReleasesigned.pdf,10-05-2022,930.0,939.5999755859376,918.5499877929688,926.1500244140624,914.2575073242188,1662201,0.0,0.0,17-05-2022,0
119,CIPLA,Cipla Limited,dividend, about final dividend at the rate of rs. 5 per share,10-May-2022 18:37:02,2022-05-10 18:37:02,10-May-2022 18:37:05,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_10052022183702_FinancialResultMar22signed.pdf,10-05-2022,930.0,939.5999755859376,918.5499877929688,926.1500244140624,914.2575073242188,1662201,0.0,0.0,17-05-2022,0
120,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended march 31, 2022.",10-May-2022 18:34:22,2022-05-10 18:34:22,10-May-2022 18:36:03,00:01:41,https://nsearchives.nseindia.com/corporate/FinancialResultMar22signed_10052022183422.pdf,10-05-2022,930.0,939.5999755859376,918.5499877929688,926.1500244140624,914.2575073242188,1662201,0.0,0.0,17-05-2022,0
121,CIPLA,Cipla Limited,appointment,cipla limited  has informed the exchange about appointment of mr. dinesh jain as interim chief financial officer of the company w.e.f. 10-may-2022,10-May-2022 16:12:48,2022-05-10 16:12:48,10-May-2022 16:12:50,00:00:02,https://nsearchives.nseindia.com/corporate/CIPLA_10052022161248_CFOAppointmentIntimation.pdf,10-05-2022,930.0,939.5999755859376,918.5499877929688,926.1500244140624,914.2575073242188,1662201,0.0,0.0,17-05-2022,0
122,CIPLA,Cipla Limited,press release, about press release dated 10-may-2022 titled cipla launches ￢ﾀﾘrt direct￢ﾀﾙ multiplex real time pcr kit for covid-19,10-May-2022 08:40:20,2022-05-10 08:40:20,10-May-2022 08:40:25,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_10052022084015_Letter10052022rc.pdf,10-05-2022,930.0,939.5999755859376,918.5499877929688,926.1500244140624,914.2575073242188,1662201,0.0,0.0,17-05-2022,0
123,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,promoter/promoter group of cipla limited has submitted a disclosure under regulation 31(4) of sebi takeover regulations for the year ended 31-mar-2022,11-Apr-2022 17:03:25,2022-04-11 17:03:25,11-Apr-2022 17:03:28,00:00:03,https://nsearchives.nseindia.com/corporate/AN_O11042022170325.xlsx,11-04-2022,1012.0,1028.300048828125,1011.5999755859376,1025.5,1012.3317260742188,2094493,0.0,0.0,20-04-2022,0
124,CIPLA,Cipla Limited,updates," regarding 'de-registration of cipla biotec south africa (pty) limited, wholly owned step-down subsidiary'.",10-Feb-2022 17:50:13,2022-02-10 17:50:13,10-Feb-2022 17:50:23,00:00:10,https://nsearchives.nseindia.com/corporate/CIPLA_10022022175013_SEDeregistrationofCiplaBiotec.pdf,10-02-2022,969.0,977.3499755859376,963.0,975.0499877929688,962.5294799804688,2044733,0.0,0.0,17-02-2022,0
125,CIPLA,Cipla Limited,resignation," regarding resignation of mr kedar upadhye as chief financial officer of the company w.e.f. may 03, 2022.",04-Feb-2022 17:32:59,2022-02-04 17:32:59,04-Feb-2022 17:33:04,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_04022022173259_CFORESIGNATION.pdf,04-02-2022,951.25,957.75,940.0,946.0999755859376,933.9512939453124,1428601,0.0,0.0,11-02-2022,0
126,CIPLA,Cipla Limited,acquisition, about acquisition of securities in amp energy green eleven private limited,04-Feb-2022 16:46:21,2022-02-04 16:46:21,04-Feb-2022 16:46:35,00:00:14,https://nsearchives.nseindia.com/corporate/CIPLA_04022022164621_StockExchangeIntimationAMPfinal4thfeb.pdf,04-02-2022,951.25,957.75,940.0,946.0999755859376,933.9512939453124,1428601,0.0,0.0,11-02-2022,0
127,CIPLA,Cipla Limited,updates," regarding 'intimation pursuant to regulation 30 of sebi (lodr) regulations, 2015 regarding slump sale of business undertakings'.",25-Jan-2022 18:49:41,2022-01-25 18:49:41,25-Jan-2022 18:49:47,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_25012022184941_CLAPSEIntimation25012022final.pdf,25-01-2022,891.4000244140625,909.0,881.0999755859375,905.6500244140624,894.020751953125,2322693,0.0,0.0,02-02-2022,1
128,CIPLA,Cipla Limited,press release," regarding a press release dated january 25, 2022, titled ""cipla announces q3 fy22 results"".",25-Jan-2022 18:11:02,2022-01-25 18:11:02,25-Jan-2022 18:11:23,00:00:21,https://nsearchives.nseindia.com/corporate/CIPLA_25012022181102_2PressRelease25012022.pdf,25-01-2022,891.4000244140625,909.0,881.0999755859375,905.6500244140624,894.020751953125,2322693,0.0,0.0,02-02-2022,1
129,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended december 31, 2021.",25-Jan-2022 17:39:00,2022-01-25 17:39:00,25-Jan-2022 17:40:31,00:01:31,https://nsearchives.nseindia.com/corporate/QuickResults25012022signed_25012022173900.pdf,25-01-2022,891.4000244140625,909.0,881.0999755859375,905.6500244140624,894.020751953125,2322693,0.0,0.0,02-02-2022,1
130,CIPLA,Cipla Limited,press release," regarding a press release dated january 13, 2022, titled ""cipla wins the prestigious frost & sullivan and teri s sustainability 4.0 award2021 as  challenger in mega large business pharma sector"".",13-Jan-2022 08:03:29,2022-01-13 08:03:29,13-Jan-2022 08:03:41,00:00:12,https://nsearchives.nseindia.com/corporate/CIPLA_13012022080329_PressReleasESigned.pdf,13-01-2022,912.0,929.1500244140624,908.7000122070312,924.0499877929688,912.1843872070312,2739659,0.0,0.0,20-01-2022,0
131,CIPLA,Cipla Limited,acquisition," about update on intimation dated 3rd november, 2021 on termination of stock purchase and merger agreement ( the spma ) with avenue therapeutics inc.",12-Jan-2022 21:59:50,2022-01-12 21:59:50,12-Jan-2022 21:59:55,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_12012022215950_avenueupdate.pdf,12-01-2022,918.4000244140624,918.4000244140624,901.2000122070312,906.2000122070312,894.5636596679688,2090537,0.0,0.0,19-01-2022,0
132,CIPLA,Cipla Limited,press release," regarding a press release dated december 28, 2021, titled ""cipla receives emergency use authorisation (eua) to launch oral anti-viral drug cipmolnuￂﾮ (molnupiravir 200 mg) in india to treat mild to moderate covid-19 at high risk of developing severe disease"".",28-Dec-2021 12:44:28,2021-12-28 12:44:28,28-Dec-2021 12:44:33,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_28122021124428_PressRelease_281221.pdf,28-12-2021,932.0,936.2999877929688,923.0499877929688,933.2999877929688,921.3156127929688,1907169,0.0,0.0,04-01-2022,0
133,CIPLA,Cipla Limited,press release," regarding a press release dated december 15, 2021, titled ""acquisition of stake in clean max auriga power llp; progresses towards championing its esg agenda."".",15-Dec-2021 17:38:12,2021-12-15 17:38:12,15-Dec-2021 17:38:22,00:00:10,https://nsearchives.nseindia.com/corporate/CIPLA_15122021173812_PressRelease.pdf,15-12-2021,896.2000122070312,901.8499755859376,891.7000122070312,895.7000122070312,884.198486328125,1192775,0.0,0.0,22-12-2021,0
134,CIPLA,Cipla Limited,acquisition, about acquisition of partnership interest in clean max auriga power llp,15-Dec-2021 16:35:18,2021-12-15 16:35:18,15-Dec-2021 16:35:24,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_15122021163518_Letter.pdf,15-12-2021,896.2000122070312,901.8499755859376,891.7000122070312,895.7000122070312,884.198486328125,1192775,0.0,0.0,22-12-2021,0
135,CIPLA,Cipla Limited,updates," regarding 'dissolution of inyanga trading 386 (pty) limited, step-down wholly owned subsidiary'.",14-Dec-2021 19:09:02,2021-12-14 19:09:02,14-Dec-2021 19:09:08,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_14122021190902_Letter.pdf,14-12-2021,893.5,907.8499755859376,891.0,895.5999755859375,884.0997314453125,2651452,0.0,0.0,21-12-2021,0
136,CIPLA,Cipla Limited,press release," regarding a press release dated november 17, 2021, titled ""cipla launches spirofyￂﾮ: strengthens its lung leadership position by facilitating early diagnosis for copd"".",17-Nov-2021 08:14:21,2021-11-17 08:14:21,17-Nov-2021 08:14:27,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_17112021081421_PressRelease17112021signed.pdf,17-11-2021,921.75,921.75,901.0,905.3499755859376,893.7244873046875,1996857,0.0,0.0,25-11-2021,0
137,CIPLA,Cipla Limited,press release," regarding a press release dated november 15, 2021, titled ""cipla ranked as one of the most sustainable healthcare companies in the dow jones sustainability emerging markets index"".",15-Nov-2021 18:26:56,2021-11-15 18:26:56,15-Nov-2021 18:26:58,00:00:02,https://nsearchives.nseindia.com/corporate/CIPLA_15112021182656_Letter15112021rc.pdf,15-11-2021,915.0,939.8499755859376,910.0999755859376,938.1500244140624,926.1033935546876,2615304,0.0,0.0,23-11-2021,0
138,CIPLA,Cipla Limited,updates, regarding 'update on the definitive agreement entered between cipla technologies llc and pulmatrix inc.  for development and commercialization of pulmazole'.,09-Nov-2021 19:45:06,2021-11-09 19:45:06,09-Nov-2021 19:45:14,00:00:08,https://nsearchives.nseindia.com/corporate/CIPLA_09112021194506_Letter_09112021.pdf,09-11-2021,913.0,925.0,909.6500244140624,914.1500244140624,902.4115600585938,843911,0.0,0.0,16-11-2021,0
139,CIPLA,Cipla Limited,acquisition," about update on intimations dated 13th november, 2018 and 8th february, 2019 on acquisition agreement entered between invagen pharmaceuticals inc. and avenue therapeutics inc.",03-Nov-2021 00:09:44,2021-11-03 00:09:44,03-Nov-2021 00:09:54,00:00:10,https://nsearchives.nseindia.com/corporate/CIPLA_03112021000944_Letter03112021.pdf,03-11-2021,909.5499877929688,914.7000122070312,903.7000122070312,912.6500244140624,900.9308471679688,1275433,0.0,0.0,11-11-2021,0
140,CIPLA,Cipla Limited,esop/esos/esps," regarding grant of 19,504 stock options and 69,011 employee stock appreciation rights.",26-Oct-2021 19:09:07,2021-10-26 19:09:07,26-Oct-2021 19:09:12,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_26102021190907_SE_Intimation_Grant_26102021.pdf,26-10-2021,908.9000244140624,914.1500244140624,900.0,907.5,895.846923828125,1405411,0.0,0.0,02-11-2021,0
141,CIPLA,Cipla Limited,press release," regarding a press release dated october 26, 2021, titled ""press release dated 26th october, 2021"".",26-Oct-2021 18:43:35,2021-10-26 18:43:35,26-Oct-2021 18:43:40,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_26102021184335_PressRelease_261021.pdf,26-10-2021,908.9000244140624,914.1500244140624,900.0,907.5,895.846923828125,1405411,0.0,0.0,02-11-2021,0
142,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended september 30, 2021.",26-Oct-2021 18:32:24,2021-10-26 18:32:24,26-Oct-2021 18:34:04,00:01:40,https://nsearchives.nseindia.com/corporate/Results_26102021183224.pdf,26-10-2021,908.9000244140624,914.1500244140624,900.0,907.5,895.846923828125,1405411,0.0,0.0,02-11-2021,0
143,CIPLA,Cipla Limited,press release," regarding a press release dated october 04, 2021, titled ""eli lilly and cipla enter into a strategic partnership in india to enhance access to lilly s key diabetes products"".",04-Oct-2021 08:13:07,2021-10-04 08:13:07,04-Oct-2021 08:13:12,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_04102021081307_Letter_04102021.pdf,04-10-2021,986.0,996.9500122070312,954.9000244140624,957.5,945.2049560546876,4097873,0.0,0.0,11-10-2021,0
144,CIPLA,Cipla Limited,shareholders meeting,"cipla limited has submitted the exchange a copy srutinizers report of  annual general meeting held on august 25, 2021. further, the company has informed the exchange regarding voting results.",26-Aug-2021 01:18:15,2021-08-26 01:18:15,26-Aug-2021 01:18:19,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_26082021011815_VotingResult.pdf,26-08-2021,912.5999755859376,916.75,906.2999877929688,911.2999877929688,899.59814453125,1522032,0.0,0.0,02-09-2021,0
145,CIPLA,Cipla Limited,shareholders meeting," regarding proceedings of annual general meeting held on august 25, 2021",25-Aug-2021 23:46:15,2021-08-25 23:46:15,25-Aug-2021 23:46:20,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_25082021234615_AGM_Proceedings.pdf,25-08-2021,917.0,923.5999755859376,905.9500122070312,912.5999755859376,900.8814086914062,1697757,0.0,0.0,01-09-2021,0
146,CIPLA,Cipla Limited,press release," regarding a press release dated august 25, 2021, titled ""cipla and kemwell biopharma announce execution of a joint venture agreement for developing, manufacturing and commercialising biosimilars"".",25-Aug-2021 15:06:06,2021-08-25 15:06:06,25-Aug-2021 15:06:14,00:00:08,https://nsearchives.nseindia.com/corporate/CIPLA_25082021150606_PressReleaseKemwell.pdf,25-08-2021,917.0,923.5999755859376,905.9500122070312,912.5999755859376,900.8814086914062,1697757,0.0,0.0,01-09-2021,0
147,CIPLA,Cipla Limited,acquisition,"cipla limited has entered into a joint venture agreement with kemwell biopharma private limited on 25th august, 2021 for incorporation of a joint venture company",25-Aug-2021 15:02:22,2021-08-25 15:02:22,25-Aug-2021 15:02:26,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_25082021150222_KemwellJVReg30.pdf,25-08-2021,917.0,923.5999755859376,905.9500122070312,912.5999755859376,900.8814086914062,1697757,0.0,0.0,01-09-2021,0
148,CIPLA,Cipla Limited,press release," regarding a press release dated august 12, 2021, titled ""cipla receives final approval for generic version of novartis pharmaceuticals corporation durezolￂﾮ (difluprednate ophthalmic emulsion 0.05%)"".",12-Aug-2021 08:30:38,2021-08-12 08:30:38,12-Aug-2021 08:30:42,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_12082021083038_Letter_12082021.pdf,12-08-2021,912.0,916.2000122070312,903.7000122070312,905.2999877929688,893.6751708984375,2127392,0.0,0.0,20-08-2021,0
149,CIPLA,Cipla Limited,press release," regarding a press release dated august 05, 2021, titled ""cipla announces q1 fy22 results"".",05-Aug-2021 19:23:27,2021-08-05 19:23:27,05-Aug-2021 19:23:32,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_05082021192327_PressRelease.pdf,05-08-2021,944.2000122070312,953.0,932.0,945.4000244140624,928.1398315429688,4022548,0.0,0.0,12-08-2021,0
150,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended june 30, 2021.",05-Aug-2021 18:59:45,2021-08-05 18:59:45,05-Aug-2021 19:01:02,00:01:17,https://nsearchives.nseindia.com/corporate/Results_30062021_05082021185945.pdf,05-08-2021,944.2000122070312,953.0,932.0,945.4000244140624,928.1398315429688,4022548,0.0,0.0,12-08-2021,0
151,CIPLA,Cipla Limited,copy of newspaper publication,"pursuant to regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015, we are enclosing herewith copies of newspaper advertisements published in business standard (english) and sakal (marathi) today i.e. 2nd august, 2021 which includes the following information:ￂﾠￂﾠ1. intimation of 85th agm of our company to be held on wednesday, 25th august, 2021, at 3.00 p.m. ist through video conferencing (vc) / other audio-visual means (oavm) and completion of email dissemination on 1st august, 2021 of the notice of agm and annual report for financial year 2020-21 to the members whose email ids are registered with the company.ￂﾠￂﾠ2. particulars regarding the facility of remote e-voting provided to shareholders of the company, to enable them to cast their votes on the resolutions proposed to be passed at the agm.ￂﾠￂﾠwith regard to the enclosed notice published in business standard (english) today, the year mentioned under the head of  end of remote e-voting  inadvertently got published as 2020 instead of 2021. the statement with the corrected date be read as  end of remote e-voting - tuesday, 24th august, 2021 (upto 5:00 pm ist) .",02-Aug-2021 23:59:14,2021-08-02 23:59:14,02-Aug-2021 23:59:18,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_02082021235914_se.pdf,02-08-2021,928.2999877929688,933.5999755859376,913.4000244140624,921.0499877929688,904.234375,2981630,0.0,0.0,09-08-2021,0
152,CIPLA,Cipla Limited,copy of newspaper publication,"pursuant to regulation 30 of the sebi (listing obligation and disclosure requirements) regulations, 2015 and in compliance with various circulars issued by the ministry of corporate affairs, we hereby enclose copies of newspaper advertisement published in business standard (english) and sakal (marathi) on 27th july, 2021 intimating the shareholders about the annual general meeting, e-voting, record date and dividend.",27-Jul-2021 21:30:18,2021-07-27 21:30:18,27-Jul-2021 21:30:22,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_27072021213017_StockExchnageintimationfornewspaperadvertismentSigned.pdf,27-07-2021,952.5,958.5,909.0,913.0999755859376,896.429443359375,3366104,0.0,0.0,03-08-2021,0
153,CIPLA,Cipla Limited,book closure,"the company vide letter dated 14th may, 2021 had intimated that the board of directors had recommended payment of dividend of rs. 5 per equity share (face value rs. 2 per equity share) for the financial year 2020-21.we hereby inform that the register of members and share transfer books of the company, will remain closed from 11th august 2021 to 25th august 2021.the dividend, once approved by the members at the 85th agm, will be paid, subject to tds, to those members whose names will appear in the company's register of members as at the close of business hours on tuesday, 10th august, 2021 (record date).",26-Jul-2021 21:28:33,2021-07-26 21:28:33,26-Jul-2021 21:28:38,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_26072021212832_SignedBookClosureSEIntimation.pdf,26-07-2021,948.0,960.0,947.0,950.5499877929688,933.1957397460938,1306026,0.0,0.0,02-08-2021,0
154,CIPLA,Cipla Limited,appointment," regarding appointment of mr ramesh prathivadibhayankara rajagopalan ( mr. p. r. ramesh )  as independent director of the company w.e.f. july 01, 2021.",30-Jun-2021 21:10:35,2021-06-30 21:10:35,30-Jun-2021 21:10:46,00:00:11,https://nsearchives.nseindia.com/corporate/CIPLA_30062021211035_AppointmentStockExchangeintimation.pdf,30-06-2021,992.2000122070312,997.0,969.1500244140624,971.9000244140624,954.156005859375,7195632,0.0,0.0,07-07-2021,0
155,CIPLA,Cipla Limited,copy of newspaper publication,"please find attached herewith copies of newspaper notice published in business standard (english) and sakal (marathi) on 30th june, 2021.the notice published is for those shareholders who have not claimed their dividend(s) for seven consecutive years or more and consequently whose shares are liable for transfer to the iepf as per section 124(6) of the companies act, 2013 read with the investor education and protection fund authority (accounting, audit, transfer and refund) rules, 2016 (including any amendments thereto or re-enactment thereof for the time being in force).this is for your information and records.",30-Jun-2021 15:58:56,2021-06-30 15:58:56,30-Jun-2021 15:59:01,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_30062021155856_Newspaperpublication.pdf,30-06-2021,992.2000122070312,997.0,969.1500244140624,971.9000244140624,954.156005859375,7195632,0.0,0.0,07-07-2021,0
156,CIPLA,Cipla Limited,press release," regarding a press release dated jun 29, 2021, titled ""cipla, dr. reddy s, emcure, sun pharma and torrent to collaborate for clinical trial of investigational anti-viral drug molnupiravir for covid-19 "".",29-Jun-2021 16:02:04,2021-06-29 16:02:04,29-Jun-2021 16:02:16,00:00:12,https://nsearchives.nseindia.com/corporate/CIPLA_29062021160204_PressRelease_29062021.pdf,29-06-2021,964.0,989.0,960.0499877929688,979.5999755859376,961.7153930664062,4300755,0.0,0.0,06-07-2021,0
157,CIPLA,Cipla Limited,press release," regarding a press release dated jun 23, 2021, titled ""cipla receives final approval for generic version of sunovion pharmaceuticals, inc. s brovanaￂﾮ "".",23-Jun-2021 10:55:16,2021-06-23 10:55:16,23-Jun-2021 10:55:22,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_23062021105516_PressRelease_23062021.pdf,23-06-2021,956.0,966.0,954.2000122070312,957.75,940.2643432617188,1807471,0.0,0.0,30-06-2021,0
158,CIPLA,Cipla Limited,press release," regarding a press release dated jun 14, 2021, titled ""avenue therapeutics receives complete response letter from the fda for iv tramadol "".",15-Jun-2021 08:59:06,2021-06-15 08:59:06,15-Jun-2021 08:59:15,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_15062021085906_PressReleaseAvenue15062021.pdf,15-06-2021,975.0,978.8499755859376,967.1500244140624,969.7000122070312,951.9961547851562,1289684,0.0,0.0,22-06-2021,0
159,CIPLA,Cipla Limited,related party transactions,"pursuant to regulation 23(9) of sebi (listing obligations and disclosure requirements) regulations, 2015, please find enclosed herewith disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards, for the half year ended 31st march, 2021.",08-Jun-2021 16:09:25,2021-06-08 16:09:25,08-Jun-2021 16:09:36,00:00:11,https://nsearchives.nseindia.com/corporate/CIPLA_08062021160925_RPTDisclosure_Final.pdf,08-06-2021,939.7999877929688,955.0,931.8499755859376,953.75,936.33740234375,2278534,0.0,0.0,15-06-2021,0
160,CIPLA,Cipla Limited,press release," regarding a press release dated may 24, 2021, titled ""roche s antibody cocktail (casirivimab and imdevimab) is now available in india, cipla to market it pan-india"".",24-May-2021 08:23:34,2021-05-24 08:23:34,24-May-2021 08:23:39,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_24052021082333_PressRelease24052021.pdf,24-05-2021,931.0,945.5,926.1500244140624,931.25,914.2481079101562,6420035,0.0,0.0,31-05-2021,0
161,CIPLA,Cipla Limited,press release," regarding a press release dated may 20, 2021, titled ""cipla launches  viragen  a polymerase chain reaction (covid-19 rt-pcr) test"".",20-May-2021 08:32:45,2021-05-20 08:32:45,20-May-2021 08:32:50,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_20052021083245_Letter20052021.pdf,20-05-2021,906.0,927.9000244140624,905.0,924.2000122070312,907.3268432617188,12378690,0.0,0.0,27-05-2021,0
162,CIPLA,Cipla Limited,esop/esos/esps, regarding grant of 163239 stock options and 361727 employee stock appreciation rights.,14-May-2021 19:28:44,2021-05-14 19:28:44,14-May-2021 19:28:53,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_14052021192844_SE_Intimation_Grant_14052021_signed.pdf,14-05-2021,909.0,921.0,900.7999877929688,904.0499877929688,887.544677734375,15048471,0.0,0.0,21-05-2021,0
163,CIPLA,Cipla Limited,appointment," regarding appointment of mr robert a. stewart as independent director of the company w.e.f. may 14, 2021.",14-May-2021 19:17:47,2021-05-14 19:17:47,14-May-2021 19:17:54,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_14052021191747_Appointment_of_Director.pdf,14-05-2021,909.0,921.0,900.7999877929688,904.0499877929688,887.544677734375,15048471,0.0,0.0,21-05-2021,0
164,CIPLA,Cipla Limited,dividend," that board of directors at its meeting held on may 14, 2021, recommended final dividend of 5 per equity share.",14-May-2021 19:03:33,2021-05-14 19:03:33,14-May-2021 19:03:42,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_14052021190333_OutcomeClosingtime_signed.pdf,14-05-2021,909.0,921.0,900.7999877929688,904.0499877929688,887.544677734375,15048471,0.0,0.0,21-05-2021,0
165,CIPLA,Cipla Limited,press release," regarding a press release dated may 14, 2021, titled ""press release dated 14th may, 2021"".",14-May-2021 18:44:43,2021-05-14 18:44:43,14-May-2021 18:44:50,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_14052021184443_PressRelease_signed.pdf,14-05-2021,909.0,921.0,900.7999877929688,904.0499877929688,887.544677734375,15048471,0.0,0.0,21-05-2021,0
166,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended march 31, 2021.",14-May-2021 18:12:57,2021-05-14 18:12:57,14-May-2021 18:14:01,00:01:04,https://nsearchives.nseindia.com/corporate/QuickResultsQCR_signed_14052021181257.pdf,14-05-2021,909.0,921.0,900.7999877929688,904.0499877929688,887.544677734375,15048471,0.0,0.0,21-05-2021,0
167,CIPLA,Cipla Limited,press release," regarding a press release dated may 10, 2021, titled ""cipla enters into a licensing agreement with lilly to expand access to covid-19 treatment in india "".",10-May-2021 08:55:43,2021-05-10 08:55:43,10-May-2021 08:55:49,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_10052021085543_Pressrelease10052021.pdf,10-05-2021,892.5,906.4500122070312,877.5,900.25,883.8140869140625,8379304,0.0,0.0,18-05-2021,0
168,CIPLA,Cipla Limited,press release," regarding a press release dated may 05, 2021, titled ""roche receives emergency use authorisation in india for its investigational antibody cocktail (casirivimab and imdevimab) used in the treatment of covid-19"".",05-May-2021 17:12:28,2021-05-05 17:12:28,05-May-2021 17:12:37,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_05052021171228_Letter05052021.pdf,05-05-2021,885.0,899.0,869.0,888.6500244140625,872.4258422851562,10491085,0.0,0.0,12-05-2021,0
169,CIPLA,Cipla Limited,press release," regarding a press release dated april 28, 2021, titled ""cipla enters into a licensing agreement with msd to expand access to investigational oral therapeutic drug for covid-19 treatment"".",28-Apr-2021 15:02:18,2021-04-28 15:02:18,28-Apr-2021 15:02:24,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_28042021150218_Letter28042021.pdf,28-04-2021,914.3499755859376,918.0,902.9500122070312,910.2000122070312,893.5823974609375,7251009,0.0,0.0,05-05-2021,0
170,CIPLA,Cipla Limited,updates," regarding 'we are enclosing certified copy of the minutes of resolutions passed through postal ballot by way of remote evoting process on 25th march, 2021. the results of postal ballot were announced vide our letter dated 26th march, 2021'.",23-Apr-2021 23:05:38,2021-04-23 23:05:38,23-Apr-2021 23:05:41,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_23042021230538_Minutes_intimation_23042021.pdf,23-04-2021,944.3499755859376,952.8499755859376,922.75,935.5999755859376,918.5186767578124,7972589,0.0,0.0,30-04-2021,0
171,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"ￂﾠpromoter/member of the promoter group of the company has informed the exchange regarding disclosure under regulation 30 and regulation 31(4) of sebi sast regulations 2011ￂﾠas at march 31, 2021.",19-Apr-2021 18:43:30,2021-04-19 18:43:30,19-Apr-2021 18:43:34,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_19042021184329_Cipla30_19042021172034.zip,19-04-2021,945.25,955.0,924.0,946.2999877929688,929.0233764648438,17805574,0.0,0.0,27-04-2021,0
172,CIPLA,Cipla Limited,shareholders meeting," a copy of srutinizers report of postal ballot. further, the company has informed the exchange regarding voting results.",26-Mar-2021 14:54:10,2021-03-26 14:54:10,26-Mar-2021 14:54:14,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_26032021145410_Letter26032021.pdf,26-03-2021,791.0,799.0,781.25,787.4500122070312,773.073486328125,2934548,0.0,0.0,06-04-2021,1
173,CIPLA,Cipla Limited,updates, regarding 're-appointment of mr. umang vohra as managing director and global chief executive officer'.,23-Mar-2021 14:37:00,2021-03-23 14:37:00,23-Mar-2021 14:37:07,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_23032021143700_Letter23032021.pdf,23-03-2021,775.0,779.4000244140625,768.4000244140625,776.0999755859375,761.9306640625,2118532,0.0,0.0,31-03-2021,1
174,CIPLA,Cipla Limited,press release," regarding a press release dated march 23, 2021, titled ""cipla therapeutics and siga technologies announce strategic partnership to support innovation and provide access to novel antibacterial drugs against biothreats"".",23-Mar-2021 08:24:30,2021-03-23 08:24:30,23-Mar-2021 08:24:35,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_23032021082430_PressRelease23032021.pdf,23-03-2021,775.0,779.4000244140625,768.4000244140625,776.0999755859375,761.9306640625,2118532,0.0,0.0,31-03-2021,1
175,CIPLA,Cipla Limited,press release," regarding a press release dated march 18, 2021, titled ""cipla pledges support to  terra carta , for a sustainable future"".",18-Mar-2021 21:29:58,2021-03-18 21:29:58,18-Mar-2021 21:30:05,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_18032021212958_PressRelease18032021.pdf,18-03-2021,776.0,778.4500122070312,750.8499755859375,755.1500244140625,741.3632202148438,2894624,0.0,0.0,25-03-2021,0
176,CIPLA,Cipla Limited,press release," regarding a press release dated march 02, 2021, titled ""cipla gulf expands partnership with alvotech for commercialization of biosimilars in australia and new zealand"".",02-Mar-2021 08:52:53,2021-03-02 08:52:53,02-Mar-2021 08:52:57,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_02032021085253_PressReleaseGulf.pdf,02-03-2021,792.5999755859375,815.0,790.7999877929688,811.7999877929688,796.9789428710938,4275166,0.0,0.0,09-03-2021,0
177,CIPLA,Cipla Limited,press release," regarding a press release dated march 02, 2021, titled ""cipla receives final approval for generic version of glaxosmithkline s imitrexￂﾮ (sumatriptan nasal spray, 20 mg)"".",02-Mar-2021 08:43:42,2021-03-02 08:43:42,02-Mar-2021 08:43:49,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_02032021084342_PressReleaseGlaxo.pdf,02-03-2021,792.5999755859375,815.0,790.7999877929688,811.7999877929688,796.9789428710938,4275166,0.0,0.0,09-03-2021,0
178,CIPLA,Cipla Limited,outcome of board meeting," regarding outcome of board meeting held on january 29, 2021.ￂﾠthe board on recommendation of the nomination and remuneration committee, has also approved cipla employee stock appreciation rights scheme- 2021 (esar scheme) under the sebi (share based employee benefits) regulations, 2014 (sbeb regulations), for providing grant of up to 1,75,00,000 stock appreciation rights (esars).the total number of equity shares to be issued toward appreciation of the esars shall not exceed 33,00,000. the exercise period of esars will be not later than five years from the respective date of vesting. this esar scheme is subject to the approval of the shareholders through postal ballot and will be instituted only after such approval has been received and will be implemented in compliance with the applicable regulations including the sbeb regulations.",29-Jan-2021 18:17:42,2021-01-29 18:17:42,29-Jan-2021 18:17:47,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_29012021181742_OutcomeMeeting.pdf,29-01-2021,847.9500122070312,850.8499755859375,820.75,825.9000244140625,810.821533203125,7185812,0.0,0.0,05-02-2021,0
179,CIPLA,Cipla Limited,press release," regarding a press release dated january 29, 2021, titled ""press release"".",29-Jan-2021 16:54:10,2021-01-29 16:54:10,29-Jan-2021 16:54:17,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_29012021165410_PressRelease.pdf,29-01-2021,847.9500122070312,850.8499755859375,820.75,825.9000244140625,810.821533203125,7185812,0.0,0.0,05-02-2021,0
180,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended december 31, 2020.",29-Jan-2021 16:33:23,2021-01-29 16:33:23,29-Jan-2021 16:35:02,00:01:39,https://nsearchives.nseindia.com/corporate/QuickResultsFinalSigned_29012021163323.zip,29-01-2021,847.9500122070312,850.8499755859375,820.75,825.9000244140625,810.821533203125,7185812,0.0,0.0,05-02-2021,0
181,CIPLA,Cipla Limited,press release," regarding a press release dated january 27, 2021, titled ""cipla champions its commitment to carbon neutrality with its 30 mw solar plant in maharashtra"".",27-Jan-2021 14:24:54,2021-01-27 14:24:54,27-Jan-2021 14:24:58,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_27012021142454_PressRelease27012021.pdf,27-01-2021,839.9000244140625,856.4500122070312,825.2000122070312,842.5,827.1184692382812,7410174,0.0,0.0,03-02-2021,0
182,CIPLA,Cipla Limited,copy of newspaper publication," about copy of newspaper publication published in newspapers viz. business standard and sakal on 7th january, 2021",07-Jan-2021 13:16:01,2021-01-07 13:16:01,07-Jan-2021 13:16:14,00:00:13,https://nsearchives.nseindia.com/corporate/CIPLA_07012021131601_NewspaperAdvt.pdf,07-01-2021,830.0,830.4500122070312,818.0,826.5499877929688,811.4596557617188,2879675,0.0,0.0,14-01-2021,0
183,CIPLA,Cipla Limited,press release," regarding a press release dated december 17, 2020, titled ""avenue therapeutics provides regulatory update for iv tramadol"".",18-Dec-2020 11:14:04,2020-12-18 11:14:04,18-Dec-2020 11:14:19,00:00:15,https://nsearchives.nseindia.com/corporate/CIPLA_18122020111404_Pressreleasefinalsigned.pdf,18-12-2020,784.25,796.0,781.5,793.4500122070312,778.9639892578125,6487014,0.0,0.0,28-12-2020,0
184,CIPLA,Cipla Limited,press release," regarding a press release dated december 16, 2020, titled ""cipla launches  ciptest  rapid antigen detection test forcovid-19 diagnosis"".",16-Dec-2020 08:33:52,2020-12-16 08:33:52,16-Dec-2020 08:33:56,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_16122020083352_Pressreleasesigned.pdf,16-12-2020,790.3499755859375,790.3499755859375,782.2999877929688,786.7999877929688,772.4353637695312,3817724,0.0,0.0,23-12-2020,0
185,CIPLA,Cipla Limited,press release," regarding a press release dated december 11, 2020, titled ""cipla announces settlement of revlimidￂﾮ (lenalidomide) capsulespatent litigation"".",11-Dec-2020 17:52:33,2020-12-11 17:52:33,11-Dec-2020 17:52:38,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_11122020175233_PressRelease11122020.pdf,11-12-2020,764.0,766.0999755859375,753.0,755.8499755859375,742.0503540039062,3178041,0.0,0.0,18-12-2020,0
186,CIPLA,Cipla Limited,related party transactions,"pursuant to regulation 23(9) of sebi (listing obligations and disclosure requirements)regulations, 2015, please find enclosed herewith disclosure of related party transactions on aconsolidated basis, in the format specified in the accounting standards, for the half year ended30th september, 2020.",03-Dec-2020 15:59:16,2020-12-03 15:59:16,03-Dec-2020 15:59:21,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_03122020155916_RPTDisclosure03122020.pdf,03-12-2020,760.0,764.7999877929688,756.0499877929688,762.1500244140625,748.2354125976562,3765555,0.0,0.0,10-12-2020,0
187,CIPLA,Cipla Limited,press release," regarding a press release dated november 18, 2020, titled ""cipla launches  covi-g  for covid-19 rapid antibody detection"".",18-Nov-2020 08:40:31,2020-11-18 08:40:31,18-Nov-2020 08:40:35,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_18112020084031_PressRelease18112020.pdf,18-11-2020,747.2999877929688,752.0,733.5,742.9500122070312,729.3859252929688,7190828,0.0,0.0,25-11-2020,0
188,CIPLA,Cipla Limited,updates, regarding 'transfer of shares as per sebi circular nos. sebi/ho/mirsd/dos3/cir/p/2018/139 dated 6th november 2018 and sebi/ho/mirsd/rtamb/cir/p/2020/166 dated 7th september 2020'.,10-Nov-2020 12:35:38,2020-11-10 12:35:38,10-Nov-2020 12:35:42,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_10112020123538_Letter101120202.pdf,10-11-2020,769.7999877929688,769.7999877929688,706.5,717.2999877929688,704.2042236328125,22558440,0.0,0.0,17-11-2020,0
189,CIPLA,Cipla Limited,press release," regarding a press release dated november 06, 2020, titled ""cipla announces q2 fy21 results"".",06-Nov-2020 18:18:54,2020-11-06 18:18:54,06-Nov-2020 18:18:57,00:00:03,https://nsearchives.nseindia.com/corporate/CIPLA_06112020181854_PressReleaser06112020.pdf,06-11-2020,797.4000244140625,802.0,786.5499877929688,789.9500122070312,775.52783203125,7765316,0.0,0.0,13-11-2020,-1
190,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended september 30, 2020.",06-Nov-2020 18:14:26,2020-11-06 18:14:26,06-Nov-2020 18:16:03,00:01:37,https://nsearchives.nseindia.com/corporate/UAFR06112020_06112020181426.zip,06-11-2020,797.4000244140625,802.0,786.5499877929688,789.9500122070312,775.52783203125,7765316,0.0,0.0,13-11-2020,-1
191,CIPLA,Cipla Limited,press release," regarding a press release dated october 28, 2020, titled ""cipla launches  elifast  (igg elisa test) for covid-19 antibody detection"".",28-Oct-2020 16:15:04,2020-10-28 16:15:04,28-Oct-2020 16:15:10,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_28102020161504_PressRelease28102020.pdf,28-10-2020,771.4000244140625,780.0,762.1500244140625,765.25,751.27880859375,7050213,0.0,0.0,04-11-2020,0
192,CIPLA,Cipla Limited,press release," regarding a press release dated october 20, 2020, titled ""cipla launches nintib (nintedanib capsules 100 mg, 150 mg) to treat idiopathic pulmonary fibrosis, in continuation of its fight against rare lung diseases"".",20-Oct-2020 15:38:05,2020-10-20 15:38:05,20-Oct-2020 15:38:12,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_20102020153805_PressRelease.pdf,20-10-2020,765.0,774.7000122070312,756.2999877929688,764.2999877929688,750.3461303710938,6029701,0.0,0.0,27-10-2020,0
193,CIPLA,Cipla Limited,copy of newspaper publication," about copy of newspaper publication, published in newspapers viz. business standard and sakal on 16th october, 2020.'",16-Oct-2020 17:45:21,2020-10-16 17:45:21,16-Oct-2020 17:45:25,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_16102020174521_Letter_Newspaper.pdf,16-10-2020,766.9500122070312,787.5,758.4000244140625,782.3499755859375,768.0665893554688,9099048,0.0,0.0,23-10-2020,0
194,CIPLA,Cipla Limited,press release," regarding a press release dated october 12, 2020, titled ""avenue therapeutics, inc. receives complete response letter from the fda for iv tramadol"".",12-Oct-2020 16:37:04,2020-10-12 16:37:04,12-Oct-2020 16:37:08,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_12102020163704_Letter_12102020.pdf,12-10-2020,805.0,819.75,800.1500244140625,813.6500244140625,798.795166015625,6612623,0.0,0.0,19-10-2020,-1
195,CIPLA,Cipla Limited,press release," regarding a press release dated september 25, 2020, titled ""cipla receives final approval for generic version of biogen idec inc. s tecfideraￂﾮ (dimethyl fumarate dr capsules 120mg, 240mg and 120mg/240mg starter pack)"".",25-Sep-2020 08:07:30,2020-09-25 08:07:30,25-Sep-2020 08:07:35,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_25092020080730_SignedLetter.pdf,25-09-2020,752.0,777.0,740.4000244140625,770.0999755859375,756.040283203125,13365087,0.0,0.0,05-10-2020,0
196,CIPLA,Cipla Limited,shareholders meeting,"cipla limited has submitted the exchange a copy srutinizers report of  annual general meeting held on august 27, 2020. further, the company has informed the exchange regarding voting results.",28-Aug-2020 11:38:41,2020-08-28 11:38:41,28-Aug-2020 11:38:48,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_28082020113841_Letter.pdf,28-08-2020,763.0,771.0,746.7000122070312,748.5999755859375,734.9327392578125,8205618,0.0,0.0,04-09-2020,0
197,CIPLA,Cipla Limited,shareholders meeting," regarding proceedings of annual general meeting held on august 27, 2020",28-Aug-2020 11:36:06,2020-08-28 11:36:06,28-Aug-2020 11:45:39,00:09:33,https://nsearchives.nseindia.com/corporate/CIPLA_28082020113606_AGMProceedings.pdf,28-08-2020,763.0,771.0,746.7000122070312,748.5999755859375,734.9327392578125,8205618,0.0,0.0,04-09-2020,0
198,CIPLA,Cipla Limited,copy of newspaper publication," about copy of newspaper publication pursuant to to sebi circular dated 6th november, 2018 w.r.t standardised norms for transfer ofsecurities in physical mode.",26-Aug-2020 15:56:39,2020-08-26 15:56:39,26-Aug-2020 15:56:44,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_26082020155639_Letter_26082020.pdf,26-08-2020,751.5,754.0,744.2000122070312,748.0,734.34375,3730702,0.0,0.0,02-09-2020,0
199,CIPLA,Cipla Limited,diversification/disinvestment," about  the company's subsidiaries have signed following agreements:1.  business transfer agreement  between quality chemicals limited, uganda, ( qcl ) and cipla quality chemical industries limited, uganda, ( cqcil ), step-down subsidiaries of the company, to sell human healthcare business of qcl to cqcil, at a consideration of usd 1,271,747. 2.  share sale and purchase agreement  between company s wholly owned subsidiary cipla (eu) limited, united kingdom, qcl, mr. emmanuel katangole, mr. fredrick mutebi kitaka and mr. george baguma to sell entire stake aggregating to 51% of the total paid-up equity share capital in qcl, held by cipla (eu) limited to mr. emmanuel katangole, mr. fredrick mutebi kitaka and mr. george baguma for a total consideration of usd 344,239. subsequent to the sale, qcl will cease to be a subsidiary of the company.",20-Aug-2020 23:40:22,2020-08-20 23:40:22,20-Aug-2020 23:40:26,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_20082020234022_CiplaQCLstakesale.pdf,20-08-2020,758.3499755859375,771.75,758.3499755859375,762.7000122070312,748.775390625,8167570,0.0,0.0,27-08-2020,0
200,CIPLA,Cipla Limited,press release," regarding a press release dated august 20, 2020, titled ""pess release dated 20th august 2020"".",20-Aug-2020 12:49:26,2020-08-20 12:49:26,20-Aug-2020 12:49:33,00:00:07,https://nsearchives.nseindia.com/corporate/CIPLA_20082020124926_Letter_20082020.pdf,20-08-2020,758.3499755859375,771.75,758.3499755859375,762.7000122070312,748.775390625,8167570,0.0,0.0,27-08-2020,0
201,CIPLA,Cipla Limited,updates," regarding 'the agreement entered into between company s wholly owned subsidiary (wos) cipla medpro south africa proprietary limited (cmsa) and regipharm medical proprietary limited, south africa, to sell its entire equity stake in anmaratￃﾩ proprietary limited, south africa, wos of cmsa as a part of group simplification. subsequent to the sale, anmaratￃﾩ proprietary limited will cease to be a subsidiary of the company. anmaratￃﾩ proprietary limited is a dormant step-down wholly owned subsidiary of the company and does not carry out any operation.'.",20-Aug-2020 00:00:50,2020-08-20 00:00:50,20-Aug-2020 00:01:07,00:00:17,https://nsearchives.nseindia.com/corporate/CIPLA_20082020000050_Letter.pdf,20-08-2020,758.3499755859375,771.75,758.3499755859375,762.7000122070312,748.775390625,8167570,0.0,0.0,27-08-2020,0
202,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended june 30, 2020.",07-Aug-2020 18:43:42,2020-08-07 18:43:42,07-Aug-2020 18:45:03,00:01:21,https://nsearchives.nseindia.com/corporate/Outcome_07082020184342.zip,07-08-2020,738.0,739.6500244140625,724.5,728.6500244140625,715.3470458984375,6159632,0.0,0.0,14-08-2020,1
203,CIPLA,Cipla Limited,press release," regarding a press release dated august 07, 2020, titled ""please find attached press release dated 7th august 2020"".",07-Aug-2020 18:28:51,2020-08-07 18:28:51,07-Aug-2020 18:28:57,00:00:06,https://nsearchives.nseindia.com/corporate/CIPLA_07082020182851_PressRelease.pdf,07-08-2020,738.0,739.6500244140625,724.5,728.6500244140625,715.3470458984375,6159632,0.0,0.0,14-08-2020,1
204,CIPLA,Cipla Limited,copy of newspaper publication," that pursuant to regulation 47 read with regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015, we are enclosing herewith copies of newspaper advertisement published in business standard (english) and sakal (marathi) today i.e. 6th august, 2020 which includes the following information:1. intimation of 84th annual general meeting (agm) of our company to be held through video conferencing / other audio-visual means and confirmation of dispatch of annual report for the financial year 2019-20, along with notice of the agm.2. particulars of the facility of e-voting provided to shareholders of the company, to enable them to cast their votes on the resolutions proposed to be passed at the agm.this is for your information and record.",06-Aug-2020 17:41:17,2020-08-06 17:41:17,06-Aug-2020 17:41:21,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_06082020174117_letter06082020rc.pdf,06-08-2020,724.9500122070312,739.7000122070312,720.0999755859375,731.0999755859375,717.7522583007812,9663886,0.0,0.0,13-08-2020,0
205,CIPLA,Cipla Limited,shareholders meeting," regarding notice of annual general meeting to be held on august 27, 2020",05-Aug-2020 02:41:05,2020-08-05 02:41:05,05-Aug-2020 02:41:14,00:00:09,https://nsearchives.nseindia.com/corporate/CIPLA_05082020024105_SEIntimationNoticeARrc.pdf,05-08-2020,720.7999877929688,729.9500122070312,716.0,722.1500244140625,708.9656982421875,5263136,0.0,0.0,12-08-2020,1
206,CIPLA,Cipla Limited,copy of newspaper publication," that pursuant to regulation 42 of the sebi (listing obligations and disclosure requirements), 2015, the register of members and share transfer books of the company will remain closed from thursday, 13th august, 2020 to thursday, 27th august, 2020 (both days inclusive) for the purpose of 84th annual general meeting to be held on 27th august, 2020 through video conferencing (vc) / other audio visual means (oavm).we are enclosing herewith the copies of newspaper notice of book closure published in business standard (english) and sakal (marathi) today, i.e. 3rd august, 2020.",03-Aug-2020 17:44:18,2020-08-03 17:44:18,03-Aug-2020 17:44:22,00:00:04,https://nsearchives.nseindia.com/corporate/CIPLA_03082020174418_Letter03082020rc.pdf,03-08-2020,724.0,734.2000122070312,701.0,710.4000244140625,697.4302368164062,12500683,0.0,0.0,10-08-2020,1
207,CIPLA,Cipla Limited,book closure," that register of members & share transfer books of the company will remain closed from 13-aug-2020 to 27-aug-2020 for the purpose of 84th annual general meeting.we are also enclosing herewith the copies of newspaper notice of book closure published in business standard (english) and sakal (marathi) today, i.e. 3rd august, 2020.",03-Aug-2020 17:11:11,2020-08-03 17:11:11,03-Aug-2020 17:11:16,00:00:05,https://nsearchives.nseindia.com/corporate/CIPLA_03082020171111_Letter03082020rc.pdf,03-08-2020,724.0,734.2000122070312,701.0,710.4000244140625,697.4302368164062,12500683,0.0,0.0,10-08-2020,1
208,CIPLA,Cipla Limited,news verification,the exchange has sought clarification from cipla limited with respect to recent news item captioned cipla all set to launch favipiravir drug for treatment of covid patients.  the response from the company is attached.,27-Jul-2020 09:31:00,2020-07-27 09:31:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_27072020093113_ClarificationLetter.PDF,27-07-2020,673.9500122070312,673.9500122070312,650.4000244140625,652.9000244140625,640.97998046875,4465020,0.0,0.0,03-08-2020,1
209,CIPLA,Cipla Limited,press release," regarding a press release dated july 24, 2020, titled ""press release   cipla receives regulatory approval for launch of ciplenza (favipiravir 200 mg) in india to treat mild to moderate covid-19"".",24-Jul-2020 16:48:00,2020-07-24 16:48:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_24072020164803_Letter14july2020.pdf,24-07-2020,673.0,681.0,658.2000122070312,666.0499877929688,653.889892578125,4962702,0.0,0.0,31-07-2020,1
210,CIPLA,Cipla Limited,restructuring,"disclosure under regulation 30 of sebi (listing obligation and disclosure requirements), 2015",21-Jul-2020 23:23:00,2020-07-21 23:23:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_21072020232346_SE21072020v1rc.pdf,21-07-2020,676.0999755859375,682.0999755859375,660.0,662.2999877929688,650.2083740234375,4314750,0.0,0.0,28-07-2020,0
211,CIPLA,Cipla Limited,updates," regarding 'update on cipla and amgen reach a settlement on pending litigation involving generic cinacalcet hydrochloride tablets (30mg, 60mg and 90mg)'.",20-Jul-2020 09:30:00,2020-07-20 09:30:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_20072020093022_Letter.pdf,20-07-2020,689.0,690.8499755859375,672.3499755859375,674.3499755859375,662.038330078125,5469496,0.0,0.0,27-07-2020,0
212,CIPLA,Cipla Limited,copy of newspaper publication," about copy of newspaper publication.in continuation with our letter dated 15th july, 2020, please find enclosed notice of the board meeting published in newspapers viz. business standard and sakal on 16th july, 2020.'",16-Jul-2020 14:46:00,2020-07-16 14:46:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_16072020144620_Letter16072020rc.pdf,16-07-2020,639.9500122070312,677.4000244140625,635.9000244140625,674.5,662.1856079101562,16098128,0.0,0.0,23-07-2020,0
213,CIPLA,Cipla Limited,press release," regarding a press release dated july 14, 2020, titled ""cipla receives final approval for generic version of shire s firazyrￂﾮ (icatibant injectable pre-filled syringe 30mg/3ml)"".",14-Jul-2020 08:28:00,2020-07-14 08:28:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_14072020082822_FinalLetter.pdf,14-07-2020,639.9500122070312,644.0,631.25,632.2999877929688,620.7560424804688,5432821,0.0,0.0,21-07-2020,0
214,CIPLA,Cipla Limited,updates, regarding 'update on the definitive agreement entered between cipla technologies llc and pulmatrix for development and commercialization of pulmazole '.,13-Jul-2020 21:53:00,2020-07-13 21:53:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_13072020215305_Letter.pdf,13-07-2020,641.0,646.0,636.5999755859375,638.3499755859375,626.6956176757812,3450069,0.0,0.0,20-07-2020,1
215,CIPLA,Cipla Limited,press release," regarding a press release dated jun 29, 2020, titled ""cipla and boehringer ingelheim forge partnership to co-market three oral anti-diabetic drugs"".",29-Jun-2020 12:33:00,2020-06-29 12:33:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_29062020123319_Letter_29062020.pdf,29-06-2020,637.0,648.0,635.4000244140625,644.9000244140625,633.1260375976562,6772032,0.0,0.0,06-07-2020,0
216,CIPLA,Cipla Limited,copy of newspaper publication,"please find enclosed herewith copies of newspaper advertisement published in business standard (english) and sakal (marathi) on 19th june 2020.the above notice is for shareholders who have not claimed their dividend(s) for seven consecutive years or more and consequently whose shares are liable for transfer to the iepf as per section 124(6) of the companies act, 2013 read with the investor education and protection fund authority (accounting, audit, transfer and refund) rules, 2016 notified by the ministry of corporate affairs and subsequent amendment(s) from time to time.this is for your information and records.",19-Jun-2020 16:18:00,2020-06-19 16:18:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_19062020161815_Letter.pdf,19-06-2020,648.8499755859375,648.8499755859375,631.5,636.2000122070312,624.5848388671875,4476020,0.0,0.0,26-06-2020,0
217,CIPLA,Cipla Limited,press release," regarding a press release dated jun 18, 2020, titled ""cipla expands partnership with roche pharma india to further improve access to key oncology medicines"".",18-Jun-2020 17:27:00,2020-06-18 17:27:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_18062020172709_Pressrelease_20200618.pdf,18-06-2020,641.6500244140625,644.7999877929688,636.4000244140625,642.0499877929688,630.3280639648438,2161524,0.0,0.0,25-06-2020,0
218,CIPLA,Cipla Limited,related party transactions,"pursuant to regulation 23(9) of sebi (listing obligations and disclosure requirements) regulations, 2015, please find enclosed herewith disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards, for the half year ended 31st march, 2020.",12-Jun-2020 20:06:00,2020-06-12 20:06:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_12062020200631_RPT_20200331.pdf,12-06-2020,616.2999877929688,645.0,616.2999877929688,643.5999755859375,631.8497314453125,5579009,0.0,0.0,19-06-2020,0
219,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"promoter of  regarding disclosure regulation 30(1), 30(2) and 31(4) of sebi (substantial acquisition of shares and takeovers) regulations, 2011",01-Jun-2020 11:25:00,2020-06-01 11:25:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_01062020112537_ciplanew_30052020195529.zip,01-06-2020,649.0,652.5999755859375,634.5499877929688,642.5,630.7698974609375,7439123,0.0,0.0,08-06-2020,0
220,CIPLA,Cipla Limited,press release," regarding a press release dated may 21, 2020, titled ""cipla limited receives final approval for generic version of migranalￂﾮ (dihydroergotamine mesylate nasal spray 4mg/ml) with a competitive generic therapy designation "".",21-May-2020 08:13:00,2020-05-21 08:13:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_21052020081344_Letter.pdf,21-05-2020,620.6500244140625,626.8499755859375,612.2999877929688,616.5999755859375,605.3427124023438,7916771,0.0,0.0,29-05-2020,1
221,CIPLA,Cipla Limited,press release," regarding a press release dated may 18, 2020, titled ""cipla files anda for generic version of gsk s advair diskus ￂﾮ"".",18-May-2020 08:12:00,2020-05-18 08:12:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_18052020081215_Letter.pdf,18-05-2020,570.5999755859375,605.0,570.5,600.4500122070312,589.487548828125,22898114,0.0,0.0,26-05-2020,0
222,CIPLA,Cipla Limited,press release," regarding a press release dated may 15, 2020, titled ""press release dated 15th may 2020"".",15-May-2020 19:12:00,2020-05-15 19:12:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_15052020191250_PressRelease_combinedsigned.pdf,15-05-2020,572.0,585.0,565.5999755859375,570.2999877929688,559.8880004882812,14388403,0.0,0.0,22-05-2020,1
223,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended march 31, 2020.",15-May-2020 18:56:52,2020-05-15 18:56:52,-,-,https://nsearchives.nseindia.com/corporate/resultssigned1_15052020185652.zip,15-05-2020,572.0,585.0,565.5999755859375,570.2999877929688,559.8880004882812,14388403,0.0,0.0,22-05-2020,1
224,CIPLA,Cipla Limited,press release," regarding a press release dated may 13, 2020, titled ""cipla enters into a licensing agreement with gilead to expand access to covid-19 treatment "".",13-May-2020 08:14:00,2020-05-13 08:14:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_13052020081425_Letter.pdf,13-05-2020,600.0,605.0,568.9000244140625,570.2000122070312,559.7898559570312,10438589,0.0,0.0,20-05-2020,1
225,CIPLA,Cipla Limited,press release," regarding a press release dated april 21, 2020, titled ""cipla stands strong with india in the battle against covid-19 "".",21-Apr-2020 12:01:00,2020-04-21 12:01:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_21042020120110_Letter.pdf,21-04-2020,578.0,609.7999877929688,570.0,592.0999755859375,581.2899169921875,14471856,0.0,0.0,28-04-2020,0
226,CIPLA,Cipla Limited,dividend updates, regarding delay in dispatch of demand drafts and dividend warrants due to the current lockdown situation.ￂﾠ,13-Apr-2020 08:29:00,2020-04-13 08:29:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_13042020082951_Letter.pdf,13-04-2020,605.0,605.0,583.0,592.8499755859375,582.0263061523438,15483858,0.0,0.0,21-04-2020,0
227,CIPLA,Cipla Limited,press release," regarding a press release dated april 09, 2020, titled ""cipla receives final approval for generic version of proventilￂﾮ hfa inhalation aerosol (albuterol sulfate inhalation aerosol 90mcg (base)/actuation)"".",09-Apr-2020 08:33:00,2020-04-09 08:33:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_09042020083338_Letter.PDF,09-04-2020,564.0,610.0,564.0,579.5999755859375,569.0181884765625,27207708,0.0,0.0,20-04-2020,0
228,CIPLA,Cipla Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",31-Mar-2020 20:14:00,2020-03-31 20:14:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31032020201420_Letter.pdf,31-03-2020,446.0,446.6000061035156,420.0,422.8500061035156,415.1300048828125,9434602,0.0,0.0,09-04-2020,1
229,CIPLA,Cipla Limited,press release," regarding a press release dated march 26, 2020, titled ""cipla receives final approval for generic version of astrazeneca pharmaceutical s nexiumￂﾮ (esomeprazole for oral suspension 10mg, 20mg and 40mg)"".",26-Mar-2020 08:26:00,2020-03-26 08:26:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_26032020082642_Letter.pdf,26-03-2020,383.0,394.7000122070313,380.5,386.1499938964844,379.10003662109375,4291225,0.0,0.0,03-04-2020,1
230,CIPLA,Cipla Limited,updates," regarding 'pursuant to regulation 30 and 47 of the sebi (listing obligations and disclosure requirements) regulations, 2015, please find enclosed newspaper cuttings of the noticepublished in business standard (english) and sakal (marathi), today, i.e. 131h march, 2020,for fixation of record date for payment of interim and one-time special dividend for thefy 2019-20.'.",13-Mar-2020 17:49:00,2020-03-13 17:49:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_13032020174940_Letter.pdf,13-03-2020,388.0,434.9500122070313,355.29998779296875,425.5499877929688,416.6983947753906,6096891,0.0,0.0,20-03-2020,-1
231,CIPLA,Cipla Limited,dividend updates," that the board of directors of the company at its meeting held today i.e. 12th march 2020, has approved payment of interim dividend of rs. 3 per equity share (i.e. 150%) and one-time special dividend of rs. 1 per equity share (i.e. 50%) of face value rs. 2 each for the financial year 2019-20. the total dividend approved is rs. 4 per equity share (i.e. 200%) of face value rs. 2 each for the financial year 2019-20. the interim dividend and one-time special dividend will be paid to the members whose names appear in the register of members or in the records of the depositories as beneficial owners of the shares of the company as on the record date i.e. friday, 20th march 2020, within 30 days from the date of meeting.",12-Mar-2020 18:43:00,2020-03-12 18:43:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_12032020184312_Outcome.pdf,12-03-2020,412.5,412.5,390.75,394.75,386.5390319824219,5636464,0.0,0.0,19-03-2020,-1
232,CIPLA,Cipla Limited,dividend," that board of directors at its meeting held on march 12, 2020, declared interim dividend of 3 per equity share and one-time special dividend of rs. 1 per equity share.",12-Mar-2020 18:21:00,2020-03-12 18:21:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_12032020182125_Outcome.pdf,12-03-2020,412.5,412.5,390.75,394.75,386.5390319824219,5636464,0.0,0.0,19-03-2020,-1
233,CIPLA,Cipla Limited,updates, regarding 'update on usfda inspection at cipla's manufacturing facility in goa'.,26-Feb-2020 08:52:00,2020-02-26 08:52:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_26022020085212_Letter.pdf,26-02-2020,406.0,425.0,405.7999877929688,422.2000122070313,413.4180603027344,8068909,0.0,0.0,04-03-2020,1
234,CIPLA,Cipla Limited,trading window," regarding the trading window closure pursuant to sebi (prohibition of insider trading) regulations, 2015",20-Feb-2020 17:05:00,2020-02-20 17:05:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_20022020170509_Letter.pdf,20-02-2020,448.0,448.7999877929688,434.5,435.75,426.6862182617188,3048500,0.0,0.0,28-02-2020,-1
235,CIPLA,Cipla Limited,record date," that the company has fixed record date as march 20, 2020 for the purpose of interim dividends",20-Feb-2020 17:04:00,2020-02-20 17:04:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_20022020170406_Cipla.pdf,20-02-2020,448.0,448.7999877929688,434.5,435.75,426.6862182617188,3048500,0.0,0.0,28-02-2020,-1
236,CIPLA,Cipla Limited,press release," regarding a press release dated february 10, 2020, titled ""cipla medpro south africa (pty) ltd signs agreement for anti - psychotic drug. "".",10-Feb-2020 21:01:00,2020-02-10 21:01:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_10022020210159_Letter.pdf,10-02-2020,444.2000122070313,451.0,442.1000061035156,444.75,435.4989929199219,3557480,0.0,0.0,17-02-2020,0
237,CIPLA,Cipla Limited,press release," regarding a press release dated february 05, 2020, titled ""please find enclosed letter dated 5th february, 2020"".",05-Feb-2020 15:34:00,2020-02-05 15:34:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_05022020153418_Letter.pdf,05-02-2020,449.5499877929688,459.1499938964844,437.5,447.5499877929688,438.2407836914063,3637403,0.0,0.0,12-02-2020,0
238,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended december 31, 2019.",05-Feb-2020 15:18:46,2020-02-05 15:18:46,-,-,https://nsearchives.nseindia.com/corporate/Letter_05022020151846.zip,05-02-2020,449.5499877929688,459.1499938964844,437.5,447.5499877929688,438.2407836914063,3637403,0.0,0.0,12-02-2020,0
239,CIPLA,Cipla Limited,updates," regarding 'usfda cgmp inspection completed at cipla's api manufacturing facility inbommasandra, bangalore'.",24-Jan-2020 21:08:00,2020-01-24 21:08:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_24012020210650_Letter_286.pdf,24-01-2020,465.0,467.75,456.8500061035156,458.8500061035156,449.30572509765625,2713370,0.0,0.0,31-01-2020,0
240,CIPLA,Cipla Limited,updates, regarding 'update on usfda inspection at cipla's manufacturing facility in goa'.,22-Jan-2020 21:31:00,2020-01-22 21:31:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_22012020213107_Letter_298.pdf,22-01-2020,474.5,480.2999877929688,470.25,471.6000061035156,461.79052734375,2380518,0.0,0.0,29-01-2020,0
241,CIPLA,Cipla Limited,updates," regarding 'in continuation to our letter dated 6th january, 2020, please find enclosed notice of the board meeting published in newspapers viz. businessstandard and sakal on 7th january, 2020.'.",07-Jan-2020 18:51:00,2020-01-07 18:51:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_07012020184946_Letter_324.pdf,07-01-2020,466.0,470.0,463.6499938964844,468.6000061035156,458.85296630859375,2365554,0.0,0.0,14-01-2020,0
242,CIPLA,Cipla Limited,press release," regarding a press release dated december 16, 2019, titled ""cipla limited acquires trademark rights of vysov"".",16-Dec-2019 16:03:00,2019-12-16 16:03:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_16122019160224_Letter_101.pdf,16-12-2019,463.0499877929688,464.75,457.5,458.25,448.71820068359375,903737,0.0,0.0,23-12-2019,0
243,CIPLA,Cipla Limited,press release," regarding a press release dated december 11, 2019, titled ""avenue therapeutics inc., usa, associate company of cipla limited announces submission of new drug application for iv tramadol "".",11-Dec-2019 21:59:00,2019-12-11 21:59:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_11122019215805_Letter_333.pdf,11-12-2019,453.0,453.1000061035156,446.7000122070313,449.9500122070313,440.5908508300781,1806996,0.0,0.0,18-12-2019,0
244,CIPLA,Cipla Limited,updates," regarding 'change in name of registrar and share transfer agent (rta) from ""karvyfintech private limited"" to ""kfin technologies private limited""'.",09-Dec-2019 19:40:00,2019-12-09 19:40:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_09122019193914_Letter_444.pdf,09-12-2019,457.3999938964844,457.75,444.6000061035156,447.8999938964844,438.5834655761719,3761784,0.0,0.0,16-12-2019,0
245,CIPLA,Cipla Limited,related party transactions," regarding disclosure of related party transactions for the half year ended september 30, 2019.",03-Dec-2019 18:54:00,2019-12-03 18:54:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_3122019185216_RPTDisclosure_30092019_291.pdf,03-12-2019,465.0,465.8500061035156,460.0,464.25,454.5934448242188,1067139,0.0,0.0,10-12-2019,0
246,CIPLA,Cipla Limited,acquisition," that its wholly owned subsidiary cipla (eu) limited, holding 60% stake in cipla pharma lanka (private) limited {cipla pharma lanka), sri lanka, has signed an agreement with citihealth imports(private) limited to acquire the remaining 40% stake in cipla pharma lanka. post-acquisition, cipla pharma lanka will become a wholly owned subsidiary.",27-Nov-2019 19:51:00,2019-11-27 19:51:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_27112019194929_SE_Letter_257.pdf,27-11-2019,475.0,475.0,464.5499877929688,468.0,458.2654113769531,3494515,0.0,0.0,04-12-2019,0
247,CIPLA,Cipla Limited,news verification,"the exchange has sought clarification from cipla limited with respect to recent news item captioned wockhardt: cipla, dr reddy's labs, carlyle & asian investment fund pag are in the fray to acquire select business segments of the company, said sources..  the response from the company is attached.",19-Nov-2019 12:44:00,2019-11-19 12:44:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_18112019152427_letter_080.pdf,19-11-2019,461.2000122070313,477.5,459.5499877929688,472.1000061035156,462.2801513671875,5080106,0.0,0.0,26-11-2019,0
248,CIPLA,Cipla Limited,updates, regarding 'usfda routine cgmp inspection completed at cipla's manufacturing facilityin patalganga'.,14-Nov-2019 15:55:00,2019-11-14 15:55:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_14112019155443_Letter_323.pdf,14-11-2019,445.2000122070313,458.2000122070313,442.6499938964844,451.3999938964844,442.0107116699219,2659601,0.0,0.0,21-11-2019,1
249,CIPLA,Cipla Limited,financial results updates," regarding unaudited financial results (standalone and consolidated) for the quarter and half year ended 30th september, 2019.",06-Nov-2019 17:32:00,2019-11-06 17:32:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_611201914107_Letter_391.pdf,06-11-2019,469.0499877929688,487.9500122070313,464.25,480.8500061035156,470.84814453125,17751556,0.0,0.0,14-11-2019,-1
250,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended september 30, 2019.",06-Nov-2019 15:51:41,2019-11-06 15:51:41,-,-,https://nsearchives.nseindia.com/corporate/Letter_06112019155141.zip,06-11-2019,469.0499877929688,487.9500122070313,464.25,480.8500061035156,470.84814453125,17751556,0.0,0.0,14-11-2019,-1
251,CIPLA,Cipla Limited,press release," regarding a press release dated november 06, 2019, titled ""please find attached letter dated 6th november, 2019"".",06-Nov-2019 14:14:00,2019-11-06 14:14:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_06112019141359_Letter_PR_148.pdf,06-11-2019,469.0499877929688,487.9500122070313,464.25,480.8500061035156,470.84814453125,17751556,0.0,0.0,14-11-2019,-1
252,CIPLA,Cipla Limited,analysts/institutional investor meet/con. call updates," regarding analysts/institutional investor meet/con. call updates .the company will host an earnings conference call at 1700 hrs ist (1930 hrs sst/hkt, 1230 hrs bst, 0730 hrs us et), during which the leadership team will discuss the financial performance and take questions. a transcript of the conference call will be available at www.cipla.com.",18-Oct-2019 15:06:00,2019-10-18 15:06:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_18102019150635_Letter_104.pdf,18-10-2019,448.5,451.1499938964844,440.1000061035156,444.1499938964844,434.9114685058594,2850227,0.0,0.0,27-10-2019,0
253,CIPLA,Cipla Limited,press release," regarding a press release dated october 17, 2019, titled ""acquisition of a novel and patented anti-infective asset, elores, from venus remedies limited."".",17-Oct-2019 19:36:00,2019-10-17 19:36:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_17102019193555_finalletter_221.pdf,17-10-2019,445.2999877929688,447.7000122070313,439.3999938964844,446.2999877929688,437.0167541503906,1818421,0.0,0.0,25-10-2019,0
254,CIPLA,Cipla Limited,updates," regarding 'in continuation to our letter dated 14th october 2019, please find enclosed notice of the board meeting published in newspaper viz. business standard and sakaal on 15th october, 2019'.",15-Oct-2019 15:29:00,2019-10-15 15:29:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_15102019152819_Letter_153.pdf,15-10-2019,440.0,448.5,435.3500061035156,446.5499877929688,437.2615661621094,3153015,0.0,0.0,23-10-2019,0
255,CIPLA,Cipla Limited,press release," regarding a press release dated september 25, 2019, titled ""cipla announces the launch of daptomycin for injection, 500 mg/vial, single-dose vials(for intravenous use only)"".",25-Sep-2019 19:44:00,2019-09-25 19:44:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_25092019194233_Letter_309.pdf,25-09-2019,449.8999938964844,450.0,432.2000122070313,434.6000061035156,425.5601501464844,3524655,0.0,0.0,03-10-2019,0
256,CIPLA,Cipla Limited,shareholders meeting,"cipla limited has submitted the exchange a copy srutinizers report of  annual general meeting held on august 16, 2019. further, the company has informed the exchange regarding voting results.",16-Aug-2019 22:38:00,2019-08-16 22:38:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_16082019223803_Letter_410.pdf,16-08-2019,477.0,483.3999938964844,474.5,476.1000061035156,466.1969299316406,1279325,0.0,0.0,23-08-2019,0
257,CIPLA,Cipla Limited,shareholders meeting," regarding proceedings of annual general meeting held on august 16, 2019",16-Aug-2019 22:32:00,2019-08-16 22:32:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_16082019223126_Letter_409.pdf,16-08-2019,477.0,483.3999938964844,474.5,476.1000061035156,466.1969299316406,1279325,0.0,0.0,23-08-2019,0
258,CIPLA,Cipla Limited,updates," regarding 'please find enclosed copy of address made by dr. y.k. hamied- chairman at the 83rd annnual general meeting of the company held on friday, 16th august, 2019 at 3.00 p.m. at birla matushri sabhagar, 19, sir vithaldas thackersey marg, new marine lines, mumbai - 400 020.'.",16-Aug-2019 22:23:00,2019-08-16 22:23:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_16082019222300_ChairmanSpeech_407.pdf,16-08-2019,477.0,483.3999938964844,474.5,476.1000061035156,466.1969299316406,1279325,0.0,0.0,23-08-2019,0
259,CIPLA,Cipla Limited,updates," regarding 'enclosed extract of consolidated unaudited financial results for the quarter ended june 30, 2019.",07-Aug-2019 16:10:00,2019-08-07 16:10:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_782019155914_Letter_314.pdf,07-08-2019,502.7000122070313,525.8499755859375,501.6499938964844,518.2999877929688,507.5191345214844,4668643,0.0,0.0,16-08-2019,-1
260,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended june 30, 2019.",07-Aug-2019 15:39:54,2019-08-07 15:39:54,-,-,https://nsearchives.nseindia.com/corporate/Letter1_07082019153954.zip,07-08-2019,502.7000122070313,525.8499755859375,501.6499938964844,518.2999877929688,507.5191345214844,4668643,0.0,0.0,16-08-2019,-1
261,CIPLA,Cipla Limited,press release," regarding a press release dated august 07, 2019, titled ""please find attached letter dated 7th august, 2019"".",07-Aug-2019 15:09:00,2019-08-07 15:09:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_07082019150829_Letter_218.pdf,07-08-2019,502.7000122070313,525.8499755859375,501.6499938964844,518.2999877929688,507.5191345214844,4668643,0.0,0.0,16-08-2019,-1
262,CIPLA,Cipla Limited,updates," regarding 'pursuant to regulation 30 of the sebi listing regulations, it is hereby informed that cipla limited (ￂﾓthe companyￂﾔ) has signed a definitive agreement today to acquire the minority stake of eight roads investment mauritius ii limited (earlier known as fil capital investments (mauritius) ii limited) in cipla health limited, subsidiary of the company. the details as required under the sebi listing regulations are enclosed.'.",07-Aug-2019 14:59:00,2019-08-07 14:59:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_07082019145737_Letter_201.pdf,07-08-2019,502.7000122070313,525.8499755859375,501.6499938964844,518.2999877929688,507.5191345214844,4668643,0.0,0.0,16-08-2019,-1
263,CIPLA,Cipla Limited,financial results updates," a copy of unaudited financial results (standalone and consolidated) for the quarter ended june 30, 2019.",07-Aug-2019 14:58:00,2019-08-07 14:58:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_782019145213_Letter_199.pdf,07-08-2019,502.7000122070313,525.8499755859375,501.6499938964844,518.2999877929688,507.5191345214844,4668643,0.0,0.0,16-08-2019,-1
264,CIPLA,Cipla Limited,press release," regarding a press release dated july 29, 2019, titled ""alvotech and cipla gulf enter into a partnership for thecommercialization of key biosimilar in select emerging markets"".",29-Jul-2019 08:39:00,2019-07-29 08:39:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_29072019083925_Letter_004.pdf,29-07-2019,531.5999755859375,534.9500122070312,520.25,522.25,508.4366455078125,735045,0.0,0.0,05-08-2019,0
265,CIPLA,Cipla Limited,press release," regarding a press release dated july 24, 2019, titled ""cipla usa furthers amr stewardship with acquisition of key anti-infective zemdriￂﾙ (iv plazomicin)"".",24-Jul-2019 21:50:00,2019-07-24 21:50:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_24072019214805_Letter_462.pdf,24-07-2019,529.0,529.0,517.0499877929688,518.75,505.0292053222656,2707033,0.0,0.0,31-07-2019,0
266,CIPLA,Cipla Limited,shareholders meeting," regarding notice of annual general meeting to be held on august 16, 2019- annual report to be read with forward looking statement",24-Jul-2019 21:26:00,2019-07-24 21:26:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_24072019212519_Letter_458.pdf,24-07-2019,529.0,529.0,517.0499877929688,518.75,505.0292053222656,2707033,0.0,0.0,31-07-2019,0
267,CIPLA,Cipla Limited,analysts/institutional investor meet/con. call updates, regarding analysts/institutional investor meet/con. call updates during which the leadership team will discuss the financial performance and take questions.,23-Jul-2019 19:26:00,2019-07-23 19:26:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_23072019192441_Letter_394.pdf,23-07-2019,531.0,535.2000122070312,521.0,528.9000244140625,514.9107666015625,2353027,0.0,0.0,30-07-2019,0
268,CIPLA,Cipla Limited,updates," regarding 'that pursuant to regulation 47 read with regulation 30 of the sebi (listing obligations and disclosure requirements) regulations, 2015, we are enclosing herewith the newspaper cuttings of the notice published in business standard (english - all india editions) and sakal (marathi) today i.e. july 23, 2019, which includes the following information:1. intimation of annual general meeting (agm) of our company and confirming despatch of annual report.2. particulars of remote e-voting, voting at the agm and live webcast of agm.3. notice of book closure for the purpose of agm and dividend, if declared under section 91 of the companies act, 2013.you are requested to kindly take above information on your records.'.",23-Jul-2019 17:58:00,2019-07-23 17:58:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_23072019175522_Letter_325.pdf,23-07-2019,531.0,535.2000122070312,521.0,528.9000244140625,514.9107666015625,2353027,0.0,0.0,30-07-2019,0
269,CIPLA,Cipla Limited,agm/book closure," that the register of members and share transfer books of the company will remain closed from august 02, 2019 to august 16, 2019 ( both days inclusive) for determination of members eligible for payment of dividend of rs 3/- per equity share i.e. 150% of the face value for financial year 2018-19.",23-Jul-2019 12:00:00,2019-07-23 12:00:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_227201971148_SEIntimationCipla20thJuly2019_056.pdf,23-07-2019,531.0,535.2000122070312,521.0,528.9000244140625,514.9107666015625,2353027,0.0,0.0,30-07-2019,0
270,CIPLA,Cipla Limited,press release," regarding a press release dated july 22, 2019, titled ""invagen pharmaceuticals inc. (cipla 's wholly owned step down subsidiary) receives final approval for generic version of pfizerￂﾒs lyricaￂﾮ (pregabalin capsules,25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg,300mg)"".",22-Jul-2019 08:35:00,2019-07-22 08:35:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_22072019083222_Letter_010.pdf,22-07-2019,536.7000122070312,540.0,526.2000122070312,530.9500122070312,516.9066162109375,1816845,0.0,0.0,29-07-2019,0
271,CIPLA,Cipla Limited,updates," regarding 'usfda cgmp inspection completed at ciplaￂﾒs api manufacturing facility in virgonagar, bengaluru'.",19-Jul-2019 21:12:00,2019-07-19 21:12:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_19072019211141_Letter_362.pdf,19-07-2019,550.7999877929688,552.0,535.5,536.7000122070312,522.5044555664062,783708,0.0,0.0,26-07-2019,0
272,CIPLA,Cipla Limited,updates," regarding 'in continuation to our letter dated 15th july, 2019, with regard to board meeting notice,please find enclosed advertisement published in newspapers viz. business standard and sakal on 16th july,2019.'.",16-Jul-2019 16:48:00,2019-07-16 16:48:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_16072019164804_Letter_197.pdf,16-07-2019,554.75,558.4500122070312,549.4000244140625,553.5499877929688,538.9087524414062,1460303,0.0,0.0,23-07-2019,0
273,CIPLA,Cipla Limited,acquisition,"we wish to inform you that cipla (eu) limited (ￂﾓcipla euￂﾔ), u.k., wholly owned subsidiary of the company has entered into a joint venture agreement with jiangsu acebright pharmaceutical co., ltd. (ￂﾓacebrightￂﾔ), china on 15th july 2019 for incorporation of a company (ￂﾓjv co.ￂﾔ) in china.",15-Jul-2019 22:41:00,2019-07-15 22:41:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_15072019223919_Letter_426.pdf,15-07-2019,559.9000244140625,560.5,548.5999755859375,550.5499877929688,535.9881591796875,842129,0.0,0.0,22-07-2019,0
274,CIPLA,Cipla Limited,related party transactions," a copy of disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended march 31, 2019.",24-Jun-2019 08:51:00,2019-06-24 08:51:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_246201984317_Letter_052.pdf,24-06-2019,548.5499877929688,552.4500122070312,545.0999755859375,549.9000244140625,535.3553466796875,981017,0.0,0.0,01-07-2019,0
275,CIPLA,Cipla Limited,resignation," regarding resignation of mr peter lankau as independent director of the company w.e.f. july 01, 2019.",21-Jun-2019 18:03:00,2019-06-21 18:03:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_21062019180231_Letter_354.pdf,21-06-2019,549.8499755859375,553.7999877929688,545.2000122070312,551.5499877929688,536.961669921875,1534007,0.0,0.0,28-06-2019,0
276,CIPLA,Cipla Limited,updates, regarding 'newspaper publication of notice to shareholders whose shares are liable to be transferred to iepf'.,17-Jun-2019 20:18:00,2019-06-17 20:18:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_17062019201802_CiplaNewspaperPublicationIEPF_392.pdf,17-06-2019,555.5,556.5999755859375,543.8499755859375,545.1500244140625,530.73095703125,1267159,0.0,0.0,24-06-2019,0
277,CIPLA,Cipla Limited,updates," regarding 'reference is made to the intimation given by the company under regulation 39 of sebi (listing obligations and disclosure requirements) regulations, 2015 on 29th may, 2019 regarding issuance of duplicate share certificate.we now wish to inform you that on 12th june, 2019, the stakeholders relationship committee of the company has approved the issuance of duplicate share certificates to shareholder as per attachment.'.",14-Jun-2019 19:10:00,2019-06-14 19:10:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_14062019190910_StockExchangeIntimation_317.pdf,14-06-2019,560.1500244140625,564.4500122070312,554.1500244140625,555.5999755859375,540.9044799804688,1808363,0.0,0.0,21-06-2019,0
278,CIPLA,Cipla Limited,updates," regarding 'reference is made to the intimation given by the company under regulation 39 of sebi (listing obligations and disclosure requirements) regulations, 2015 on 29th may, 2019 regarding issuance of duplicate share certificate.we now wish to inform you that on 12th june, 2019, the stakeholders relationship committee of the company has approved the issuance of duplicate share certificates to shareholder as per attachment.'.",14-Jun-2019 19:10:00,2019-06-14 19:10:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_14062019190910_StockExchangeIntimation_317.pdf,14-06-2019,560.1500244140625,564.4500122070312,554.1500244140625,555.5999755859375,540.9044799804688,1808363,0.0,0.0,21-06-2019,0
279,CIPLA,Cipla Limited,press release," regarding a press release dated jun 03, 2019, titled ""cipla step down associate avenue therapeutics announces positive topline data from second pivotal phase 3 study of intravenous tramadol in the management of postoperative pain"".",04-Jun-2019 12:12:00,2019-06-04 12:12:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_04062019121001_Letter_038.pdf,04-06-2019,564.0,575.0,561.0999755859375,562.6500244140625,547.7681274414062,1558827,0.0,0.0,12-06-2019,0
280,CIPLA,Cipla Limited,acquisition,cipla limited has signed an agreement on 23rd may 2019 to acquire 26% stake on a fully diluted basis in ampsolar power systems private limited.,23-May-2019 17:12:00,2019-05-23 17:12:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_23052019170742_Letter_290.pdf,23-05-2019,561.9000244140625,568.9000244140625,543.75,564.75,549.8125610351562,5640728,0.0,0.0,30-05-2019,0
281,CIPLA,Cipla Limited,publish audited results, regarding newspaper publication of the extract of consolidated audited financial results for the quarter and year ended 31 51 march. 2019.,22-May-2019 16:04:00,2019-05-22 16:04:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_2252019135145_Letter1_265.pdf,22-05-2019,562.0,574.0,550.0499877929688,553.0,538.373291015625,7762734,0.0,0.0,29-05-2019,0
282,CIPLA,Cipla Limited,press release," regarding a press release dated may 22, 2019, titled ""cipla announces q4 and fy19 resultsￂﾠ"".",22-May-2019 13:43:00,2019-05-22 13:43:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_22052019134253_Letter_138.pdf,22-05-2019,562.0,574.0,550.0499877929688,553.0,538.373291015625,7762734,0.0,0.0,29-05-2019,0
283,CIPLA,Cipla Limited,dividend," that board of directors at its meeting held on may 22, 2019, recommended final dividend of 3 per equity share.",22-May-2019 13:20:00,2019-05-22 13:20:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_22052019131855_Letter_117.pdf,22-05-2019,562.0,574.0,550.0499877929688,553.0,538.373291015625,7762734,0.0,0.0,29-05-2019,0
284,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended march 31, 2019.",22-May-2019 13:17:17,2019-05-22 13:17:17,-,-,https://nsearchives.nseindia.com/corporate/Letter_22052019131717.zip,22-05-2019,562.0,574.0,550.0499877929688,553.0,538.373291015625,7762734,0.0,0.0,29-05-2019,0
285,CIPLA,Cipla Limited,updates," regarding 'in furtherance to the letter dated 6th march 2019 (copy enclosed), the chief judge stark of the u.s. district court of delaware denied amgen, inc.ￂﾒs request for preliminary injunction to stop ciplaￂﾒs continued sale of its generic cinacalcet hydrochloride tablets 30mg, 60mg, 90mg in the usa.'.",03-May-2019 09:12:00,2019-05-03 09:12:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_03052019091048_Letter_013.pdf,03-05-2019,568.0,573.0,561.6500244140625,564.5,549.569091796875,2758638,0.0,0.0,10-05-2019,0
286,CIPLA,Cipla Limited,press release," regarding a press release dated april 30, 2019, titled ""cipla receives final approval for generic version of gilead sciences, incￂﾒs letairisￂﾮ (ambrisentan tabs, 5mg & 10mg)"".",30-Apr-2019 08:26:00,2019-04-30 08:26:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_30042019082516_Letter_006.pdf,30-04-2019,569.9000244140625,571.0499877929688,558.6500244140625,565.0,550.0559692382812,1914026,0.0,0.0,08-05-2019,0
287,CIPLA,Cipla Limited,press release," regarding a press release dated april 22, 2019, titled ""cipla appoints dr. raju mistry as global chief people officer"".",22-Apr-2019 20:15:00,2019-04-22 20:15:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_22042019201409_Letter_532.pdf,22-04-2019,560.0,566.0,556.5999755859375,561.0999755859375,546.2590942382812,1205612,0.0,0.0,30-04-2019,0
288,CIPLA,Cipla Limited,disc. under reg.30 of sebi (sast) reg.2011,"the promoter along with pac has submitted to the exchange a copy of annual disclosure under regulation 30(2) and 30(3) of sebi (substantial acquisition of shares and takeovers), regulations, 2011 as on march 31, 2019.",18-Apr-2019 18:44:00,2019-04-18 18:44:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_18042019173306_Cipla_340.pdf,18-04-2019,562.0,566.6500244140625,553.2000122070312,561.5499877929688,546.6971435546875,2306549,0.0,0.0,26-04-2019,0
289,CIPLA,Cipla Limited,updates," regarding 'pursuant to regulation 47 of the sebi (listing obligations and disclosure requirements) regulations, 2015, please find enclosed herewith the copy of advertisement published in newspapers viz. business standard and sakal on 18th april, 2019.'.",18-Apr-2019 15:11:00,2019-04-18 15:11:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_18042019150915_Letter_184.pdf,18-04-2019,562.0,566.6500244140625,553.2000122070312,561.5499877929688,546.6971435546875,2306549,0.0,0.0,26-04-2019,0
290,CIPLA,Cipla Limited,acquisition,"we wish to inform that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement on 16th april 2019, to acquire 30% stake in brandmed (pty) limited (""brandmed"").",16-Apr-2019 17:12:00,2019-04-16 17:12:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_16042019170802_Letter_203.pdf,16-04-2019,570.0,571.75,556.5999755859375,559.3499755859375,544.5553588867188,2246831,0.0,0.0,25-04-2019,0
291,CIPLA,Cipla Limited,updates, regarding 'cipla's wholly owned subsidiary in usa i.e. cipla technologies llc has signed the definitive agreement today with pulmatrix inc.'.,15-Apr-2019 18:36:00,2019-04-15 18:36:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_15042019183559_Letter_306.pdf,15-04-2019,555.0,569.2000122070312,552.0,566.2999877929688,551.3215942382812,2252373,0.0,0.0,24-04-2019,0
292,CIPLA,Cipla Limited,disc. under reg.30 of sebi (sast) reg.2011,"the promoter along with pac has submitted to the exchange a copy of annual disclosure under regulation 30(1) and 30(2) of sebi (substantial acquisition of shares and takeovers), regulations, 2011 as on march 31, 2019.",12-Apr-2019 09:31:00,2019-04-12 09:31:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_12042019091628_Cipla_020.pdf,12-04-2019,547.9500122070312,556.7000122070312,545.2999877929688,554.8499755859375,540.1743774414062,4347530,0.0,0.0,23-04-2019,0
293,CIPLA,Cipla Limited,press release," regarding a press release dated april 12, 2019, titled ""cipla launches niveoliￂﾙ, indiaￂﾒs first extrafine ics-laba combination hfa inhaler"".",12-Apr-2019 08:27:00,2019-04-12 08:27:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_12042019081945_Letter_001.pdf,12-04-2019,547.9500122070312,556.7000122070312,545.2999877929688,554.8499755859375,540.1743774414062,4347530,0.0,0.0,23-04-2019,0
294,CIPLA,Cipla Limited,updates," regarding 'update with respect to signing of binding term sheet between company's wholly owned subsidiary, cipla technologies llc and pulmatrix inc.'.we wish to inform that the company's wholly owned subsidiary in usa i.e. cipla technologies llc, has signed a binding term sheet today with pulmatrix inc., (""pulmatrix"") for an investment in phase 2 ready asset co-development and licensing opportunity for pulmazole (inhaled ltraconazole) for an upfront consideration of usd 22 million. entry into a definitive agreement is contingent upon pulmatrix raising additional funds from the market. upon signing the definitive agreement, the co-development cost towards development and the total free cash flow in relation to commercialization of pulmazole will be further shared by both the parties in a phased manner.",01-Apr-2019 19:22:00,2019-04-01 19:22:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_01042019191317_Letter_650.pdf,01-04-2019,516.2999877929688,528.75,516.2999877929688,525.6500244140625,511.7467651367188,4091454,0.0,0.0,08-04-2019,0
295,CIPLA,Cipla Limited,resignation," regarding resignation of ms ireena vittal as independent director of the company w.e.f. april 01, 2019.",25-Mar-2019 16:20:00,2019-03-25 16:20:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_25032019161609_Letter_151.pdf,25-03-2019,525.5999755859375,528.7000122070312,516.2000122070312,526.8499755859375,512.9150390625,1874898,0.0,0.0,02-04-2019,0
296,CIPLA,Cipla Limited,updates," thatￂﾠ the company's wholly owned subsidiary goldencross pharma private limited has completed the closing of wellthy therapeutics private limited (""wellthy""), transaction representing an acquisition of 11.71% stake in wellthy on fully diluted basis onￂﾠ march 08, 2019.",08-Mar-2019 19:24:00,2019-03-08 19:24:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract3_83201919611_Letter_274.pdf,08-03-2019,541.0,543.4000244140625,538.25,539.9500122070312,525.6685180664062,2618767,0.0,0.0,15-03-2019,0
297,CIPLA,Cipla Limited,updates," regarding 'that the company and its subsidiary cipla usa, inc., (hereafter referred to as ￂﾓciplaￂﾔ) announced a phased launch of generic cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) in the usa. the launch is a subject of ongoing litigation.  ciplaￂﾒs cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) is ab-rated generic therapeutic equivalent version of sensiparￂﾮ, a branded drug marketed by amgen, inc. cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (hpt) in adult patients with chronic kidney disease (ckd) on dialysis, for the treatment of hypercalcemia in adult patients with parathyroid carcinoma, and for treatment of severe hypercalcemia in adult patients with primary hpt who are unable to undergo parathyroidectomy.'.",06-Mar-2019 08:37:00,2019-03-06 08:37:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_06032019083539_Letter_007.pdf,06-03-2019,551.0,552.0,541.9500122070312,547.5499877929688,533.0674438476562,1587182,0.0,0.0,13-03-2019,0
298,CIPLA,Cipla Limited,news clarification,"the exchange had sought clarification from the company with respect to news item captioned- "" mylan recalls spray made at cipla unit"". in this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) whether such event stated in published news were taking place? if so, you are advised to provide the said information along with the sequence of events in chronological order. b) the material impact of this article on the company. c) whether company are aware of any information that has not been announced to the exchanges under regulation 30 of listing regulations. if so, you are advised to provide the said information and the reasons for not disclosing the same to the exchange earlier as required under regulation 30 of the listing regulations. the response from the company is enclosed.ￂﾠ",18-Feb-2019 21:08:00,2019-02-18 21:08:00,-,-,https://nsearchives.nseindia.com/corporate/saileep_182201921755_Letter_324.pdf,18-02-2019,542.0,545.0499877929688,532.2999877929688,541.1500244140625,526.8368530273438,1590101,0.0,0.0,25-02-2019,0
299,CIPLA,Cipla Limited,acquisition," that the companys wholly owned subsidiary goldencross pharma private ltd has singed an agreement on february 18, 2019 to acquire 11.71 % stake in wellthy therapeutics private ltd.",18-Feb-2019 20:07:00,2019-02-18 20:07:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract3_182201920053_Letter_307.pdf,18-02-2019,542.0,545.0499877929688,532.2999877929688,541.1500244140625,526.8368530273438,1590101,0.0,0.0,25-02-2019,0
300,CIPLA,Cipla Limited,press release," regarding a press release dated february 18, 2019, titled ""cipla wins portion of state arv tender"".",18-Feb-2019 19:56:00,2019-02-18 19:56:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_18022019195525_Letter_298.pdf,18-02-2019,542.0,545.0499877929688,532.2999877929688,541.1500244140625,526.8368530273438,1590101,0.0,0.0,25-02-2019,0
301,CIPLA,Cipla Limited,press release," regarding a press release dated february 07, 2019, titled ""cipla receives final approval for generic version ofeli lilly & co.ￂﾒs adcircaￂﾮ (tadalafil tablets 20mg)"".",07-Feb-2019 08:38:00,2019-02-07 08:38:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_07022019083646_Letter_005.pdf,07-02-2019,537.0999755859375,546.5999755859375,528.1500244140625,532.9000244140625,518.804931640625,4417618,0.0,0.0,15-02-2019,0
302,CIPLA,Cipla Limited,updates," that pursuant to regulation 47 of the securities and exchange board of india (listingobligations and disclosure requirements) regulations, 2015, please find enclosedextract of consolidated unaudited financial results for the quarter and nine months ended31""1 december, 2018.",06-Feb-2019 15:38:00,2019-02-06 15:38:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract3_622019152130_Letter_225.pdf,06-02-2019,510.5,546.7000122070312,504.1000061035156,534.9500122070312,520.80078125,8775759,0.0,0.0,14-02-2019,0
303,CIPLA,Cipla Limited,press release," regarding a press release dated february 06, 2019, titled ""please find attached press release dated 6th february 2019"".",06-Feb-2019 15:01:00,2019-02-06 15:01:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_06022019150024_Letter_179.pdf,06-02-2019,510.5,546.7000122070312,504.1000061035156,534.9500122070312,520.80078125,8775759,0.0,0.0,14-02-2019,0
304,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended december 31, 2018.",06-Feb-2019 14:51:54,2019-02-06 14:51:54,-,-,https://nsearchives.nseindia.com/corporate/Letter_06022019145154.zip,06-02-2019,510.5,546.7000122070312,504.1000061035156,534.9500122070312,520.80078125,8775759,0.0,0.0,14-02-2019,0
305,CIPLA,Cipla Limited,press release," regarding a press release dated january 28, 2019, titled ""cipla receives final approval for generic version ofpfizerￂﾒs depo-proveraￂﾮ (medroxyprogesteroneinjectable, 150mg/ml )"".",28-Jan-2019 08:29:00,2019-01-28 08:29:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_28012019082825_Letter_012.pdf,28-01-2019,509.0,509.0,489.1000061035156,492.1499938964844,479.1328125,3215535,0.0,0.0,04-02-2019,0
306,CIPLA,Cipla Limited,allotment of esop/esps, regarding allotment of  26963 equity shares under esop scheme of the company,21-Jan-2019 18:31:00,2019-01-21 18:31:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_21012019182839_Letter_285.pdf,21-01-2019,510.0,514.2000122070312,508.2000122070313,509.25,495.7804870605469,1150380,0.0,0.0,28-01-2019,0
307,CIPLA,Cipla Limited,updates," regarding 'please find enclosed herewith the copy of advertisement published in newspapers viz. business standard and sakal on 8th january, 2019.'.",08-Jan-2019 16:02:00,2019-01-08 16:02:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_08012019160137_Letter_094.pdf,08-01-2019,516.0,517.2000122070312,511.25,513.6500244140625,500.0641784667969,1765015,0.0,0.0,15-01-2019,0
308,CIPLA,Cipla Limited,registrar & share transfer agent update, regarding the registrar & share transfer agent update-change of name of the company's registrar and share transfer agent,18-Dec-2018 15:17:00,2018-12-18 15:17:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_18122018151404_Letter_078.pdf,18-12-2018,524.0,527.0,520.0499877929688,522.9000244140625,509.069580078125,1628240,0.0,0.0,26-12-2018,0
309,CIPLA,Cipla Limited,allotment of esop/esps," regarding allotment of  248883 equity shares under esop (inadvertently the number of shares allotted on december 06, 2018, has been mentioned as 2,50,310 equity shares instead of 2,48,883 equity shares).",13-Dec-2018 19:01:00,2018-12-13 19:01:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_13122018190124_CiplaLimitedReviseReg30initmationofESOPallotment_156.pdf,13-12-2018,532.0,533.7999877929688,519.2000122070312,527.0,513.0609741210938,2234487,0.0,0.0,20-12-2018,0
310,CIPLA,Cipla Limited,press release," regarding a press release dated november 13, 2018, titled ""invagen (a cipla subsidiary) announces acquisition agreement with avenue therapeutics for specialty hospital business in the us"".",13-Nov-2018 09:09:00,2018-11-13 09:09:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract4_131120189212_Letter_443.pdf,13-11-2018,534.0,534.0,526.5,528.0999755859375,514.1318969726562,2410643,0.0,0.0,20-11-2018,0
311,CIPLA,Cipla Limited,press release," regarding a press release dated november 12, 2018, titled ""cipla receives final approval for generic version ofrocheￂﾒs valcyteￂﾮ (valganciclovir tablets 450mg)"".",12-Nov-2018 08:40:00,2018-11-12 08:40:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_12112018083934_Letter_914.pdf,12-11-2018,530.0,541.9000244140625,529.0499877929688,531.8499755859375,517.7827758789062,7669697,0.0,0.0,19-11-2018,0
312,CIPLA,Cipla Limited,press release," regarding a press release dated november 05, 2018, titled ""press release dt. 05th november, 2018"".",05-Nov-2018 13:29:00,2018-11-05 13:29:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_05112018132833_Letter_483.pdf,05-11-2018,607.4000244140625,617.5,557.0999755859375,563.0499877929688,548.1575317382812,12941350,0.0,0.0,13-11-2018,-1
313,CIPLA,Cipla Limited,updates," regarding 'extract of consolidated unaudited financial results for the quarter and half year ended september 30, 2018. '.",05-Nov-2018 13:19:00,2018-11-05 13:19:00,-,-,https://nsearchives.nseindia.com/corporate/listcontract1_511201813177_Letter_463.pdf,05-11-2018,607.4000244140625,617.5,557.0999755859375,563.0499877929688,548.1575317382812,12941350,0.0,0.0,13-11-2018,-1
314,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended september 30, 2018.",05-Nov-2018 12:38:46,2018-11-05 12:38:46,-,-,https://nsearchives.nseindia.com/corporate/Letter_05112018123846.zip,05-11-2018,607.4000244140625,617.5,557.0999755859375,563.0499877929688,548.1575317382812,12941350,0.0,0.0,13-11-2018,-1
315,CIPLA,Cipla Limited,press release," regarding a press release dated october 29, 2018, titled ""cipla receives final approval for generic version ofaralez pharmaceuticals, inc.ￂﾒs toprol xlￂﾮ(metoprolol succinate) er tablets 50mg, 100mg,200mg."".",29-Oct-2018 08:39:00,2018-10-29 08:39:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_29102018083811_Letter_006.pdf,29-10-2018,602.3499755859375,638.2000122070312,601.4500122070312,635.1500244140625,618.3504638671875,1614423,0.0,0.0,05-11-2018,-1
316,CIPLA,Cipla Limited,updates, regarding 'completion of acquisition of mirren (pty) limited by company's whollyowned subsidiary i.e. cipla medpro south africa (pty) limited on 22nd october 2018'.,23-Oct-2018 11:24:00,2018-10-23 11:24:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_23102018112313_Mirrenacquisition_953.pdf,23-10-2018,628.7999877929688,632.0,616.0,622.3499755859375,605.8890380859375,1370461,0.0,0.0,30-10-2018,0
317,CIPLA,Cipla Limited,updates," regarding 'enclosed herewith minutes of the 82nd annual general meeting of the company held on 30th august, 2018.'.",09-Oct-2018 15:40:00,2018-10-09 15:40:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_09102018152945_Letter_062.pdf,09-10-2018,639.5,643.0999755859375,625.25,639.3499755859375,622.4393920898438,1535781,0.0,0.0,16-10-2018,0
318,CIPLA,Cipla Limited,press release," regarding a press release dated september 17, 2018, titled ""ciplaqcil - bell ringing and first day of trading on the uganda securities exchange"".",17-Sep-2018 13:51:00,2018-09-17 13:51:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_17092018134952_PressReleaseCipla_048.pdf,17-09-2018,673.0,673.0,660.4000244140625,664.9000244140625,647.313720703125,2220455,0.0,0.0,25-09-2018,0
319,CIPLA,Cipla Limited,press release," regarding a press release dated september 11, 2018, titled ""ciplaￂﾒs new triple combination antiretroviral drug approved"".",11-Sep-2018 20:09:00,2018-09-11 20:09:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_11092018200718_Letter_257.pdf,11-09-2018,670.0999755859375,675.0,650.5999755859375,654.9000244140625,637.578125,3399042,0.0,0.0,19-09-2018,0
320,CIPLA,Cipla Limited,shareholders meeting,"cipla limited has submitted the exchange a copy srutinizers report of  annual general meeting held on august 30, 2018. further, the company has informed the exchange regarding voting results.",31-Aug-2018 18:57:00,2018-08-31 18:57:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31082018185343_Letter_525.pdf,31-08-2018,649.5499877929688,664.0,649.5499877929688,662.1500244140625,644.6363525390625,3056580,0.0,0.0,07-09-2018,0
321,CIPLA,Cipla Limited,shareholders meeting," regarding proceedings of annual general meeting held on august 30, 2018",31-Aug-2018 13:51:00,2018-08-31 13:51:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31082018135005_Letter_215.pdf,31-08-2018,649.5499877929688,664.0,649.5499877929688,662.1500244140625,644.6363525390625,3056580,0.0,0.0,07-09-2018,0
322,CIPLA,Cipla Limited,updates," regarding 'please find attached stock exchange intimation dt. august 16, 2018.'.",16-Aug-2018 22:19:00,2018-08-16 22:19:00,-,-,https://nsearchives.nseindia.com/corporate/StockExchangeIntimationCQCIL_16082018221921_452.zip,16-08-2018,644.7000122070312,660.0,634.25,648.3499755859375,631.201416015625,3925549,0.0,0.0,24-08-2018,0
323,CIPLA,Cipla Limited,press release," regarding a press release dated august 10, 2018, titled ""cipla receives final approval for generic reyatazￂﾮ (atazanavir caps 100mg,150mg,200mg, 300mg)"".",10-Aug-2018 18:47:00,2018-08-10 18:47:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_10082018184700_149.zip,10-08-2018,624.9500122070312,628.5,614.5,621.0499877929688,601.7027587890625,3168280,0.0,0.0,20-08-2018,0
324,CIPLA,Cipla Limited,press release," regarding a press release dated august 10, 2018, titled ""cipla partners with msn laboratories for marketingand distribution of generic xelodaￂﾮ (capecitabinetabs 150mg and 500mg)"".",10-Aug-2018 18:03:00,2018-08-10 18:03:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_10082018180325_059.zip,10-08-2018,624.9500122070312,628.5,614.5,621.0499877929688,601.7027587890625,3168280,0.0,0.0,20-08-2018,0
325,CIPLA,Cipla Limited,financial results updates," regarding revised extract of consolidated unaudited financial results for the quarter ended june 30, 2018",08-Aug-2018 20:21:00,2018-08-08 20:21:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_08082018202144_500.zip,08-08-2018,629.0,645.4500122070312,623.5999755859375,632.5499877929688,612.844482421875,4121062,0.0,0.0,16-08-2018,0
326,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended june 30, 2018.",08-Aug-2018 16:12:22,2018-08-08 16:12:22,-,-,https://nsearchives.nseindia.com/corporate/Letter_08082018161222.zip,08-08-2018,629.0,645.4500122070312,623.5999755859375,632.5499877929688,612.844482421875,4121062,0.0,0.0,16-08-2018,0
327,CIPLA,Cipla Limited,press release," regarding a press release dated august 08, 2018, titled ""please find attached press release dated 8 august 2018"".",08-Aug-2018 15:46:00,2018-08-08 15:46:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_08082018154605_205.zip,08-08-2018,629.0,645.4500122070312,623.5999755859375,632.5499877929688,612.844482421875,4121062,0.0,0.0,16-08-2018,0
328,CIPLA,Cipla Limited,press release," regarding a press release dated august 07, 2018, titled ""cipla receives final approval for generic voltarenￂﾮ gel (diclofenac sodium topical gel, 1%)"".",07-Aug-2018 08:23:00,2018-08-07 08:23:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_07082018082345_633.zip,07-08-2018,642.9000244140625,642.9000244140625,627.0999755859375,629.4500122070312,609.8411865234375,2414266,0.0,0.0,14-08-2018,0
329,CIPLA,Cipla Limited,agm/book closure," that the register of members and share transfer books of the company shall remain closed from august 16, 2018 to august 30, 2018 (both days inclusive) for the purpose of annual general meeting of the company scheduled to be held on august 30, 2018 and determining the persons entitled for dividend for the year ended march 31, 2018.",03-Aug-2018 19:39:00,2018-08-03 19:39:00,-,-,https://nsearchives.nseindia.com/corporate/BookClosure_03082018193904_559.zip,03-08-2018,640.9500122070312,647.5999755859375,639.0,641.0499877929688,621.0797119140625,1530339,0.0,0.0,10-08-2018,0
330,CIPLA,Cipla Limited,shareholders meeting," regarding notice of annual general meeting to be held on august 30, 2018",03-Aug-2018 19:32:00,2018-08-03 19:32:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_03082018193202_553.zip,03-08-2018,640.9500122070312,647.5999755859375,639.0,641.0499877929688,621.0797119140625,1530339,0.0,0.0,10-08-2018,0
331,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
332,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
333,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
334,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
335,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
336,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
337,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
338,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
339,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
340,CIPLA,Cipla Limited,acquisition," that the company's wholly owned subsidiary cipla medpro south africa (pty) limited has signed an agreement to acquire 100% stake in mirren (pty) limited, south africa on 11th july 2018. a detailed press release and disclosure as required under the sebi (listing obligations and disclosure requirements) regulations, 2015 are enclosed as annexure- i.",12-Jul-2018 08:25:00,2018-07-12 08:25:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressRelease_12072018082549_308.zip,12-07-2018,629.4000244140625,636.7000122070312,622.7000122070312,633.3499755859375,613.6195678710938,2177684,0.0,0.0,19-07-2018,0
341,CIPLA,Cipla Limited,updates," regarding 'newspaper publication pursuant to section 124(6) of the companies act, 2013 read with the investor education and protection fund authority (accounting, audit, transfer and refund) rules, 2016.'.",27-Jun-2018 11:46:00,2018-06-27 11:46:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_27062018114634_717.zip,27-06-2018,602.5,606.9500122070312,593.0,602.2999877929688,583.536865234375,2520918,0.0,0.0,04-07-2018,0
342,CIPLA,Cipla Limited,press release," regarding a press release dated jun 21, 2018, titled ""cipla receives final approval forgeneric depo-testosteroneￂﾮ (testosteronecypionate for injection 100mg/ml and 200mg/ml)"".",21-Jun-2018 08:40:00,2018-06-21 08:40:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_21062018084028_451.zip,21-06-2018,608.7999877929688,609.7000122070312,602.0,603.5,584.699462890625,3052143,0.0,0.0,28-06-2018,0
343,CIPLA,Cipla Limited,press release," regarding a press release dated jun 19, 2018, titled ""cipla receives final approval forgeneric sustivaￂﾮ (efavirenz tablets 600mg)"".",19-Jun-2018 16:16:00,2018-06-19 16:16:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_19062018161610_125.zip,19-06-2018,606.25,610.4500122070312,598.2000122070312,601.8499755859375,583.1008911132812,2992184,0.0,0.0,26-06-2018,0
344,CIPLA,Cipla Limited,press release," regarding a press release dated jun 13, 2018, titled ""cipla receives final approval for generic isuprelￂﾮ(isoproterenol hydrochloride injection usp, 0.2mg/ml)"".",13-Jun-2018 19:49:00,2018-06-13 19:49:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_13062018194949_288.zip,13-06-2018,569.9500122070312,593.5,569.9500122070312,582.0999755859375,563.9661254882812,4657712,0.0,0.0,20-06-2018,0
345,CIPLA,Cipla Limited,press release," regarding a press release dated jun 13, 2018, titled ""press release"".",13-Jun-2018 18:23:00,2018-06-13 18:23:00,-,-,https://nsearchives.nseindia.com/corporate/CiplaPressReleaseCQCIL_13062018182336_237.zip,13-06-2018,569.9500122070312,593.5,569.9500122070312,582.0999755859375,563.9661254882812,4657712,0.0,0.0,20-06-2018,0
346,CIPLA,Cipla Limited,press release," regarding a press release dated jun 08, 2018, titled ""price cut on medicine will help preserve the health of more people living with hiv"".",08-Jun-2018 13:29:00,2018-06-08 13:29:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_08062018132954_099.zip,08-06-2018,541.7999877929688,562.0,538.75,559.6500244140625,542.215576171875,4815940,0.0,0.0,15-06-2018,1
347,CIPLA,Cipla Limited,press release," regarding a press release dated jun 08, 2018, titled ""cipla partners with eli lilly & company to market diabetes drug basaglar"".",08-Jun-2018 12:33:00,2018-06-08 12:33:00,-,-,https://nsearchives.nseindia.com/corporate/letter1_08062018123324_070.zip,08-06-2018,541.7999877929688,562.0,538.75,559.6500244140625,542.215576171875,4815940,0.0,0.0,15-06-2018,1
348,CIPLA,Cipla Limited,financial results updates," regarding  a copy of extract of consolidated audited financial results for the quarter and year ended march 31, 2018.",22-May-2018 18:04:00,2018-05-22 18:04:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_22052018180416_487.zip,22-05-2018,524.7999877929688,531.0999755859375,507.2000122070313,524.0,507.6760559082031,3080285,0.0,0.0,29-05-2018,0
349,CIPLA,Cipla Limited,press release," regarding a press release dated may 22, 2018, titled ""cipla announces q4 & fy18 results"".",22-May-2018 16:25:00,2018-05-22 16:25:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_22052018162520_349.zip,22-05-2018,524.7999877929688,531.0999755859375,507.2000122070313,524.0,507.6760559082031,3080285,0.0,0.0,29-05-2018,0
350,CIPLA,Cipla Limited,dividend," that board of directors at its meeting held on may 22, 2018, recommended final dividend of rs. 3 per equity share.",22-May-2018 16:14:00,2018-05-22 16:14:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_22052018161408_337.zip,22-05-2018,524.7999877929688,531.0999755859375,507.2000122070313,524.0,507.6760559082031,3080285,0.0,0.0,29-05-2018,0
351,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended march 31, 2018.",22-May-2018 16:09:57,2018-05-22 16:09:57,-,-,https://nsearchives.nseindia.com/corporate/Letter_22052018160957.zip,22-05-2018,524.7999877929688,531.0999755859375,507.2000122070313,524.0,507.6760559082031,3080285,0.0,0.0,29-05-2018,0
352,CIPLA,Cipla Limited,press release," regarding a press release dated may 09, 2018, titled ""cipla receives final approval for generic vazculepￂﾮ, generic phenylephrine hydrochloride injection usp, 10 mg/ml single-dose vial and generic aromasinￂﾮ"".",09-May-2018 18:28:00,2018-05-09 18:28:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_09052018182847_901.zip,09-05-2018,591.4000244140625,596.0,585.5499877929688,588.0,569.6823120117188,652527,0.0,0.0,16-05-2018,0
353,CIPLA,Cipla Limited,press release," regarding a press release dated may 02, 2018, titled ""cipla receives final approval for generic vazculepￂﾮ,generic phenylephrine hydrochloride injection usp, 10mg/ml single-dose vial and generic aromasinￂﾮ"".",02-May-2018 08:30:00,2018-05-02 08:30:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_02052018083021_112.zip,02-05-2018,610.0,621.9000244140625,608.9500122070312,612.0,592.9346923828125,1862999,0.0,0.0,09-05-2018,0
354,CIPLA,Cipla Limited,news verification,"the exchange has sought clarification from cipla limited with respect to recent news item captioned ""cipla gains 4% after usfda inspection with no data integrity or repeat observations"". the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. cipla limited has submitted their response.",17-Apr-2018 11:05:00,2018-04-17 11:05:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_17042018110503.zip,17-04-2018,585.5499877929688,588.3499755859375,575.7000122070312,579.9500122070312,561.8831787109375,2688507,0.0,0.0,24-04-2018,0
355,CIPLA,Cipla Limited,diversification/disinvestment," that with reference to company's letter dated june 08, 2017, the closing conditions in relation to disinvestment of entire 99% equity stake held by companyￂﾒs joint venture company in uae i.e. saba investment limited in al jabal for drugs and medical appliances company limited, yemen (ￂﾓajdmsￂﾔ) have been fulfilled. consequently, ajdms have ceased to be subsidiary of saba investment limited with effect from march 26, 2018.",26-Mar-2018 19:56:00,2018-03-26 19:56:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_26032018195633_312.zip,26-03-2018,538.1500244140625,544.5999755859375,532.9500122070312,541.7999877929688,524.9215698242188,1105319,0.0,0.0,04-04-2018,1
356,CIPLA,Cipla Limited,press release," regarding a press release dated march 26, 2018, titled ""cipla launches authorized generic of aloxiￂﾮ(palonosetron hcl injection 0.25 mg/5 ml)"".",26-Mar-2018 08:33:00,2018-03-26 08:33:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_26032018083341_010.zip,26-03-2018,538.1500244140625,544.5999755859375,532.9500122070312,541.7999877929688,524.9215698242188,1105319,0.0,0.0,04-04-2018,1
357,CIPLA,Cipla Limited,news verification,"the exchange has sought clarification from cipla limited with respect to recent news item captioned ""cipla shares drop 7% on usfda observations for goa unit."". the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. cipla limited has submitted their response.",20-Mar-2018 12:09:00,2018-03-20 12:09:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_7358_reply_20032018120907.zip,20-03-2018,555.0999755859375,561.8499755859375,522.9000244140625,552.9000244140625,535.67578125,9119209,0.0,0.0,27-03-2018,0
358,CIPLA,Cipla Limited,allotment of securities," regarding allotment of 20108 securities pursuant to esop/esps at its meeting held on march 16, 2018",16-Mar-2018 18:22:00,2018-03-16 18:22:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_16032018182255_458.zip,16-03-2018,570.0999755859375,574.0,557.0499877929688,559.4000244140625,541.9732666015625,1867538,0.0,0.0,23-03-2018,0
359,CIPLA,Cipla Limited,press release," regarding a press release dated february 27, 2018, titled ""cipla partners with roche pharma india to creategreater access to key medicines&#61623;"".",27-Feb-2018 19:15:00,2018-02-27 19:15:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_27022018191507_977.zip,27-02-2018,591.7000122070312,598.9000244140625,583.0999755859375,586.5,568.2290649414062,1349590,0.0,0.0,07-03-2018,0
360,CIPLA,Cipla Limited,allotment of securities," regarding allotment of 103953 securities pursuant to esop/esps at its meeting held on february 16, 2018",16-Feb-2018 21:07:00,2018-02-16 21:07:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_16022018210730_278.zip,16-02-2018,611.2999877929688,613.9500122070312,605.5,611.0999755859375,592.0626831054688,906025,0.0,0.0,23-02-2018,0
361,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended december 31, 2017.",07-Feb-2018 16:11:30,2018-02-07 16:11:30,-,-,https://nsearchives.nseindia.com/corporate/Letter_07022018161130.zip,07-02-2018,578.5,579.9000244140625,554.2000122070312,569.25,551.5164794921875,3161498,0.0,0.0,15-02-2018,1
362,CIPLA,Cipla Limited,press release," regarding a press release dated february 07, 2018, titled ""cipla q3 fy18 results reflect continuously improvingquality of earnings backed by strong momentum acrosskey regions"".",07-Feb-2018 14:25:00,2018-02-07 14:25:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_07022018142507_229.zip,07-02-2018,578.5,579.9000244140625,554.2000122070312,569.25,551.5164794921875,3161498,0.0,0.0,15-02-2018,1
363,CIPLA,Cipla Limited,press release," regarding a press release dated january 29, 2018, titled ""cipla receives final approval forgeneric vireadￂﾮ tablets"".",29-Jan-2018 08:42:00,2018-01-29 08:42:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_29012018084242_243.zip,29-01-2018,624.9500122070312,628.4000244140625,611.0999755859375,615.0,595.8411865234375,1564268,0.0,0.0,05-02-2018,-1
364,CIPLA,Cipla Limited,allotment of securities," regarding allotment of 50413 securities pursuant to esop/esps at its meeting held on january 04, 2018",04-Jan-2018 18:50:00,2018-01-04 18:50:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_04012018185026_523.zip,04-01-2018,609.4500122070312,618.4000244140625,603.4500122070312,616.75,597.5366821289062,990602,0.0,0.0,11-01-2018,0
365,CIPLA,Cipla Limited,allotment of securities," regarding allotment of 122572 securities pursuant to esop/esps at its meeting held on december 04, 2017",04-Dec-2017 17:15:00,2017-12-04 17:15:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_04122017171510_119.zip,04-12-2017,599.2999877929688,602.7999877929688,588.7999877929688,596.7000122070312,578.111328125,660077,0.0,0.0,11-12-2017,0
366,CIPLA,Cipla Limited,updates," regarding 'cipla holding b.v., a subsidiary of the company has entered into an agreement to sell its 100% equity stake in cipla croatia d.o.o., croatia to pharmas d.o.o., croatia in order to align with company's strategy to operate via a b2b model in europe. '.",01-Dec-2017 08:33:00,2017-12-01 08:33:00,-,-,https://nsearchives.nseindia.com/corporate/LETTER_01122017083354.zip,01-12-2017,604.5,606.0,593.7000122070312,598.0999755859375,579.4676513671875,747562,0.0,0.0,08-12-2017,0
367,CIPLA,Cipla Limited,press release," regarding a press release dated november 30, 2017, titled ""cipla launches q-tib globally, a novel fixed dose combination in a single tablet for t.b. prophylaxis in hiv"".",30-Nov-2017 13:24:00,2017-11-30 13:24:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_30112017132438.zip,30-11-2017,605.0,607.8499755859375,597.0499877929688,600.9000244140625,582.1805419921875,1612910,0.0,0.0,07-12-2017,0
368,CIPLA,Cipla Limited,press release," regarding a press release dated november 20, 2017, titled ""cipla receives final approvalfor generic dacogenￂﾮ"".",20-Nov-2017 08:50:00,2017-11-20 08:50:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_20112017085008_522.zip,20-11-2017,605.5499877929688,608.0,596.0999755859375,604.25,585.4260864257812,1609788,0.0,0.0,27-11-2017,0
369,CIPLA,Cipla Limited,press release," regarding a press release dated november 17, 2017, titled ""cipla receives final approval forgeneric pulmicort respulesￂﾮ"".",17-Nov-2017 08:39:00,2017-11-17 08:39:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_17112017083930_075.zip,17-11-2017,607.0,614.9000244140625,600.6500244140625,608.5499877929688,589.5921630859375,1448847,0.0,0.0,24-11-2017,0
370,CIPLA,Cipla Limited,allotment of securities," regarding allotment of 129297 securities pursuant to esop/esps at its meeting held on november 13, 2017",13-Nov-2017 19:12:00,2017-11-13 19:12:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_13112017191250_342.zip,13-11-2017,610.2999877929688,611.2999877929688,595.7000122070312,602.0999755859375,583.343017578125,1109147,0.0,0.0,20-11-2017,0
371,CIPLA,Cipla Limited,press release," regarding a press release dated november 07, 2017, titled ""cipla q2 fy18 results demonstrate strong growth acrossbusinesses and the benefit of operating leverage"".",07-Nov-2017 14:19:00,2017-11-07 14:19:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_07112017141935_163.zip,07-11-2017,663.4000244140625,663.4000244140625,602.0,607.5499877929688,588.623291015625,7331364,0.0,0.0,14-11-2017,0
372,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended september 30, 2017.",07-Nov-2017 13:53:23,2017-11-07 13:53:23,-,-,https://nsearchives.nseindia.com/corporate/Letter_07112017135323.zip,07-11-2017,663.4000244140625,663.4000244140625,602.0,607.5499877929688,588.623291015625,7331364,0.0,0.0,14-11-2017,0
373,CIPLA,Cipla Limited,press release (revised)," regarding a revised press release dated october 27, 2017, titled ""ciplaￂﾒs us subsidiary receives final approvalfor generic renvelaￂﾮ tablets"".",27-Oct-2017 10:48:00,2017-10-27 10:48:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_27102017104851_476.zip,27-10-2017,625.0,629.7999877929688,616.2000122070312,625.0499877929688,605.5781860351562,2198491,0.0,0.0,03-11-2017,0
374,CIPLA,Cipla Limited,press release," regarding a press release dated october 27, 2017, titled ""ciplaￂﾒs us subsidiary receives final approvalfor generic renvelaￂﾮ tablets"".",27-Oct-2017 08:54:00,2017-10-27 08:54:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_27102017085432_450.zip,27-10-2017,625.0,629.7999877929688,616.2000122070312,625.0499877929688,605.5781860351562,2198491,0.0,0.0,03-11-2017,0
375,CIPLA,Cipla Limited,allotment of securities," regarding allotment of 7474 securities pursuant to esop/esps at its meeting held on september 21, 2017",22-Sep-2017 10:57:00,2017-09-22 10:57:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_22092017105747_018.zip,22-09-2017,591.9000244140625,600.0,582.4500122070312,585.3499755859375,567.114990234375,4003845,0.0,0.0,29-09-2017,0
376,CIPLA,Cipla Limited,press release," regarding a press release dated august 11, 2017, titled ""cipla announces q1fy 18 resultsstrong focus on operational efficiency drivesmargin expansion"".",11-Aug-2017 13:45:00,2017-08-11 13:45:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_11082017134529_261.zip,11-08-2017,545.0,563.7000122070312,525.4500122070312,541.4000244140625,524.5339965820312,4337214,0.0,0.0,21-08-2017,0
377,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended june 30, 2017.",11-Aug-2017 13:30:20,2017-08-11 13:30:20,-,-,https://nsearchives.nseindia.com/corporate/Letter_11082017133020.zip,11-08-2017,545.0,563.7000122070312,525.4500122070312,541.4000244140625,524.5339965820312,4337214,0.0,0.0,21-08-2017,0
378,CIPLA,Cipla Limited,allotment of securities," regarding allotment of 12112 securities pursuant to esop/esps at its meeting held on august 03, 2017",03-Aug-2017 18:41:00,2017-08-03 18:41:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_03082017184135_614.zip,03-08-2017,568.5499877929688,575.0,553.7999877929688,557.1500244140625,539.79345703125,1065451,0.0,0.0,10-08-2017,0
379,CIPLA,Cipla Limited,analysts/institutional investor meet/con. call updates," a copy of the schedule of earnings conference call to be held on august 11, 2017.",27-Jul-2017 14:46:00,2017-07-27 14:46:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_27072017144609_020.zip,27-07-2017,573.7000122070312,579.4000244140625,565.0,568.7000122070312,550.983642578125,1853099,0.0,0.0,03-08-2017,0
380,CIPLA,Cipla Limited,press release," regarding a press release dated july 25, 2017, titled ""cipla launches quality-assured rectal artesunatesuppositories for severe malaria in young children"".",25-Jul-2017 15:36:00,2017-07-25 15:36:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_25072017153654_980.zip,25-07-2017,571.0,571.4000244140625,562.4000244140625,564.4000244140625,544.8798828125,510032,0.0,0.0,01-08-2017,0
381,CIPLA,Cipla Limited,agm/book closure," that the register of members and share transfer books of the company shall remain closed from july 28, 2017 to august 11, 2017(both days inclusive) for the purpose of annual general meeting of the company is scheduled to be held on august 11, 2017 and dividend",17-Jul-2017 07:56:00,2017-07-17 07:56:00,-,-,https://nsearchives.nseindia.com/corporate/BookClosure_17072017075645_062.zip,17-07-2017,549.0,559.0,546.7000122070312,556.5,537.2530517578125,692893,0.0,0.0,24-07-2017,0
382,CIPLA,Cipla Limited,shareholders meeting," regarding notice of annual general meeting to be held on august 11, 2017",14-Jul-2017 18:32:00,2017-07-14 18:32:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_14072017183201_318.zip,14-07-2017,544.25,551.1500244140625,540.8499755859375,548.0499877929688,529.0952758789062,960041,0.0,0.0,21-07-2017,0
383,CIPLA,Cipla Limited,allotment of securities," regarding allotment of 115611 securities pursuant to esop/esps at its meeting held on july 06, 2017",06-Jul-2017 18:49:00,2017-07-06 18:49:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_06072017184928_399.zip,06-07-2017,546.3499755859375,547.9000244140625,540.0999755859375,542.8499755859375,524.0751342773438,556426,0.0,0.0,13-07-2017,0
384,CIPLA,Cipla Limited,updates," that saba investment limited, a subsidiary of the company has entered into an agreement to sell its entire 99% equity stake in al jabal for drugs and medical appliances company limited, yemen to mr. khalil ghaleb ali al-jabal.",09-Jun-2017 08:22:00,2017-06-09 08:22:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_09062017082204_036.zip,09-06-2017,554.5,555.7999877929688,545.25,551.0999755859375,532.039794921875,867969,0.0,0.0,16-06-2017,0
385,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"samina vaziralli has submitted to the exchange, vide letter dated june 08, 2017 a copy of disclosure under regulation 10(6) in respect of acquisition under regulation 10 of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",08-Jun-2017 17:36:00,2017-06-08 17:36:00,-,-,https://nsearchives.nseindia.com/corporate/Regulation10_08062017173644.zip,08-06-2017,538.75,554.7000122070312,537.0999755859375,550.1500244140625,531.122802734375,1396596,0.0,0.0,15-06-2017,0
386,CIPLA,Cipla Limited,financial results updates," regarding the financial results for the quarter and year ended march 31, 2017.",06-Jun-2017 18:01:00,2017-06-06 18:01:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_06062017180127_285.zip,06-06-2017,537.7000122070312,539.5499877929688,522.3499755859375,534.6500244140625,516.1588134765625,765557,0.0,0.0,13-06-2017,0
387,CIPLA,Cipla Limited,updates," that the closing conditions in relation to divestment of entire stake held by company's wholly owned subsidiary lnyanga trading 386 proprietary limited in cipla vet proprietary limited (""cipla vet""), south africa and cipla agrimed proprietary limited (""cipla agrimed""), south africa have been fulfilled. consequently, cipla vet and cipla agrimed have ceased to be subsidiaries of lnyanga trading 386 proprietary limited with effect from june 01, 2017.",01-Jun-2017 20:05:00,2017-06-01 20:05:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_01062017200505_943.zip,01-06-2017,519.7000122070312,529.9000244140625,513.0499877929688,515.5499877929688,497.7193603515625,1433241,0.0,0.0,08-06-2017,1
388,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"samina vaziralli has submitted to the exchange, vide letter dated may 31, 2017 a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10 of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",31-May-2017 20:06:00,2017-05-31 20:06:00,-,-,https://nsearchives.nseindia.com/corporate/Regulation_10(5)_31052017200601.zip,31-05-2017,514.7999877929688,520.0999755859375,505.0,516.3499755859375,498.49163818359375,1366315,0.0,0.0,07-06-2017,0
389,CIPLA,Cipla Limited,allotment of securities," regarding allotment of 7949 securities pursuant to esop/esps at its meeting held on may 25, 2017",25-May-2017 16:43:00,2017-05-25 16:43:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_25052017164335_093.zip,25-05-2017,522.0,525.0,496.3999938964844,504.0,486.5688171386719,4378940,0.0,0.0,01-06-2017,0
390,CIPLA,Cipla Limited,press release," regarding a press release dated may 25, 2017, titled ""cipla announces q4 & fy 17 results - continued strong performance across key markets"".",25-May-2017 16:25:00,2017-05-25 16:25:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_25052017162534_060.zip,25-05-2017,522.0,525.0,496.3999938964844,504.0,486.5688171386719,4378940,0.0,0.0,01-06-2017,0
391,CIPLA,Cipla Limited,dividend," that board of directors at its meeting held on may 25, 2017, recommended final dividend of rs. 2 per equity share.",25-May-2017 16:20:00,2017-05-25 16:20:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_25052017162035_050.zip,25-05-2017,522.0,525.0,496.3999938964844,504.0,486.5688171386719,4378940,0.0,0.0,01-06-2017,0
392,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended march 31, 2017.",25-May-2017 16:14:23,2017-05-25 16:14:23,-,-,https://nsearchives.nseindia.com/corporate/Letter_25052017161423.zip,25-05-2017,522.0,525.0,496.3999938964844,504.0,486.5688171386719,4378940,0.0,0.0,01-06-2017,0
393,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on april 26, 2017 allotted 39,601 equity shares of rs. 2/-each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a.",26-Apr-2017 17:47:00,2017-04-26 17:47:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_26042017174732_738.zip,26-04-2017,549.7999877929688,561.0,545.4000244140625,556.75,537.4944458007812,1425158,0.0,0.0,04-05-2017,0
394,CIPLA,Cipla Limited,updates," that the company intimation dated december 14, 2016 with respect to joint venture agreement ( ""jv agreement"") entered into by cipla holding b.v. the netherlands, a wholly owned subsidiary of the company with ahran tejarat company, iran.",17-Apr-2017 08:11:00,2017-04-17 08:11:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_17042017081145_028.zip,17-04-2017,580.0,580.0,573.0499877929688,576.5,556.5614624023438,487497,0.0,0.0,24-04-2017,0
395,CIPLA,Cipla Limited,updates," that the companys wholly owned subsidiary ie cipla medpro south africa (pty) limited has completed acquisition of anmarate (pty) limited on april 12, 2017.",12-Apr-2017 19:52:00,2017-04-12 19:52:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_12042017195248_281.zip,12-04-2017,575.0,582.0,570.6500244140625,579.4000244140625,559.361083984375,1188457,0.0,0.0,20-04-2017,0
396,CIPLA,Cipla Limited,disc. under reg.30 of sebi (sast) reg.2011,"m k hamied has submitted to the exchange a copy of disclosure under regulation 30(1) and 30(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",11-Apr-2017 18:23:00,2017-04-11 18:23:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_11042017182323.zip,11-04-2017,590.0,591.6500244140625,575.0999755859375,580.0499877929688,559.9885864257812,2103296,0.0,0.0,19-04-2017,0
397,CIPLA,Cipla Limited,press release," regarding a press release dated april 06, 2017, titled ""cipla usa enters into collaboration with medrx"".",06-Apr-2017 12:47:00,2017-04-06 12:47:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_06042017124702_211.zip,06-04-2017,591.5,593.6500244140625,587.0499877929688,590.2999877929688,569.884033203125,1436914,0.0,0.0,13-04-2017,0
398,CIPLA,Cipla Limited,news clarification,"the exchange had sought clarification from the company with respect to recent news item captioned ""usfda issued import alert on cipla s tadalafil drug mafe at bhagwanpur unit"". in this regard, exchange has advised the company to provide clarification/confirmation on the news item in detail including the following: a) whether such event/negotiations/article stated in published news were taking place? if so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the company. b) whether company is aware of any information that has not been announced to the exchanges under regulation 30 of listing regulations. the response from the company is attached.",23-Mar-2017 20:26:00,2017-03-23 20:26:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_23032017202641.zip,23-03-2017,595.7999877929688,598.2000122070312,582.2000122070312,596.25,575.6282958984375,1555876,0.0,0.0,30-03-2017,0
399,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on march 16, 2017 allotted 38,333 equity shares of rs. 2/-each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a.",16-Mar-2017 18:16:00,2017-03-16 18:16:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_16032017181603_236.zip,16-03-2017,605.0999755859375,605.9000244140625,598.0499877929688,601.4000244140625,580.6002197265625,852049,0.0,0.0,23-03-2017,0
400,CIPLA,Cipla Limited,press release," regarding a press release dated march 04, 2017 titled ""cipla agrees to divest its animal health business in south africa and sub-saharan africa"".",06-Mar-2017 08:29:00,2017-03-06 08:29:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_06032017082944_246.zip,06-03-2017,592.0,595.0,588.2000122070312,590.0999755859375,569.6910400390625,943409,0.0,0.0,14-03-2017,0
401,CIPLA,Cipla Limited,press release," regarding a press release dated february 17, 2017, titled ""cipla launches hepatitis b vaccine in india"".",17-Feb-2017 13:21:00,2017-02-17 13:21:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_17022017132150_512.zip,17-02-2017,585.9000244140625,596.4500122070312,580.6500244140625,593.25,572.7320556640625,1209276,0.0,0.0,27-02-2017,0
402,CIPLA,Cipla Limited,updates," that this has reference to company's earlier letter dated september 01, 2016 providing the contact details of key managerial personnel who are severally authorized to determine materiality of an event or information and make disclosures to the stock exchange(s) pursuant to regulation 30(5) of the securities and exchange board of india (lodr) regulations, 2015.",09-Feb-2017 15:01:00,2017-02-09 15:01:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_09022017150154.zip,09-02-2017,611.0,611.5499877929688,584.4500122070312,587.6500244140625,567.3258666992188,4192748,0.0,0.0,16-02-2017,0
403,CIPLA,Cipla Limited,press release," regarding a press release dated february 08, 2017, titled ""cipla q3 fy17 results demonstrate continued improvement in profitability"".",08-Feb-2017 16:57:00,2017-02-08 16:57:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_08022017165747_914.zip,08-02-2017,600.0,609.0,597.75,603.2000122070312,582.337890625,2122225,0.0,0.0,15-02-2017,0
404,CIPLA,Cipla Limited,updates," that the board of directors at their meeting held on february 08, 2017 has further deliberated on the proposal relating to fund raising and has decided to seek approval of the shareholders in future at an appropriate time depending upon the funding requirements and investment opportunities.",08-Feb-2017 16:53:00,2017-02-08 16:53:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_08022017165329.zip,08-02-2017,600.0,609.0,597.75,603.2000122070312,582.337890625,2122225,0.0,0.0,15-02-2017,0
405,CIPLA,Cipla Limited,change in company secretary/compliance officer," that as part of the planned transition, mr. mital sanghvi is moving into a senior business finance role within the company. accordingly, the board of directors of the company at its meeting held on february 08, 2017 has noted his relinquishment of office as company secretary, key managerial personnel and compliance officer of the company with effect from february 09,2017. further, based on the recommendation of the nomination and remuneration committee, the board of directors of the company at its meeting february 08, 2017 has approved the appointment of mr. rajendra chopra as the company secretary and key managerial personnel of the company with effect from 9th february 2017.",08-Feb-2017 16:50:00,2017-02-08 16:50:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_08022017165029_906.zip,08-02-2017,600.0,609.0,597.75,603.2000122070312,582.337890625,2122225,0.0,0.0,15-02-2017,0
406,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended december 31, 2016.",08-Feb-2017 16:37:54,2017-02-08 16:37:54,-,-,https://nsearchives.nseindia.com/corporate/Letter_08022017163754.zip,08-02-2017,600.0,609.0,597.75,603.2000122070312,582.337890625,2122225,0.0,0.0,15-02-2017,0
407,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on february 08, 2017 allotted 39,691 equity shares of rs. 2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a.",08-Feb-2017 11:38:00,2017-02-08 11:38:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_08022017113846_620.zip,08-02-2017,600.0,609.0,597.75,603.2000122070312,582.337890625,2122225,0.0,0.0,15-02-2017,0
408,CIPLA,Cipla Limited,updates," vide letter dated february 01, 2017 that ""this is further to our letter dated january 18 2017 (copy enclosed for reference). we would like to inform you that the closing conditions in relation to the sale of entire stake held by goldencross pharma private limited (""goldencress"") in four m prepack private limited (""four m prepack"") have been completed. consequently, four m prepack ceases to be a subsidiary of goldencross with effect from february 01, 2017"".",01-Feb-2017 17:13:00,2017-02-01 17:13:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_01022017171346_926.zip,01-02-2017,573.0,579.25,566.2999877929688,572.1500244140625,552.3617553710938,873328,0.0,0.0,08-02-2017,1
409,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on january 23, 2017 allotted 19,128 equity shares of rs. 2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a.",24-Jan-2017 08:33:00,2017-01-24 08:33:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_24012017083325_010.zip,24-01-2017,574.7000122070312,581.2999877929688,574.0999755859375,579.9000244140625,559.8438110351562,527089,0.0,0.0,01-02-2017,0
410,CIPLA,Cipla Limited,updates," that goldencross pharma private limited, wholly owned subsidiary of the company, has entered in to a definitive agreement to sell its 100% equity stake in four m propack limited, india to shriji polymers (india) limited for a consideration of rs. 13.5 crores and an additional sum derived on the basis of the value of mutual funds, cash and bank balance, tax refunds, etc. at the time of closing estimated at around rs. 5.7 crores.",18-Jan-2017 17:30:00,2017-01-18 17:30:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_18012017173026_137.zip,18-01-2017,588.7999877929688,593.4000244140625,577.3499755859375,580.7999877929688,560.712646484375,591422,0.0,0.0,25-01-2017,0
411,CIPLA,Cipla Limited,press release," regarding a press release dated january 09, 2017, titled ""cipla appoints peter lankau as anindependent director on its board"".",09-Jan-2017 13:10:00,2017-01-09 13:10:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_09012017131033_264.zip,09-01-2017,583.5499877929688,588.9500122070312,574.9000244140625,576.7000122070312,556.7544555664062,545949,0.0,0.0,16-01-2017,0
412,CIPLA,Cipla Limited,appointment of director," that the board of directors of the company through a circular resolution on january 09, 2017 has appointed mr. peter lankau as an additional director of the company with effect from january 10, 2017 to hold office as an independent director of the company.",09-Jan-2017 13:04:00,2017-01-09 13:04:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_09012017130415_260.zip,09-01-2017,583.5499877929688,588.9500122070312,574.9000244140625,576.7000122070312,556.7544555664062,545949,0.0,0.0,16-01-2017,0
413,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on january 02, 2017 allotted 18,542 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a. consequently, the issued share capital of the company stands increased to rs. 1,61,08,32,634 comprising of 80,54,16,317 equity shares of face value rs.2/ each. the paid-up & subscribed share capital of the company stands increased to rs. 1,60,88,25,844 comprising of 80,44, 12,922 equity shares of face value rs.2/ each.",02-Jan-2017 18:23:00,2017-01-02 18:23:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_02012017182310_553.zip,02-01-2017,569.75,572.4500122070312,563.25,566.0,546.424560546875,520139,0.0,0.0,09-01-2017,0
414,CIPLA,Cipla Limited,press release," regarding a press release dated december 23, 2016, titled ""cipla s flagship product sereflo  receivesfinal approval from uk mhra"".",23-Dec-2016 14:56:00,2016-12-23 14:56:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_23122016145616_718.zip,23-12-2016,561.0,589.1500244140625,552.0,582.2999877929688,562.1608276367188,2585856,0.0,0.0,30-12-2016,0
415,CIPLA,Cipla Limited,outcome of board meeting," regarding the outcome of board meeting held on december 19, 2016.",19-Dec-2016 17:13:00,2016-12-19 17:13:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_19122016171347_308.zip,19-12-2016,565.0,574.5,561.4000244140625,569.1500244140625,549.465576171875,997716,0.0,0.0,26-12-2016,0
416,CIPLA,Cipla Limited,press release," regarding a press release dated december 19, 2016, titled ""cipla receives final approval for generic tricor  tablets"".",19-Dec-2016 13:04:00,2016-12-19 13:04:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_19122016130454_191.zip,19-12-2016,565.0,574.5,561.4000244140625,569.1500244140625,549.465576171875,997716,0.0,0.0,26-12-2016,0
417,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on december 16, 2016 allotted 1,27,399 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a. consequently, the issued share capital of the company stands increased to rs.1,61,07,95,550 comprising of 80,53,97,775 equity shares of face value rs.2/ each. the paid-up & subscribed share capital of the company stands increased to rs.1,60,87,88, 760 comprising of 80,43,94,380 equity shares of face value rs.2/ each.",16-Dec-2016 11:16:00,2016-12-16 11:16:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_16122016111619_410.zip,16-12-2016,562.9000244140625,569.9000244140625,561.3499755859375,566.2000122070312,546.6177368164062,665505,0.0,0.0,23-12-2016,0
418,CIPLA,Cipla Limited,updates," that cipla holding b.v., a wholly owned subsidiary of the company in netherlands (""cipla netherlands""), has entered into a joint venture agreement with ahran tejarat company (""jv partner"").",15-Dec-2016 08:26:00,2016-12-15 08:26:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_15122016082654_063.zip,15-12-2016,568.0,576.5499877929688,559.0999755859375,563.1500244140625,543.6730346679688,1032429,0.0,0.0,22-12-2016,0
419,CIPLA,Cipla Limited,press release," regarding a press release dated december 08, 2016, titled ""cipla receives final approval for generic baraclude tablets"".",08-Dec-2016 11:38:00,2016-12-08 11:38:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_08122016113805_049.zip,08-12-2016,573.5,583.9000244140625,570.2000122070312,582.75,562.59521484375,1177494,0.0,0.0,15-12-2016,0
420,CIPLA,Cipla Limited,press release," regarding a press release dated november 29, 2016, titled ""cipla appoints ireena vittal as anindependent director on its board"".",29-Nov-2016 11:24:00,2016-11-29 11:24:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_29112016112437_076.zip,29-11-2016,573.0,573.9500122070312,564.2999877929688,569.1500244140625,549.465576171875,832424,0.0,0.0,06-12-2016,0
421,CIPLA,Cipla Limited,appointment of director," that the board of directors of the company through a circular resolution on november 28, 2016 has appointed ms. ireena vittal as an additional director of the company with effect from december 01, 2016 to hold office as an independent director of the company.",28-Nov-2016 17:09:00,2016-11-28 17:09:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_28112016170906_743.zip,28-11-2016,569.2999877929688,577.0,568.0499877929688,570.5499877929688,550.817138671875,1224023,0.0,0.0,05-12-2016,0
422,CIPLA,Cipla Limited,updates," a copy of notice published in the newspapers on november 23, 2016 under the investor education and protection fund authority (accounting, audit, transfer and refund) rules, 2016.",23-Nov-2016 13:16:00,2016-11-23 13:16:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_23112016131640_815.zip,23-11-2016,554.9000244140625,559.4000244140625,547.1500244140625,552.7999877929688,533.6810302734375,1520986,0.0,0.0,30-11-2016,0
423,CIPLA,Cipla Limited,press release," regarding a press release dated november 23, 2016, titled ""cipla eu divests stake in chase pharmaceuticals to allergan"".",23-Nov-2016 12:31:00,2016-11-23 12:31:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_23112016123125_796.zip,23-11-2016,554.9000244140625,559.4000244140625,547.1500244140625,552.7999877929688,533.6810302734375,1520986,0.0,0.0,30-11-2016,0
424,CIPLA,Cipla Limited,updates," regarding a statement dated november 10, 2016 uploaded by company's ugandan subsidiary i.e, cipla quality chemical industries limited titled ""cipla quality chemical industries ltd (ciplaqcil) announcement of intention for initial public offering (ipo).""",11-Nov-2016 08:19:00,2016-11-11 08:19:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_11112016081903_606.zip,11-11-2016,559.7000122070312,564.0,545.25,547.9500122070312,528.998779296875,1232505,0.0,0.0,21-11-2016,0
425,CIPLA,Cipla Limited,press release," regarding a press release dated november 09, 2016, titled ""cipla announces q2 fy17 results - improved profitability in base business & strengthened r&d pipeline"".",09-Nov-2016 17:06:00,2016-11-09 17:06:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_09112016170649_325.zip,09-11-2016,512.0999755859375,532.0,486.5499877929688,526.2999877929688,508.0975341796875,3810958,0.0,0.0,17-11-2016,0
426,CIPLA,Cipla Limited,financial result updates,", the financial results for the period ended september 30, 2016.",09-Nov-2016 16:40:03,2016-11-09 16:40:03,-,-,https://nsearchives.nseindia.com/corporate/Letter_09112016164003.zip,09-11-2016,512.0999755859375,532.0,486.5499877929688,526.2999877929688,508.0975341796875,3810958,0.0,0.0,17-11-2016,0
427,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on november 09, 2016 allotted 51,317 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a.",09-Nov-2016 14:15:00,2016-11-09 14:15:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_09112016141545_175.zip,09-11-2016,512.0999755859375,532.0,486.5499877929688,526.2999877929688,508.0975341796875,3810958,0.0,0.0,17-11-2016,0
428,CIPLA,Cipla Limited,esops/esos/esps," that nomination and remuneration committee of the company at its meeting held on november 09, 2016, has approved the grant of 5,87,970 stock options to employees of the company and its subsidiary companies, in terms of employee stock option scheme 2013-a (""esos 2013-a""). the said options carry the right to apply for equal number of equity shares of the company of face value of rs.2/- each.",09-Nov-2016 13:23:00,2016-11-09 13:23:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_09112016132318_140.zip,09-11-2016,512.0999755859375,532.0,486.5499877929688,526.2999877929688,508.0975341796875,3810958,0.0,0.0,17-11-2016,0
429,CIPLA,Cipla Limited,analysts/institutional investor meet/con. call updates," regarding schedule of press conference and earnings conference call to be held on november 09, 2016.",07-Nov-2016 12:58:00,2016-11-07 12:58:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_07112016125824_309.zip,07-11-2016,549.5,555.75,544.0,545.75,526.8748779296875,939497,0.0,0.0,15-11-2016,0
430,CIPLA,Cipla Limited,updates," that this has reference to company's earlier disclosures regarding pending legal cases relating to alleged overcharging in respect of certain drugs under the drugs (price control) order, 1995.the hon'ble supreme court has on october 21, 2016, decided in favour of union of india in an appeal filed against the company and others out of the judgement of the hon'ble allahabad high court.the other petitions filed in the bombay high court on completely separate sets of grounds relating to alleged overcharged amounts are pending and are still subject to the interim stay granted by the hon'ble supreme court in july, 2016.",21-Oct-2016 14:57:00,2016-10-21 14:57:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_21102016145705.zip,21-10-2016,597.5,597.5,570.0,583.25,563.077880859375,1792780,0.0,0.0,28-10-2016,0
431,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on october 18, 2016 allotted 5,193 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a.",18-Oct-2016 18:43:00,2016-10-18 18:43:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_18102016184327_577.zip,18-10-2016,587.0,594.0,582.25,592.75,572.2493896484375,1213156,0.0,0.0,25-10-2016,0
432,CIPLA,Cipla Limited,updates," a copy of notice published in newspaper informing that the company intends to apply to the central government under section 196 read with schedule v and other applicable provisions of the companies act, 2013 for seeking its approval to the appointment of mr. umang vohra as managing director of the company designated as ""managing director and global chief executive officer"" for a period of five years with effect from september 1, 2016.",04-Oct-2016 11:16:00,2016-10-04 11:16:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_04102016111612_058.zip,04-10-2016,590.2999877929688,603.8499755859375,590.2999877929688,597.7999877929688,577.124755859375,1656807,0.0,0.0,13-10-2016,0
433,CIPLA,Cipla Limited,analysts/institutional investor meet/con. call updates, regarding schedule of analyst / institutional investor meetings with the company.,03-Oct-2016 18:01:00,2016-10-03 18:01:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_03102016180140_380.zip,03-10-2016,584.7000122070312,591.7000122070312,582.2000122070312,588.8499755859375,568.4842529296875,1146677,0.0,0.0,10-10-2016,0
434,CIPLA,Cipla Limited,news verification,"the exchange has sought clarification from cipla limited with respect to recent news item captioned ""usfda inspected cipla's goa facility last week. usfda inspected units 1,5,4,8 & 9 of co's goa plant."". the exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. cipla limited has submitted their response.",30-Sep-2016 13:07:00,2016-09-30 13:07:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_6477_reply_30092016130754.zip,30-09-2016,601.8499755859375,603.9000244140625,562.25,580.0499877929688,559.9885864257812,6967821,0.0,0.0,07-10-2016,0
435,CIPLA,Cipla Limited,updates," vide letter dated september 30, 2016 that ""us fda recently concluded audit of our 3 manufacturing facilities at goa and has issued 4 observations across these 3 facilities. these observations were primarily procedural in nature and the company has already responded to these observations. we continue to operate our facilities with a high level of compliance & control.""",30-Sep-2016 12:26:00,2016-09-30 12:26:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_30092016122647_014.zip,30-09-2016,601.8499755859375,603.9000244140625,562.25,580.0499877929688,559.9885864257812,6967821,0.0,0.0,07-10-2016,0
436,CIPLA,Cipla Limited,"regulation 44(3) of sebi (lodr), reg., 2015"," regarding the detailed voting results of the annual general meeting of the company held on september 28, 2016.",29-Sep-2016 20:21:00,2016-09-29 20:21:00,-,-,https://nsearchives.nseindia.com/corporate/VotingResults_29092016202126_780.zip,29-09-2016,608.0,611.0,585.75,602.8499755859375,582.0000610351562,2252434,0.0,0.0,06-10-2016,0
437,CIPLA,Cipla Limited,"regulation 44(3) of sebi (lodr), reg., 2015"," regarding the details of the voting results at the annual general meeting of the company held on september 28, 2016.",29-Sep-2016 20:15:00,2016-09-29 20:15:00,-,-,https://nsearchives.nseindia.com/corporate/VotingResults_29092016201544_778.zip,29-09-2016,608.0,611.0,585.75,602.8499755859375,582.0000610351562,2252434,0.0,0.0,06-10-2016,0
438,CIPLA,Cipla Limited,annual general meeting updates," a copy of proceedings of the annual general meeting of the company held on september 28, 2016.",29-Sep-2016 17:46:00,2016-09-29 17:46:00,-,-,https://nsearchives.nseindia.com/corporate/AGMProceedings_29092016174625_558.zip,29-09-2016,608.0,611.0,585.75,602.8499755859375,582.0000610351562,2252434,0.0,0.0,06-10-2016,0
439,CIPLA,Cipla Limited,annual general meeting updates," a copy of chairman speech of annual general meeting of the company held on september 28, 2016.",29-Sep-2016 11:30:00,2016-09-29 11:30:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_29092016113026_127.zip,29-09-2016,608.0,611.0,585.75,602.8499755859375,582.0000610351562,2252434,0.0,0.0,06-10-2016,0
440,CIPLA,Cipla Limited,analysts/institutional investor meet/con. call updates, regarding schedule of analyst / institutional investor meetings with the company.,21-Sep-2016 13:16:00,2016-09-21 13:16:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_21092016131625_142.zip,21-09-2016,602.8499755859375,607.0,597.0999755859375,601.3499755859375,580.5519409179688,1578461,0.0,0.0,28-09-2016,0
441,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on september 01, 2016 allotted 6,00,000 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantee under employee stock option scheme 2013.consequently, the issued share capital of the company stands increased to rs.1,61,04,27,732 comprising of 80,52, 13,866 equity shares of face value rs.2/- each. the paid-up & subscribed share capital of the company stands increased to rs.1,60,84,20,942 comprising of 80,42, 10,471 equity shares of face value rs.2/-each.",02-Sep-2016 08:22:00,2016-09-02 08:22:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_02092016082225_034.zip,02-09-2016,580.2999877929688,581.0999755859375,571.5,577.9500122070312,556.0388793945312,880437,0.0,0.0,12-09-2016,0
442,CIPLA,Cipla Limited,updates," regarding updates on contact details of key managerial personnel who are severally authorized to determine materiality of an event or information and make disclosures to the stock exchange(s) pursuant to regulation 30(5) of the securities and exchange board of india (listing obligations and disclosure requirements) regulations, 2015.",01-Sep-2016 18:28:00,2016-09-01 18:28:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_01092016182828_769.zip,01-09-2016,575.0,581.2999877929688,571.0,579.1500244140625,557.1934204101562,960422,0.0,0.0,09-09-2016,0
443,CIPLA,Cipla Limited,annual general meeting updates," a copy of notice of annual general meeting of the members of the company to be held on september 28, 2016.",30-Aug-2016 19:23:00,2016-08-30 19:23:00,-,-,https://nsearchives.nseindia.com/corporate/DisclosureAGMNotice_30082016192358_438.zip,30-08-2016,570.0,581.4500122070312,567.7000122070312,576.0999755859375,554.2589111328125,1075723,0.0,0.0,07-09-2016,0
444,CIPLA,Cipla Limited,analysts/institutional investor meet/con. call updates, regarding schedule of analyst / institutional investor meeting with the company.,30-Aug-2016 17:59:00,2016-08-30 17:59:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_30082016175952_375.zip,30-08-2016,570.0,581.4500122070312,567.7000122070312,576.0999755859375,554.2589111328125,1075723,0.0,0.0,07-09-2016,0
445,CIPLA,Cipla Limited,analysts/institutional investor meet/con. call updates, that the schedule of analyst / institutional investor meetings with the company.,19-Aug-2016 12:31:00,2016-08-19 12:31:00,-,-,https://nsearchives.nseindia.com/corporate/Letter19082016_19082016123135_108.zip,19-08-2016,552.8499755859375,560.5499877929688,552.5,556.7999877929688,535.690673828125,1598177,0.0,0.0,26-08-2016,0
446,CIPLA,Cipla Limited,agm/book closure," that the register of members & share transfer books of the company will remain closed from september 15, 2016 to september 28, 2016 (both days inclusive) for the purpose of dividend and annual general meeting (agm) of the company to be held on september 28, 2016.",12-Aug-2016 19:14:00,2016-08-12 19:14:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_12082016191454.zip,12-08-2016,524.0,526.4000244140625,512.0999755859375,515.9500122070312,496.389404296875,2124886,0.0,0.0,22-08-2016,1
447,CIPLA,Cipla Limited,date of payment of dividend," that the dividend for the year ended march 31, 2016, subject to the approval of shareholders, will now be dispatched/ credited on or after october 3, 2016.",12-Aug-2016 19:08:00,2016-08-12 19:08:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_12082016190858_477.zip,12-08-2016,524.0,526.4000244140625,512.0999755859375,515.9500122070312,496.389404296875,2124886,0.0,0.0,22-08-2016,1
448,CIPLA,Cipla Limited,press release," regarding a press release dated august 12, 2016 in relation to financial results for the quarter ended june 30, 2016.",12-Aug-2016 16:16:00,2016-08-12 16:16:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_12082016161655_181.zip,12-08-2016,524.0,526.4000244140625,512.0999755859375,515.9500122070312,496.389404296875,2124886,0.0,0.0,22-08-2016,1
449,CIPLA,Cipla Limited,press release," regarding a press release dated august 12, 2016 titled "" cipla names umang vohra as md & global ceo; samina vaziralli is executive vice-chairman "".",12-Aug-2016 15:51:00,2016-08-12 15:51:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_12082016155137_125.zip,12-08-2016,524.0,526.4000244140625,512.0999755859375,515.9500122070312,496.389404296875,2124886,0.0,0.0,22-08-2016,1
450,CIPLA,Cipla Limited,financial result updates," the standalone & consolidated financial results along with the limited review report for the period ended june 30, 2016.",12-Aug-2016 15:36:50,2016-08-12 15:36:50,-,-,https://nsearchives.nseindia.com/corporate/FinancialResults_12082016153650.zip,12-08-2016,524.0,526.4000244140625,512.0999755859375,515.9500122070312,496.389404296875,2124886,0.0,0.0,22-08-2016,1
451,CIPLA,Cipla Limited,esops/esos/esps," that nomination and remuneration committee of the company at its meeting held on august 11, 2016 has approved the grant of 20,280 stock options to employee of the company, in terms of employee stock option scheme 2013-a (""esos 2013-a""). the said options carry the right to apply for equal number of equity shares of the company of face value of rs. 2/-each.",11-Aug-2016 19:21:00,2016-08-11 19:21:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_11082016192102_639.zip,11-08-2016,521.5,525.5,517.9000244140625,523.9500122070312,504.0860290527344,761596,0.0,0.0,19-08-2016,1
452,CIPLA,Cipla Limited,updates," a copy of schedule of press conference and earnings conference call to be held on august 12, 2016.",09-Aug-2016 11:22:00,2016-08-09 11:22:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_09082016112222_070.zip,09-08-2016,537.7999877929688,540.0,530.1500244140625,532.9500122070312,512.7449951171875,886532,0.0,0.0,17-08-2016,0
453,CIPLA,Cipla Limited,updates," that the contact details of key managerial personnel who are severally authorized to determine materiality of an event or information and make disclosures to the stock exchange(s) pursuant to regulation 30(5) of the securities and exchange board of india (listing obligations and disclosure requi rements) regulations, 2015.consequent to appointment of mr. kedar upadhye as global chief financial officer with effect from august 1, 2016.",04-Aug-2016 10:39:00,2016-08-04 10:39:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_04082016103953_051.zip,04-08-2016,531.2000122070312,534.0,523.0,526.9500122070312,506.9724426269531,1564658,0.0,0.0,11-08-2016,0
454,CIPLA,Cipla Limited,press release," regarding press release dated august 01, 2016 title ""cipla appoints kedar upadhye as global chief financial officer.""",01-Aug-2016 11:16:00,2016-08-01 11:16:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_01082016111651_122.zip,01-08-2016,528.7999877929688,535.0,521.5,524.0499877929688,504.182373046875,955999,0.0,0.0,08-08-2016,0
455,CIPLA,Cipla Limited,updates," that this has reference to earlier letter dated june 08, 2016. we wish to inform you that mr kedar upadhye has joined the company as global chief financial officer with effect from august 01, 2016. consequently mr umang vohra relinquishes office as global chief officer of the company with effect from august 01, 2016. mr vohra will continue as global chief operating officer of the company.",01-Aug-2016 10:14:00,2016-08-01 10:14:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_01082016101425_077.zip,01-08-2016,528.7999877929688,535.0,521.5,524.0499877929688,504.182373046875,955999,0.0,0.0,08-08-2016,0
456,CIPLA,Cipla Limited,updates," regarding pending legal cases relating to alleged overcharging in respect of certain drugs under the drugs (price control), order, 1995.",22-Jul-2016 19:29:00,2016-07-22 19:29:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_22072016192959_579.zip,22-07-2016,516.0,522.9000244140625,512.3499755859375,520.4000244140625,500.6707153320313,1188747,0.0,0.0,29-07-2016,0
457,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company held on july 15, 2016 allotted 5,679 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantee under employee stock option scheme 2013-a",15-Jul-2016 20:10:00,2016-07-15 20:10:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_15072016201007_544.zip,15-07-2016,513.9500122070312,518.9000244140625,510.2000122070313,516.4000244140625,496.82232666015625,1004156,0.0,0.0,22-07-2016,0
458,CIPLA,Cipla Limited,analysts meet," that the representative of the company met investors (i.e blackrock indus capital partners and vontobel asset management inc.) in new york on july 06, 2016.",07-Jul-2016 12:19:00,2016-07-07 12:19:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_07072016121931_328.zip,07-07-2016,505.5,517.3499755859375,504.0499877929688,514.2999877929688,494.8019714355469,2078580,0.0,0.0,14-07-2016,0
459,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on june 21, 2016 allotted 36,196 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a. consequently, the issued share capital of the company stands increased to rs.1,60,92,16,374 comprising of 80,46,08,187 equity shares of face value rs.2/ each. the paid-up & subscribed share capital of the company stands increased to rs.1,60,72,09,584 comprising of 80,36,04,792 equity shares of face value rs.2/-each.",21-Jun-2016 20:05:00,2016-06-21 20:05:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_21062016200536_154.zip,21-06-2016,490.0,490.0,480.2999877929688,483.3999938964844,465.0734252929688,861422,0.0,0.0,28-06-2016,0
460,CIPLA,Cipla Limited,analysts meet, regarding schedule of analyst / institutional investor meetings with the company.,15-Jun-2016 13:50:00,2016-06-15 13:50:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_15062016135029_447.zip,15-06-2016,485.8999938964844,492.5499877929688,483.7999877929688,490.0499877929688,471.4712829589844,1860880,0.0,0.0,22-06-2016,0
461,CIPLA,Cipla Limited,analysts meet," vide letter dated june 10, 2016 regarding the schedule of analyst/institutional investor meetings.",10-Jun-2016 14:03:00,2016-06-10 14:03:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_10062016140359_141.zip,10-06-2016,475.0,486.6000061035156,474.5,476.4500122070313,458.3869018554688,1704257,0.0,0.0,17-06-2016,0
462,CIPLA,Cipla Limited,analysts meet, regarding the schedule of analyst / institutional investor meeting with the company.,08-Jun-2016 16:45:00,2016-06-08 16:45:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_08062016164536_280.zip,08-06-2016,471.8500061035156,474.0,468.0,472.1499938964844,454.2499084472656,811331,0.0,0.0,15-06-2016,0
463,CIPLA,Cipla Limited,appointment of chief financial officer," that the board of directors at its meeting held on june 08, 2016, has inter-alia approved the appointment of mr. kedar upadhye as global chief financial officer of the company who will assume office on or before august 16, 2016.",08-Jun-2016 13:28:00,2016-06-08 13:28:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_08062016132808_146.zip,08-06-2016,471.8500061035156,474.0,468.0,472.1499938964844,454.2499084472656,811331,0.0,0.0,15-06-2016,0
464,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on may 31, 2016 allotted 1,12,013 equity shares of rs. 2/- each pursuant to exercise of the stock options by the option grantee under employee stock option scheme 2013-a. consequently, the issued share capital of the company stands increased to rs. 1,60,91,43,982 comprising of 80,45,71,991 equity shares of face value rs.2/ each. the paid-up & subscribed share capital of the company stands increased to rs. 1,60,71,37,192 comprising of 80,35,68,596 equity shares of face value rs.2/-each.",31-May-2016 18:02:00,2016-05-31 18:02:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_31052016180255_977.zip,31-05-2016,475.3999938964844,479.25,471.0,472.6499938964844,454.73095703125,2368362,0.0,0.0,07-06-2016,0
465,CIPLA,Cipla Limited,outcome of board meeting," that the board of directors of the company at its meeting held on may 24, 2016 have, subject to the approval of shareholders, recommended the appointment of walker chandiok & co llp, chartered accountants, as statutory auditors of the company to hold office from the conclusion of ensuing 80th annual general meeting till the conclusion of 85th annual general meeting.",24-May-2016 19:08:00,2016-05-24 19:08:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_1_24052016190829.zip,24-05-2016,499.9500122070313,505.2000122070313,491.5499877929688,494.0499877929688,475.3196716308594,2526624,0.0,0.0,31-05-2016,0
466,CIPLA,Cipla Limited,outcome of board meeting," that the board of directors of the company at its meeting held on may 24, 2016 have, subject to the approval of shareholders, recommended the appointment of walker chandiok & co llp, chartered accountants, as statutory auditors of the company to hold office from the conclusion of ensuing annual general meeting till the conclusion of annual general meeting.",24-May-2016 18:46:00,2016-05-24 18:46:00,-,-,https://nsearchives.nseindia.com/corporate/Auditor_24052016184655_874.zip,24-05-2016,499.9500122070313,505.2000122070313,491.5499877929688,494.0499877929688,475.3196716308594,2526624,0.0,0.0,31-05-2016,0
467,CIPLA,Cipla Limited,updates," a copy of investor presentation q4 fy 16 earnings release dated may 24, 2016.",24-May-2016 18:14:00,2016-05-24 18:14:00,-,-,https://nsearchives.nseindia.com/corporate/InvestorPresentation_24052016181449_850.zip,24-05-2016,499.9500122070313,505.2000122070313,491.5499877929688,494.0499877929688,475.3196716308594,2526624,0.0,0.0,31-05-2016,0
468,CIPLA,Cipla Limited,press release," regarding a press release dated may 24, 2016, titled "" cipla announces q4 and full year fy16 audited financial results"".",24-May-2016 18:14:00,2016-05-24 18:14:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_24052016181448_849.zip,24-05-2016,499.9500122070313,505.2000122070313,491.5499877929688,494.0499877929688,475.3196716308594,2526624,0.0,0.0,31-05-2016,0
469,CIPLA,Cipla Limited,dividend," that the board of directors of the company at its meeting held on may 24, 2016 has recommended payment of dividend of rs.2 per equity share (face value rs 2 per equity share) for the year 2015-16. the dividend, subject to the approval of shareholders, will be dispatched /credited on or after august 29, 2016.",24-May-2016 18:00:00,2016-05-24 18:00:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_24052016180033.zip,24-05-2016,499.9500122070313,505.2000122070313,491.5499877929688,494.0499877929688,475.3196716308594,2526624,0.0,0.0,31-05-2016,0
470,CIPLA,Cipla Limited,financial result updates," the standalone & consolidated financial results along with the auditors report for the period ended march 31, 2016.",24-May-2016 17:58:03,2016-05-24 17:58:03,-,-,https://nsearchives.nseindia.com/corporate/FinancialResults_24052016175803.zip,24-05-2016,499.9500122070313,505.2000122070313,491.5499877929688,494.0499877929688,475.3196716308594,2526624,0.0,0.0,31-05-2016,0
471,CIPLA,Cipla Limited,updates," that regarding schedule of earnings conference call to be held on may 24, 2016.",18-May-2016 19:49:00,2016-05-18 19:49:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_18052016194935_615.zip,18-05-2016,522.5499877929688,526.75,520.0499877929688,524.5499877929688,504.6633911132813,653047,0.0,0.0,25-05-2016,-1
472,CIPLA,Cipla Limited,trading window," that in terms of the company's code of conduct to regulate, monitor and report trading by insiders, the ""trading window"" for dealing in the securities of the company will remain closed from may 17 2016 till completion of 48 hours after the audited financial results are made public.",16-May-2016 17:35:00,2016-05-16 17:35:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_16052016173546.zip,16-05-2016,533.8499755859375,533.8499755859375,520.3499755859375,521.7999877929688,502.01763916015625,883516,0.0,0.0,23-05-2016,0
473,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on april 28, 2016 allotted 72,301 equity shares of rs. 2/-each pursuant to exercise of the stock options by the option grantees under employees stock option scheme 2013-a. consequently, the issued share capital of the company stands increased to rs. 1,60,89,19,956 comprising of 80,44,59,978 equity shares of face value rs. 2/-each. the paid-up & subscribed share capital of the company stands increased to rs. 1,60,69,13,166 comprising of 80,34,56,583 equity shares of face value rs. 2/-each.",28-Apr-2016 19:02:00,2016-04-28 19:02:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_28042016190249_456.zip,28-04-2016,538.9000244140625,543.75,525.0,528.25,508.2230529785156,3088525,0.0,0.0,05-05-2016,0
474,CIPLA,Cipla Limited,esops/esos/esps," that nomination and remuneration committee of the company at its meeting held on april 28, 2016 has approved the grant of 27,702 stock options to employees of the company and its subsidiary company, in terms of employee stock option scheme 2013-a (""esos 2013-a"").",28-Apr-2016 18:30:00,2016-04-28 18:30:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_28042016183013_434.zip,28-04-2016,538.9000244140625,543.75,525.0,528.25,508.2230529785156,3088525,0.0,0.0,05-05-2016,0
475,CIPLA,Cipla Limited,updates," vide letter dated april 12, 2016 that "" this has reference to our earlier disclosures dated 9th july 2015, 20th july 2015, 21st july 2015, 27th november 2015, 10th december 2015, 21st january 2016, 16th february 2016 and 1st march 2016. we would like to inform you that the board of directors of cipla health limited, a subsidiary of the company, at their meeting held on 12th april 2016 allotted shares to fil capital investments (mauritius) ii limited and consequently, the transaction has now been completed"".",13-Apr-2016 09:01:00,2016-04-13 09:01:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_13042016090158_048.zip,13-04-2016,505.1499938964844,515.0,504.0,511.8999938964844,492.4929504394531,3642720,0.0,0.0,25-04-2016,0
476,CIPLA,Cipla Limited,updates," that cipla (eu) limited, uk (""cipla uk""), a wholly owned subsidiary of the company, has pursuant to the approval of the board of cipla uk, made an additional investment of usd 3 million in chase pharmaceuticals corporation inc., us (""chase"") towards full settlement of its obligation under the agreed arrangement for investment in chase. consequently, cipla uk's total investment in chase would aggregate to approximately uso 5.12 million for a 16.7% stake on a fully diluted basis.",16-Mar-2016 08:28:00,2016-03-16 08:28:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_16032016082846_850.zip,16-03-2016,524.9000244140625,534.7999877929688,516.2000122070312,531.0,510.868896484375,2221318,0.0,0.0,23-03-2016,0
477,CIPLA,Cipla Limited,allotment of securities," that nomination and remuneration committee of the company on march 02, 2016 allotted 10,000 equity shares of rs. 2/- each pursuant to exercise of the stock options by the option grantee under employee stock option scheme 2013-a. consequently, the issued share capital of the company stands increased to rs. 1,60,87,75,354 comprising of 80,43,87,677 equity shares efface value rs.2/- each. the paid-up & subscribed share capital of the company stands increased to rs. 1,60,67,68,564 comprising of 80,33,84,282 equity shares of face value rs.2/-each.",02-Mar-2016 16:56:00,2016-03-02 16:56:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_02032016165608_241.zip,02-03-2016,523.5,532.0,519.4000244140625,525.5999755859375,505.6736145019531,3422308,0.0,0.0,10-03-2016,0
478,CIPLA,Cipla Limited,updates," that the company's consumer healthcare business has been transferred to cipla health limited, subsidiary of the company with effect from the close of business hours on february 29, 2016.",01-Mar-2016 19:01:00,2016-03-01 19:01:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_01032016190106_955.zip,01-03-2016,515.0,521.4000244140625,509.6000061035156,516.3499755859375,496.774169921875,2146110,0.0,0.0,09-03-2016,0
479,CIPLA,Cipla Limited,press release," regarding a press release dated february 18, 2016 regarding ""cipla completes acquisition of generic businesses in us"".",18-Feb-2016 08:47:00,2016-02-18 08:47:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_18022016084745_031.zip,18-02-2016,527.0999755859375,529.4000244140625,520.5999755859375,524.4000244140625,504.51904296875,1967772,0.0,0.0,25-02-2016,0
480,CIPLA,Cipla Limited,updates," that based on the press release dated february 15, 2016 issued by the government of india, ministry of finance, department of economic affairs (fipb unit), it appears that the government has based on the recommendations of the foreign investment promotion board, approved the proposed investment by fil capital investments (mauritius) ii limited in cipla health limited, subsidiary of the company.",16-Feb-2016 17:01:00,2016-02-16 17:01:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_16022016170152_248.zip,16-02-2016,545.9500122070312,549.5,520.4500122070312,524.0499877929688,504.182373046875,2664696,0.0,0.0,23-02-2016,0
481,CIPLA,Cipla Limited,press release (revised)," regarding a revised press release dated february 10,2016, titled ""cipla announces q3 fy1516 unaudited consolidated financial results"".",11-Feb-2016 18:29:00,2016-02-11 18:29:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_11022016182913_509.zip,11-02-2016,530.0,548.7000122070312,517.2999877929688,540.8499755859375,520.3453369140625,5647601,0.0,0.0,18-02-2016,0
482,CIPLA,Cipla Limited,press release," regarding a press release dated february 10, 2016 titled ""cipla announces q3 fy1516 unaudited consolidated financial results"".",10-Feb-2016 16:45:00,2016-02-10 16:45:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_10022016164555_818.zip,10-02-2016,555.0,558.9500122070312,534.0,538.5999755859375,518.1806030273438,2425499,0.0,0.0,17-02-2016,0
483,CIPLA,Cipla Limited,financial result updates," the standalone & consolidated financial results along with the limited review report for the period ended december 31, 2015.",10-Feb-2016 16:25:51,2016-02-10 16:25:51,-,-,https://nsearchives.nseindia.com/corporate/Results_10022016162551.zip,10-02-2016,555.0,558.9500122070312,534.0,538.5999755859375,518.1806030273438,2425499,0.0,0.0,17-02-2016,0
484,CIPLA,Cipla Limited,esops/esos/esps," that nomination and remuneration committee of the company on february 09, 2016 has approved the grant of 11,408 stock options to employees of the company and its subsidiary companies, in terms of employee stock option scheme 2013-a(""esos 2013-a"")",09-Feb-2016 18:16:00,2016-02-09 18:16:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_09022016181644_430.zip,09-02-2016,564.9000244140625,571.2000122070312,551.0999755859375,555.8499755859375,534.7766723632812,1357674,0.0,0.0,16-02-2016,-1
485,CIPLA,Cipla Limited,allotment of securities," that nomination and remuneration committee of the company on february 09, 2016 allotted 52,296 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a.",09-Feb-2016 16:38:00,2016-02-09 16:38:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_09022016163838_328.zip,09-02-2016,564.9000244140625,571.2000122070312,551.0999755859375,555.8499755859375,534.7766723632812,1357674,0.0,0.0,16-02-2016,-1
486,CIPLA,Cipla Limited,updates," that regarding the schedule of press conference call to be held on february 10, 2016.",05-Feb-2016 16:33:00,2016-02-05 16:33:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_05022016163326_220.zip,05-02-2016,555.0,573.2999877929688,544.0999755859375,570.1500244140625,548.5345458984375,864080,0.0,0.0,12-02-2016,-1
487,CIPLA,Cipla Limited,trading window," that in terms of the company s code of conduct to regulate, monitor and report trading by insiders, the trading window for dealing in the securities of the company will remain closed from february 03, 2016 till completion of 48 hours after the unaudited financial results are made public.",02-Feb-2016 18:49:00,2016-02-02 18:49:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_02022016184955.zip,02-02-2016,601.0,606.0499877929688,562.0,574.0,552.2386474609375,1779141,0.0,0.0,09-02-2016,0
488,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"dr. y. k. hamied has submitted to the exchange vide its letter dated february 1, 2016 a copy of disclosure under regulation 10(6) in respect of acquisition under regulation 10 of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",02-Feb-2016 12:08:00,2016-02-02 12:08:00,-,-,https://nsearchives.nseindia.com/corporate/ykh_02022016120859.zip,02-02-2016,601.0,606.0499877929688,562.0,574.0,552.2386474609375,1779141,0.0,0.0,09-02-2016,0
489,CIPLA,Cipla Limited,allotment of securities," that nomination and remuneration committee of the company on january 25, 2016 allotted 83,140 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a.",25-Jan-2016 19:18:00,2016-01-25 19:18:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_25012016191824_470.zip,25-01-2016,590.0,590.0,579.2000122070312,580.5999755859375,558.5883178710938,910559,0.0,0.0,02-02-2016,0
490,CIPLA,Cipla Limited,updates," that the company has on january 22, 2016 completed the transfer formalities in relation to the divestment of its entire 25% stake held on biomab holding limited, hong kong (""biomab""). consequently, the company ceases to hold any stake in biomab.",22-Jan-2016 19:45:00,2016-01-22 19:45:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_22012016194514_189.zip,22-01-2016,582.7999877929688,588.5,577.4000244140625,581.9000244140625,559.839111328125,1297154,0.0,0.0,01-02-2016,0
491,CIPLA,Cipla Limited,updates," that fil capital investments (mauritius) ii limited have informed the company that they have received intimation from the competition commission of india (""cci"") that the cci has granted its approval with respect to, inter-alia, the proposed investment by fil capital investment (mauritius) ii limited in cipla health limited, subsidiary of the company. the order of the cci will be sent to fil capital investments (mauritius) ii limited subsequently.the investment is still subject to, amongst other conditions precedent, approval from the foreign investment promotion board and the transfer of company's consumer healthcare business to cipla health limited.",21-Jan-2016 19:57:00,2016-01-21 19:57:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_21012016195738_743.zip,21-01-2016,600.25,601.4500122070312,576.5499877929688,580.25,558.2517700195312,1452498,0.0,0.0,29-01-2016,0
492,CIPLA,Cipla Limited,credit rating, that credit analysis and research limited (care) has reaffirmed a 'care aaa/a1+' rating to the various bank facilities for an aggregate amount of rs.3310.50 crores.,21-Jan-2016 18:50:00,2016-01-21 18:50:00,-,-,https://nsearchives.nseindia.com/corporate/CreditRating_21012016185030_717.zip,21-01-2016,600.25,601.4500122070312,576.5499877929688,580.25,558.2517700195312,1452498,0.0,0.0,29-01-2016,0
493,CIPLA,Cipla Limited,credit rating, that credit analysis and research limited (care) has reaffirmed a 'care aaa / a 1+' rating to the various bank facilities for an aggregate amount of rs. 3310.50 crores .,21-Jan-2016 17:53:00,2016-01-21 17:53:00,-,-,https://nsearchives.nseindia.com/corporate/Credit_Rating_21012016175351.zip,21-01-2016,600.25,601.4500122070312,576.5499877929688,580.25,558.2517700195312,1452498,0.0,0.0,29-01-2016,0
494,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"dr. y k hamied has submitted to the exchange vide its letter dated january 21, 2016 a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10(1) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",21-Jan-2016 17:34:00,2016-01-21 17:34:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_105_21012016173420.zip,21-01-2016,600.25,601.4500122070312,576.5499877929688,580.25,558.2517700195312,1452498,0.0,0.0,29-01-2016,0
495,CIPLA,Cipla Limited,updates," regarding the schedule of investor conference is as under : 1) name of conference : jp morgan global healthcare conference, san francisco, usa. 2) date and time : january 12, 2016 at 3.30 p.m. (san francisco time)the presentation that will be made at the conference is available on the company's website.",12-Jan-2016 19:58:00,2016-01-12 19:58:00,-,-,https://nsearchives.nseindia.com/corporate/Letter_12012016195856_329.zip,12-01-2016,609.0,616.9000244140625,605.7000122070312,611.4500122070312,588.268798828125,1278522,0.0,0.0,19-01-2016,0
496,CIPLA,Cipla Limited,press release," regarding a press release dated january 07, 2016, titled ""cipla announces its management council"".",07-Jan-2016 16:05:00,2016-01-07 16:05:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_07012016160554_478.zip,07-01-2016,648.0,650.0,629.0,637.4500122070312,613.283203125,732335,0.0,0.0,14-01-2016,0
497,CIPLA,Cipla Limited,allotment of securities," that nomination and remuneration committee of the company on december 18, 2015 allotted 63,483 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a.",21-Dec-2015 09:01:00,2015-12-21 09:01:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_21122015090120_019.zip,21-12-2015,649.7999877929688,649.7999877929688,641.0999755859375,643.7000122070312,619.2962036132812,738842,0.0,0.0,29-12-2015,0
498,CIPLA,Cipla Limited,updates," that the contact details of key managerial personnel who are severally authorised to determine materiality of an event or information and make disclosures to the stock exchange(s) pursuant to regulation 30(5) of the securities and exchange board of india (listing obligations and disclosure requirements) regulations, 2015.",16-Dec-2015 20:02:00,2015-12-16 20:02:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_16122015200254.zip,16-12-2015,642.9500122070312,643.9500122070312,637.0999755859375,638.6500244140625,614.4376220703125,1166504,0.0,0.0,23-12-2015,0
499,CIPLA,Cipla Limited,updates," that the board of directors of cipla limited (""company"") have on december 10, 2015, approved the transfer of the consumer healthcare business of the company to cipla health limited (""cipla health"") on a going concern basis by way of a slump sale for a lumpsum consideration of rs. 16 crore.",10-Dec-2015 18:00:00,2015-12-10 18:00:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_10122015180054.zip,10-12-2015,625.0499877929688,640.8499755859375,622.0,636.7999877929688,612.6577758789062,1030589,0.0,0.0,17-12-2015,0
500,CIPLA,Cipla Limited,press release," regarding a press release dated december 03, 2015 titled ""cipla launches novel ""5 in 1"" anti-ageing skin care product cutisera  developed by stempeutics"".",03-Dec-2015 14:38:00,2015-12-03 14:38:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_pr_03122015143826.zip,03-12-2015,652.75,656.0,642.25,651.2000122070312,626.5117797851562,1484709,0.0,0.0,10-12-2015,0
501,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on december 02, 2015 allotted 70,557 equity shares of rs. 2/- each pursuant to exercise of the stock options by the option grantees under employee stock option scheme 2013-a"".",02-Dec-2015 18:30:00,2015-12-02 18:30:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_02122015183010_232.zip,02-12-2015,648.5999755859375,661.4000244140625,648.5,658.4000244140625,633.4388427734375,1610659,0.0,0.0,09-12-2015,-1
502,CIPLA,Cipla Limited,press release," regarding a press release dated november 30, 2015, titled ""cipla ready to launch low-dose efavirenz 400 mg"".",30-Nov-2015 11:38:00,2015-11-30 11:38:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_pr_30112015113807.zip,30-11-2015,643.0,651.5,639.0,643.6500244140625,619.2481079101562,2146672,0.0,0.0,07-12-2015,0
503,CIPLA,Cipla Limited,updates," with to the earlier announcement dated july 09 2015, july 20, 2015 and july 21, 2015. the company would like to inform that the company, cipla health limited and fil capital investments (mauritius) ii limited have november 27, 2015 signed an investment agreement. the investment is subject to, amongst other conditions precedent, approvals from the foreign investment promotion board and the competition commission of india, and the transfer of cipla s consumer healthcare business to cipla health limited.",30-Nov-2015 08:24:00,2015-11-30 08:24:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_30112015082435_135.zip,30-11-2015,643.0,651.5,639.0,643.6500244140625,619.2481079101562,2146672,0.0,0.0,07-12-2015,0
504,CIPLA,Cipla Limited,reappointment," that the board of directors of the company at its meeting held on november 5, 2015 has re-appointed mr. s. radhakrishnan as a whole-time director for a term of two years w.e.f. november 12, 2015.",05-Nov-2015 17:14:00,2015-11-05 17:14:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_05112015171429.zip,05-11-2015,675.0,675.4000244140625,655.2000122070312,658.0499877929688,633.1021118164062,1833741,0.0,0.0,16-11-2015,0
505,CIPLA,Cipla Limited,press release," regarding a press release dated november 5, 2015 titled ""cipla announces q2 fy1516 unaudited consolidated financial results"".",05-Nov-2015 17:00:00,2015-11-05 17:00:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_05112015170048.zip,05-11-2015,675.0,675.4000244140625,655.2000122070312,658.0499877929688,633.1021118164062,1833741,0.0,0.0,16-11-2015,0
506,CIPLA,Cipla Limited,financial result updates, the standalone & consolidated financial results along with the limited review report for the period ended 30-sep-2015.,05-Nov-2015 16:47:39,2015-11-05 16:47:39,-,-,https://nsearchives.nseindia.com/corporate/Cipla_05112015164739.zip,05-11-2015,675.0,675.4000244140625,655.2000122070312,658.0499877929688,633.1021118164062,1833741,0.0,0.0,16-11-2015,0
507,CIPLA,Cipla Limited,esops/esos/esps," regarding ""grant of options under the employee stock option scheme 2013-a"".",04-Nov-2015 19:27:00,2015-11-04 19:27:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_04112015192743.zip,04-11-2015,680.0,680.9500122070312,668.0999755859375,670.7000122070312,645.2726440429688,1321427,0.0,0.0,13-11-2015,-1
508,CIPLA,Cipla Limited,press release," regarding a press release dated october 29, 2015 titled ""cipla strengthens its focus on biotech"".",29-Oct-2015 16:16:00,2015-10-29 16:16:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_29102015161634_167.zip,29-10-2015,699.0,704.9000244140625,689.5,691.5499877929688,665.3322143554688,2975896,0.0,0.0,05-11-2015,0
509,CIPLA,Cipla Limited,updates," that the company has entered into a definitive agreement to sell its entire 25% stake in biomab holding limited, hong kong (""bhl"") to biomab brilliant limited, british virgin islands which holds the remaining 75% stake in bhl, for a total consideration of usd 25,775,000.",29-Oct-2015 16:04:00,2015-10-29 16:04:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_29102015160442.zip,29-10-2015,699.0,704.9000244140625,689.5,691.5499877929688,665.3322143554688,2975896,0.0,0.0,05-11-2015,0
510,CIPLA,Cipla Limited,trading window," that the trading window for dealing in the securities of the company will remain closed from october 29, 2015 till completion of 48 hours after the unaudited financial results are made public.",28-Oct-2015 19:12:00,2015-10-28 19:12:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_28102015191235.zip,28-10-2015,682.25,702.25,675.7999877929688,696.0499877929688,669.661376953125,1537365,0.0,0.0,04-11-2015,0
511,CIPLA,Cipla Limited,press release," regarding a press release dated october 08, 2015, titled ""cipla medpro (pty) ltd. partners with serum institute india(sii) to provide vaccines in south africa"".",08-Oct-2015 14:21:00,2015-10-08 14:21:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_pr_08102015142109.zip,08-10-2015,688.0,689.5,672.0499877929688,680.25,654.4605102539062,2304302,0.0,0.0,15-10-2015,0
512,CIPLA,Cipla Limited,updates," that cipla (eu) limited, a wholly owned subsidiary of the company has entered into a definitive agreement with biopharm spa for establishing a joint venture company in algeria.",07-Oct-2015 19:44:00,2015-10-07 19:44:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_07102015194445.zip,07-10-2015,668.9000244140625,683.5999755859375,660.5999755859375,680.7999877929688,654.9895629882812,2160153,0.0,0.0,14-10-2015,0
513,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"shirin hamied has submitted to the exchange vide its letter dated september 22, 2015 a copy of disclosure under regulation 10(6) in respect of acquisition under regulation 10 of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",22-Sep-2015 19:29:00,2015-09-22 19:29:00,-,-,https://nsearchives.nseindia.com/corporate/SMKH_10(6)_22092015192923.zip,22-09-2015,653.0,653.2999877929688,642.0999755859375,644.1500244140625,619.7290649414062,1673424,0.0,0.0,30-09-2015,0
514,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"m k hamied has submitted to the exchange vide its letter dated september 22, 2015 a copy of disclosure under regulation 10(6) in respect of acquisition under regulation 10 of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",22-Sep-2015 16:29:00,2015-09-22 16:29:00,-,-,https://nsearchives.nseindia.com/corporate/MKH_10(6)_22092015162925.zip,22-09-2015,653.0,653.2999877929688,642.0999755859375,644.1500244140625,619.7290649414062,1673424,0.0,0.0,30-09-2015,0
515,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"shirin hamied has submitted to the exchange vide its letter dated september 11, 2015 a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10(1) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",11-Sep-2015 19:02:00,2015-09-11 19:02:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_10_11092015190218.zip,11-09-2015,660.0,662.75,648.9000244140625,653.1500244140625,628.3878784179688,1179996,0.0,0.0,21-09-2015,0
516,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"m k hamied has submitted to the exchange vide its letter dated september 11, 2015 a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10(1) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",11-Sep-2015 18:22:00,2015-09-11 18:22:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_106_11092015182228.zip,11-09-2015,660.0,662.75,648.9000244140625,653.1500244140625,628.3878784179688,1179996,0.0,0.0,21-09-2015,0
517,CIPLA,Cipla Limited,press release," regarding a press release dated september 04, 2015, titled, ""cipla to acquire 100% of generic businesses in us for $550m"".",04-Sep-2015 09:06:00,2015-09-04 09:06:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_pr_04092015090629.zip,04-09-2015,676.25,679.7999877929688,646.5,649.5499877929688,624.9244384765625,4428049,0.0,0.0,11-09-2015,0
518,CIPLA,Cipla Limited,updates," that cipla (eu) limited, u.k., the wholly owned subsidiary of the company, has entered into definitive agreements to acquire 100% stake in two us based companies, lnvagen pharmaceuticals inc. (""lnvagen"") and exelan pharmaceuticals inc. (""exelan"").",04-Sep-2015 09:03:00,2015-09-04 09:03:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_01_04092015090353.zip,04-09-2015,676.25,679.7999877929688,646.5,649.5499877929688,624.9244384765625,4428049,0.0,0.0,11-09-2015,0
519,CIPLA,Cipla Limited,press release," regarding a press release dated september 1, 2015 titled ""cipla appoints umang vohra and prabir jha to its management team"".",01-Sep-2015 17:14:00,2015-09-01 17:14:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_presss_01092015171436.zip,01-09-2015,682.0,688.4000244140625,657.0,663.1500244140625,638.0087890625,2567389,0.0,0.0,08-09-2015,0
520,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"dr y.k. hamied has submitted to the exchange vide its letter dated september 1, 2015 a copy of disclosure under regulation 10(6) in respect of acquisition under regulation 10 of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",01-Sep-2015 13:14:00,2015-09-01 13:14:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_106_01092015131432.zip,01-09-2015,682.0,688.4000244140625,657.0,663.1500244140625,638.0087890625,2567389,0.0,0.0,08-09-2015,0
521,CIPLA,Cipla Limited,disclosure of voting pattern - clause 35a," regarding the details of the voting result of the annual general meeting of the company held on august 27, 2015, as per clause 35a of the listing agreement.",31-Aug-2015 08:20:00,2015-08-31 08:20:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_dis35a_31082015082032.zip,31-08-2015,659.7999877929688,685.0,655.0999755859375,682.1500244140625,656.2884521484375,2172057,0.0,0.0,07-09-2015,0
522,CIPLA,Cipla Limited,annual general meeting updates," regarding proceedings of annual general meeting held on august 27, 2015.",28-Aug-2015 17:51:00,2015-08-28 17:51:00,-,-,https://nsearchives.nseindia.com/corporate/AGMProceedings_28082015175129_408.zip,28-08-2015,675.0,679.7000122070312,655.0,659.8499755859375,634.8338623046875,2111583,0.0,0.0,04-09-2015,0
523,CIPLA,Cipla Limited,updates," a copy of chairman's speech delivered at the annual general meeting of the company held on august 27, 2015.",28-Aug-2015 13:19:00,2015-08-28 13:19:00,-,-,https://nsearchives.nseindia.com/corporate/ChairmanSpeech_28082015131956_281.zip,28-08-2015,675.0,679.7000122070312,655.0,659.8499755859375,634.8338623046875,2111583,0.0,0.0,04-09-2015,0
524,CIPLA,Cipla Limited,updates," a copy of chairman's speech delivered at the annual general meeting of the company held on august 27, 2015.",28-Aug-2015 12:03:00,2015-08-28 12:03:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_agm_28082015120352.zip,28-08-2015,675.0,679.7000122070312,655.0,659.8499755859375,634.8338623046875,2111583,0.0,0.0,04-09-2015,0
525,CIPLA,Cipla Limited,disclosure under insider trading regulation," vide letter dated august 24, 2015 a copy of disclosure under the provisions of regulation 7(2) of the sebi (prohibition of insider trading) regulations, 2015.",27-Aug-2015 18:33:00,2015-08-27 18:33:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_7_10001_27082015183334.zip,27-08-2015,652.0,667.7999877929688,640.0,660.9500122070312,635.8921508789062,3929856,0.0,0.0,03-09-2015,0
526,CIPLA,Cipla Limited,disclosure under insider trading regulation," vide letter dated august 25, 2015 a copy of disclosure under the provisions of regulation 7(2) of the sebi (prohibition of insider trading) regulations, 2015.",27-Aug-2015 16:04:00,2015-08-27 16:04:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_7_20001_27082015160452.zip,27-08-2015,652.0,667.7999877929688,640.0,660.9500122070312,635.8921508789062,3929856,0.0,0.0,03-09-2015,0
527,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"dr y.k. hamied has submitted to the exchange vide its letter dated august 24, 2015  a copy of disclosure under regulation 10(5) in respect of acquisition under regulation 10(1)(a) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",25-Aug-2015 08:38:00,2015-08-25 08:38:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_dis10_25082015083833.zip,25-08-2015,649.0,654.0,605.7000122070312,645.4000244140625,620.9317016601562,4891926,0.0,0.0,01-09-2015,0
528,CIPLA,Cipla Limited,press release," regarding the press release dated august 14, 2015 w.r.t financial results for the quarter ended june 30, 2015.",14-Aug-2015 19:22:00,2015-08-14 19:22:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_14082015192249_866.zip,14-08-2015,735.0,741.75,730.25,739.5999755859375,711.5603637695312,3238561,0.0,0.0,21-08-2015,-1
529,CIPLA,Cipla Limited,financial result updates, the standalone & consolidated financial results for the period ended 30-jun-2015.,14-Aug-2015 19:21:48,2015-08-14 19:21:48,-,-,https://nsearchives.nseindia.com/corporate/UnauditedFinancialResults_14082015192148.zip,14-08-2015,735.0,741.75,730.25,739.5999755859375,711.5603637695312,3238561,0.0,0.0,21-08-2015,-1
530,CIPLA,Cipla Limited,press release," regarding a press release dated august 11, 2015, titled ""cipla announces a new respiratory inhaler: synchrobreathe (sb), a state-of-the-art breath-actuated inhaler which will bring relief to millions of patients with obstructive airway disease(oad, asthma and copd)"".",11-Aug-2015 12:18:00,2015-08-11 12:18:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_11082015121840.zip,11-08-2015,719.0,729.0,713.9500122070312,719.2000122070312,691.9337768554688,1636795,2.0,0.0,18-08-2015,0
531,CIPLA,Cipla Limited,resignation of director," that dr. nachiket mar, independent director has resigned from the directorship of the company with effect from august 7, 2015. the company places on record its appreciation for the valuable services rendered by dr. mar as a member of the board and of its various committees.",07-Aug-2015 18:30:00,2015-08-07 18:30:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_update_07082015183043.zip,07-08-2015,724.7000122070312,728.8499755859375,713.5,715.1500244140625,686.1134643554688,980254,0.0,0.0,14-08-2015,0
532,CIPLA,Cipla Limited,trading window," that the ""trading window"" for dealing in the securities of the company will remain closed from august 7, 2015 till completion of 48 hours after the unaudited financial results are made public.",06-Aug-2015 18:59:00,2015-08-06 18:59:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_BM_06082015185933.zip,06-08-2015,720.25,731.0999755859375,718.0499877929688,723.4000244140625,694.0285034179688,1374485,0.0,0.0,13-08-2015,0
533,CIPLA,Cipla Limited,updates," that further to their letter dated may 21, 2015, the company have re-negotiated the terms of the agreement and have entered into an amendment for upfront payment of the consideration amount instead of payment in tranches over a period of 5 years. accordingly, the revised consideration is approx. usd 26 million (usd 25,995,730) payable upfront upon completion of conditions precedent.",24-Jul-2015 10:38:00,2015-07-24 10:38:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_update_24072015103853.zip,24-07-2015,675.0,685.7999877929688,671.75,678.0999755859375,650.5676879882812,1177924,0.0,0.0,31-07-2015,0
534,CIPLA,Cipla Limited,press release," regarding a press release dated july 21, 2015 titled ""cipla announces an investment led by fidelity growth partners india into the newly launched consumer healthcare business"".",21-Jul-2015 19:01:00,2015-07-21 19:01:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_21072015190110.zip,21-07-2015,683.0,688.75,660.0999755859375,662.5,635.6011352539062,1019824,0.0,0.0,28-07-2015,0
535,CIPLA,Cipla Limited,updates," that the board of directors of the company on july 20, 2015 approved a potential investment by fil capital investments(mauritius) ii limited, or any of its affiliate in a wholly owned subsidiary of cipla limited(proposed to be incorporated) to whom cipla will be divesting its consumer healthcare business on a going-concern basis.",21-Jul-2015 08:08:00,2015-07-21 08:08:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_21072015080854_022.zip,21-07-2015,683.0,688.75,660.0999755859375,662.5,635.6011352539062,1019824,0.0,0.0,28-07-2015,0
536,CIPLA,Cipla Limited,press release," regarding a press release dated july 09, 2015 titled ""cipla board announces appointment of samina vaziralli to the board of directors"".",09-Jul-2015 18:38:00,2015-07-09 18:38:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_press_09072015183830.zip,09-07-2015,647.0,654.9000244140625,637.3499755859375,641.1500244140625,615.1179809570312,1165623,0.0,0.0,16-07-2015,1
537,CIPLA,Cipla Limited,outcome of board meeting," regarding outcome of meeting of the board of directors of the company held on july 9, 2015.",09-Jul-2015 17:55:00,2015-07-09 17:55:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_updates_09072015175511.zip,09-07-2015,647.0,654.9000244140625,637.3499755859375,641.1500244140625,615.1179809570312,1165623,0.0,0.0,16-07-2015,1
538,CIPLA,Cipla Limited,outcome of board meeting," that the board of directors of the company at its meeting held on july 9, 2015 has appointed mrs. samina vaziralli (daughter of mr. m. k. hamied, vice-chairman) as an additional director and whole-time director designated as ""executive director"" with effect from july 10, 2015. the company is seeking approval of shareholders at the ensuing annual general meeting for the said appointment.",09-Jul-2015 17:52:00,2015-07-09 17:52:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_09072015175256.zip,09-07-2015,647.0,654.9000244140625,637.3499755859375,641.1500244140625,615.1179809570312,1165623,0.0,0.0,16-07-2015,1
539,CIPLA,Cipla Limited,allotment of securities," that the nomination and remuneration committee of the company on july 01, 2015 allotted 13,818 equity shares of rs. 2/- each pursuant to exercise of the stock option grantee under employee stock option scheme 2013-a.   consequently, the issued share capital of the company stands increased to rs. 1,60,82,16,402 comprising of 80,41,08,201 equity shares of face value rs. 2/- each. the paid-up & subscribed share capital of the company stands increased to rs. 1,60,62,09,612 comprising of 80,31,04,806 equity shares of face value rs. 2/- each.",01-Jul-2015 20:57:00,2015-07-01 20:57:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_07012015205703_1.zip,01-07-2015,619.0,637.2000122070312,616.75,634.9000244140625,609.121826171875,1789439,0.0,0.0,08-07-2015,0
540,CIPLA,Cipla Limited,allotment of securities," that nomination and remuneration committee of the company on june 17, 2015 allotted 1,30,548 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantee under employee stock option scheme 2013-b.  consequently, the issued share capital of the company stands increased to rs.1,60,81,88,766 comprising of 80,40,94,383 equity shares of face value rs.2/- each. the paid-up & subscribed share capital of the company stands increased to rs.1,60,61,81,976 comprising of 80,30,90,988 equity shares of face value rs.2/-each",18-Jun-2015 08:24:00,2015-06-18 08:24:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_Allo_06182015082401_1.zip,18-06-2015,618.4000244140625,622.5999755859375,602.0999755859375,607.0499877929688,582.4025268554688,2134429,0.0,0.0,25-06-2015,0
541,CIPLA,Cipla Limited,press release," regarding a press release dated june 8, 2015 titled ""  stempeutics receives japan process patent for its novel stem cell drug stempeucel """,08-Jun-2015 12:15:00,2015-06-08 12:15:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_press_06082015121502_1.zip,08-06-2015,619.9000244140625,621.7000122070312,609.0,614.7000122070312,589.7420043945312,1535540,0.0,0.0,15-06-2015,0
542,CIPLA,Cipla Limited,press release," regarding a press release dated june 3, 2015 titled ""cipla announces us fda approval for the world's first paediatric lopinavir and ritonavir oral pellets for the treatment of aids in infants and young children"".",03-Jun-2015 16:01:00,2015-06-03 16:01:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_press_06032015160102_1.zip,03-06-2015,642.2000122070312,643.5499877929688,631.0999755859375,635.1500244140625,609.3616333007812,1140795,0.0,0.0,10-06-2015,-1
543,CIPLA,Cipla Limited,press release," regarding a press release dated june 1, 2015 titled ""stempeutics receives orphan drug designation (odd) in the european union for its novel stem cell drug stempeucel for the treatment of thromboangiitis obliterans"".",01-Jun-2015 15:25:00,2015-06-01 15:25:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_press_06012015152501_1.zip,01-06-2015,645.5,672.75,645.5,662.0999755859375,635.2173461914062,2655528,0.0,0.0,08-06-2015,-1
544,CIPLA,Cipla Limited,change in director(s)," that at the board meeting held on may 29, 2015, a separation agreement is being entered into between mr. rajesh garg and the company under which mr. rajesh garg will demit office as a director, whole-time director and chief financial officer of the company with effect from june 12, 2015.",29-May-2015 19:40:00,2015-05-29 19:40:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_05292015194002_2.zip,29-05-2015,646.8499755859375,660.0,641.2000122070312,650.4500122070312,624.0404052734375,3757040,0.0,0.0,05-06-2015,0
545,CIPLA,Cipla Limited,"code of conduct under sebi(pit) reg., 2015"," that the board of directors of the company at its meeting held on may 29, 2015 adopted the following:  (a) code of practices and procedures for fair disclosure of unpublished price sensitive information  (b) code of conduct to regulate, monitor and report trading by insiders  a copy of the ""code of practices and procedure for fair disclosure of unpublished price sensitive information of cipla limited"" is enclosed.",29-May-2015 19:14:00,2015-05-29 19:14:00,-,-,https://nsearchives.nseindia.com/corporate/Code_05292015191402_1.zip,29-05-2015,646.8499755859375,660.0,641.2000122070312,650.4500122070312,624.0404052734375,3757040,0.0,0.0,05-06-2015,0
546,CIPLA,Cipla Limited,dividend," that the board of directors at its meeting held on may 29, 2015 recommended payment of dividend of rs 2/- per equity share (face value rs. 2 per equity share) for the year 2014-15.",29-May-2015 18:35:00,2015-05-29 18:35:00,-,-,https://nsearchives.nseindia.com/corporate/Dividend_05292015183501_1.zip,29-05-2015,646.8499755859375,660.0,641.2000122070312,650.4500122070312,624.0404052734375,3757040,0.0,0.0,05-06-2015,0
547,CIPLA,Cipla Limited,press release," regarding the press release dated may 29,2015 with respect to the financial results for the year quarter ended march 31, 2015.",29-May-2015 18:35:00,2015-05-29 18:35:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_05292015183502_2.zip,29-05-2015,646.8499755859375,660.0,641.2000122070312,650.4500122070312,624.0404052734375,3757040,0.0,0.0,05-06-2015,0
548,CIPLA,Cipla Limited,financial result updates, the standalone & consolidated financial results for the period ended 31-mar-2015.,29-May-2015 18:15:03,2015-05-29 18:15:03,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_result_05292015181503_.zip,29-05-2015,646.8499755859375,660.0,641.2000122070312,650.4500122070312,624.0404052734375,3757040,0.0,0.0,05-06-2015,0
549,CIPLA,Cipla Limited,press release," regarding a press release dated may 27, 2015, titled, ""cipla announces the next steps in its relationship with serum institute - an exclusive distribution agreement for flu vaccine 'nasovac-s' for india"".",27-May-2015 14:53:00,2015-05-27 14:53:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_pr_05272015145301_1.zip,27-05-2015,657.7999877929688,669.6500244140625,653.0,661.0999755859375,634.258056640625,1529286,0.0,0.0,03-06-2015,0
550,CIPLA,Cipla Limited,trading window," that the ""trading window"" for dealing in the securities of the company will remain closed from may 21, 2015 till completion of 48 hours after the audited financial results are made public.",21-May-2015 17:49:00,2015-05-21 17:49:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_BM_05212015174902_2.zip,21-05-2015,688.4500122070312,688.4500122070312,669.4000244140625,674.3499755859375,646.969970703125,1596030,0.0,0.0,28-05-2015,0
551,CIPLA,Cipla Limited,updates," that ""cipla (eu) limited, u.k., the wholly owned subsidiary of the company, has entered into a definitive agreement to acquire a 51% stake in quality chemicals limited, uganda (""qcl"") from the existing shareholders of qcl. as per the agreement, the cash consideration for 51% stake is payable in tranches with approx. usd 8 million payable upfront on completion and 5 equal installments of usd 4.41 million payable at annual intervals thereafter .  qcl was incorporated in the year 1997 and is engaged in the business of import and distribution of pharmaceutical and consumer products. qcl also holds a 22.05% stake in the company's subsidiary in uganda, cipla quality chemical industries limited (""cqcil""). consequent to this acquisition, company's effective stake (held through its subsidiaries) in cqcil will increase from the existing 51.05% to 62.30% . this acquisition will further strengthen the company's overall presence in the african market.  the turnover of qcl for the financial year ending dec 2012, dec 2013 and dec 2014 was ugandan shilling 15.76 billion, ugandan shilling 17.02 billion and ugandan shilling 14.85 billion respectively .  the transaction is expected to be completed by end of july 2015, subject to completion of certain conditions precedent.  none of the persons belonging to promoter / promoter group(s) of the company has any interest in the transaction and it is not a related party transaction for the company"".",21-May-2015 17:13:00,2015-05-21 17:13:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_05212015171302_1.zip,21-05-2015,688.4500122070312,688.4500122070312,669.4000244140625,674.3499755859375,646.969970703125,1596030,0.0,0.0,28-05-2015,0
552,CIPLA,Cipla Limited,esops/esos/esps," that the nomination and remuneration committee of the board of directors of the company at its meeting held on april 28, 2015 has approved the grant of 10,217 stock options to the employee of subsidiary company, in terms of employee stock option scheme 2013-a (""esos 2013-a""). the said options carry the right to apply for equal number of equity shares of the company of face value of rs.2/- each. the terms of grant inter-alia are as under:    1. vesting: the options would vest not earlier than 1 year and not later than 2 years from the date of grant of options  2. exercise period: 5 years from the date of vesting of options  3. exercise price per option: rs. 2/- ",28-Apr-2015 21:00:00,2015-04-28 21:00:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_04282015210006_1.zip,28-04-2015,625.0,635.0,618.75,631.6500244140625,606.0038452148438,1434089,0.0,0.0,06-05-2015,0
553,CIPLA,Cipla Limited,disc. under reg.30 of sebi (sast) reg.2011,"m. k. hamied has submitted to the exchange vide letter dated april 03, 2015 a copy of disclosure under regulation 30(1) and 30(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011.",17-Apr-2015 11:46:00,2015-04-17 11:46:00,-,-,https://nsearchives.nseindia.com/corporate/ciplaltd_mkhamied_04172015114602_2.zip,17-04-2015,679.0,689.0,672.0999755859375,680.4000244140625,652.7742919921875,2231820,0.0,0.0,24-04-2015,-1
554,CIPLA,Cipla Limited,updates," vide letter dated april 08, 2015 that "" cipla (eu) limited, u.k., a wholly owned subsidiary of the company, has entered into a definitive agreement for acquisition of 100% stake in duomed produtos farmaceuticos ltda. (""duomed""), a limited liability company in brazil for a cash consideration of brazilian real (r$) 1,293,600 (approx. inr 2.6 crores).  duomed was incorporated on 10th june 2013. it has in place approval of anvisa (brazilian health authority) and other regulatory authorities to import and distribute pharmaceutical products in brazil. the acquisition is part of company's front-end strategy and will expedite its product registrations in brazil.  none of the persons belonging to promoter/ promoter group(s) of the company has any interest in the transaction and it is not a related party transaction for the company.  the transaction is expected to be completed by end of may 2015, subject to certain closing deliverables.",09-Apr-2015 08:21:00,2015-04-09 08:21:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_update_09042015_04092015082103_1.zip,09-04-2015,741.7000122070312,741.8499755859375,715.2999877929688,719.4500122070312,690.2389526367188,1409699,0.0,0.0,17-04-2015,-1
555,CIPLA,Cipla Limited,press release," regarding a press release dated march 25, 2015 titled ""cipla announces the launch of generic drug sofosbuvir in india under the brand name 'hepcvir'"".",25-Mar-2015 12:45:00,2015-03-25 12:45:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA-CIPLAress_03252015124502_1.zip,25-03-2015,714.4000244140625,718.4500122070312,706.2999877929688,711.4500122070312,682.5635986328125,1175071,0.0,0.0,01-04-2015,0
556,CIPLA,Cipla Limited,press release," regarding a press release dated march 23, 2015 titled ""stempeutics receives advanced therapy medicinal product (atmp) classification from european medicines agency (ema) for its novel stem cell drug  stempeucel """".",23-Mar-2015 12:30:00,2015-03-23 12:30:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_press_03232015123001_1.zip,23-03-2015,703.5,712.2999877929688,694.0,701.2999877929688,672.8257446289062,825791,0.0,0.0,30-03-2015,0
557,CIPLA,Cipla Limited,press release," regarding a press release dated march 4, 2015 titled ""stempeutics receives us process patent for its novel stem cell drug stempeucel"".",04-Mar-2015 14:52:00,2015-03-04 14:52:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_press_03042015145202_1.zip,04-03-2015,736.0,747.5,722.0,727.0499877929688,697.5302734375,1975785,0.0,0.0,12-03-2015,0
558,CIPLA,Cipla Limited,news clarification,"the exchange had sought clarification from cipla limited with respect to a news item captioned ""cipla to launch generic of gilead's hepatitis c drug"". the company has submitted a copy of press release dated september 15, 2014 as clarification to above news"". ",13-Feb-2015 17:43:00,2015-02-13 17:43:00,-,-,https://nsearchives.nseindia.com/corporate/NEWSCLARIFICATION_CIPLA_02132015174301_1.zip,13-02-2015,661.0,701.8499755859375,659.0,667.25,640.1583251953125,6373168,0.0,0.0,23-02-2015,0
559,CIPLA,Cipla Limited,press release," regarding a press release dated february 13, 2015, titled ""cipla wins usd 188.95 million of global fund arv tender"".",13-Feb-2015 10:34:00,2015-02-13 10:34:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_pr_02132015103401_1.zip,13-02-2015,661.0,701.8499755859375,659.0,667.25,640.1583251953125,6373168,0.0,0.0,23-02-2015,0
560,CIPLA,Cipla Limited,updates," that the company has entered into a binding term sheet with its existing partner biopharm spa, for establishing a joint venture company in algeria. ",13-Feb-2015 08:33:00,2015-02-13 08:33:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_02132015083302_1.zip,13-02-2015,661.0,701.8499755859375,659.0,667.25,640.1583251953125,6373168,0.0,0.0,23-02-2015,0
561,CIPLA,Cipla Limited,acquisition," that company has signed a definitive agreement to acquire 60% stake in jay precision pharmaceuticals private limited, mumbai for a cash consideration of rs. 96 crore.",12-Feb-2015 19:16:00,2015-02-12 19:16:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_02122015191602_1.zip,12-02-2015,641.0,665.5499877929688,633.0499877929688,660.6500244140625,633.8262329101562,4022095,0.0,0.0,20-02-2015,0
562,CIPLA,Cipla Limited,press release," regarding a press release dated february 12, 2015, titled ""cipla announces q3 fy1415 unaudited consolidated financial results"".",12-Feb-2015 18:24:00,2015-02-12 18:24:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_PR_02122015182402_1.zip,12-02-2015,641.0,665.5499877929688,633.0499877929688,660.6500244140625,633.8262329101562,4022095,0.0,0.0,20-02-2015,0
563,CIPLA,Cipla Limited,financial result updates, the standalone & consolidated financial results for the period ended 31-dec-2014.,12-Feb-2015 18:11:02,2015-02-12 18:11:02,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31DEC_02122015181101_.zip,12-02-2015,641.0,665.5499877929688,633.0499877929688,660.6500244140625,633.8262329101562,4022095,0.0,0.0,20-02-2015,0
564,CIPLA,Cipla Limited,esops/esos/esps," that the nomination and remuneration committee of the board of directors of the company at its meeting held on february 11, 2015 has approved the grant of 62,148 stock options to employees of the company and its subsidiary companies, in terms of employee stock option scheme 2013-a (""esos 2013-a""). the said options carry the right to apply for equal number of equity shares of the company of face value of rs.2/- each.",11-Feb-2015 18:40:00,2015-02-11 18:40:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_01_02112015184002_1.zip,11-02-2015,640.1500244140625,640.7999877929688,631.0499877929688,636.4500122070312,610.6088256835938,1671824,0.0,0.0,19-02-2015,1
565,CIPLA,Cipla Limited,press release," regarding a press release dated february 9, 2015 titled ""cipla s u.k. subsidiary enters into a joint venture agreement with existing partners -cooper pharma and  the pharmaceutical institute (phi)"".",09-Feb-2015 17:23:00,2015-02-09 17:23:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_press_02092015172301_1.zip,09-02-2015,650.0,656.0,626.25,629.6500244140625,604.0848999023438,1213162,0.0,0.0,16-02-2015,1
566,CIPLA,Cipla Limited,updates," that cipla (eu) limited, u.k., a wholly owned subsidiary of the company, has entered into a joint venture (jv) agreement with company's existing business partners in morocco - societe marocaine de cooperation pharmaceutique (""cooper pharma"") and the pharmaceutical institute (phi).",09-Feb-2015 16:03:00,2015-02-09 16:03:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_02092015160302_1.zip,09-02-2015,650.0,656.0,626.25,629.6500244140625,604.0848999023438,1213162,0.0,0.0,16-02-2015,1
567,CIPLA,Cipla Limited,trading window," that in terms of company's code of internal procedures and conduct for prevention of insider trading, the ""trading window"" for dealing in the securities of the company will remain closed from february 04, 2015 till completion of 24 hours after the unaudited financial results are made public.",04-Feb-2015 16:24:00,2015-02-04 16:24:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_BM_02042015162402_1.zip,04-02-2015,680.4000244140625,688.0,666.5999755859375,678.0,650.4717407226562,1326140,0.0,0.0,11-02-2015,-1
568,CIPLA,Cipla Limited,allotment of securities," that nomination and remuneration committee of the company on january 23, 2015 allotted 39,083 equity shares of rs.2/- each pursuant to exercise of the stock options by the option grantee under employee stock option scheme 2013-a.    consequently, the issued share capital of the company stands increased to rs.1,60,79,27,670 comprising of 80,39,63,835 equity shares of face value rs.2/- each. the paid-up & subscribed share capital of the company stands increased to rs.1,60,59,20,880 comprising 80,29,60,440 equity shares of face value rs.2/-each.",23-Jan-2015 18:36:00,2015-01-23 18:36:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_01232015183602_1.zip,23-01-2015,659.9000244140625,686.5,654.5999755859375,677.6500244140625,650.1361083984375,2255956,0.0,0.0,02-02-2015,0
569,CIPLA,Cipla Limited,disclosure of voting pattern - clause 35a, regarding details of voting results of postal ballot/e-voting pursuant to clause 35a of the listing agreement.,12-Jan-2015 20:24:00,2015-01-12 20:24:00,-,-,https://nsearchives.nseindia.com/corporate/VotingResults_01122015202401_1.zip,12-01-2015,630.9000244140625,637.0,625.9500122070312,630.75,605.1403198242188,1094136,0.0,0.0,19-01-2015,0
570,CIPLA,Cipla Limited,press release," regarding a press release dated december 23, 2014  titled ""cipla medpro wins r2 billion of state arv tender"".",23-Dec-2014 14:48:00,2014-12-23 14:48:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_press_12232014144801_1.zip,23-12-2014,619.5,633.9000244140625,612.5499877929688,630.0999755859375,604.5165405273438,1378766,0.0,0.0,31-12-2014,0
571,CIPLA,Cipla Limited,news clarification,"the exchange had sought clarification from cipla limited with respect to a news item captioned ""novartis drags cipla to court"". the company has clarified that ""as part of company's mission to provide affordable access, company continues to launch various products in various markets including india to serve the needs of patients. the company has accordingly launched product unibrez recently. novartis india limited has approached delhi high court to restrain the company from marketing this product. the matter is sub-judice. the above development is in the ordinary course of business. the company has over 1500 products in its portfolio which generate annual revenue of over rs.10,000 crores and hence the revenues/profits from the product is not expected to be material in the current financial year"".",17-Dec-2014 19:40:00,2014-12-17 19:40:00,-,-,https://nsearchives.nseindia.com/corporate/NEWSCLARIFICATION_CIPLA_12172014194002_1.zip,17-12-2014,618.0,619.7000122070312,597.7999877929688,605.5,580.91552734375,2116349,0.0,0.0,24-12-2014,0
572,CIPLA,Cipla Limited,updates," that meditab holdings limited, mauritius, a wholly owned subsidiary of the company, has entered into a definitive agreement to sell its entire 48.22% equity interest in jiangsu cdymax pharmaceuticals co. ltd., china (""jiangsu"") to an affiliate of one of the other shareholders of jiangsu, for a total consideration of usd 18.5 million.the closing of the transaction is subject to receipt of applicable regulatory approvals in china.",10-Dec-2014 10:52:00,2014-12-10 10:52:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_01_12102014105202_1.zip,10-12-2014,641.0,652.0,636.0499877929688,649.8499755859375,623.4646606445312,1467006,0.0,0.0,17-12-2014,-1
573,CIPLA,Cipla Limited,press release," regarding a press release dated december 03,2014  titled "" meda and cipla sue apotex to enforce dymista patents"".",03-Dec-2014 12:49:00,2014-12-03 12:49:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_PR_12032014124901_1.zip,03-12-2014,642.0,663.0,637.0,650.2000122070312,623.800537109375,4859501,0.0,0.0,10-12-2014,0
574,CIPLA,Cipla Limited,postal ballot updates, a copy of notice of postal ballot along with the specimen of postal ballot form being despatched to the members.,01-Dec-2014 19:08:00,2014-12-01 19:08:00,-,-,https://nsearchives.nseindia.com/corporate/CoveringletterNSE_12012014190802_1.zip,01-12-2014,636.8499755859375,649.5499877929688,629.4000244140625,643.0499877929688,616.9407958984375,2014699,0.0,0.0,08-12-2014,0
575,CIPLA,Cipla Limited,press release," regarding a press release dated november 27, 2014 titled ""medicines for malaria announces collaborations with cipla and strides"".",27-Nov-2014 14:27:00,2014-11-27 14:27:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_11272014142702_1.zip,27-11-2014,630.0,642.0,626.2999877929688,637.5499877929688,611.6641845703125,2119129,0.0,0.0,04-12-2014,0
576,CIPLA,Cipla Limited,press release," regarding a press release dated november 20, 2014 titled ""cipla announces a distribution agreement with serum institute of india for affordable paediatric vaccines in europe"".",20-Nov-2014 11:10:00,2014-11-20 11:10:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_press_11202014111002_1.zip,20-11-2014,600.0,623.9500122070312,595.6500244140625,618.5,593.3875732421875,2261492,0.0,0.0,27-11-2014,0
577,CIPLA,Cipla Limited,disclosure under insider trading regulation," vide its letter dated november 13, 2014 that dr nachiket mor, appointed as an director holds 'nil' equity shares of the company. further, the company has submitted a copy of disclosure under regulation 13 of sebi (pit) regulations, 1992.",13-Nov-2014 19:58:00,2014-11-13 19:58:00,-,-,https://nsearchives.nseindia.com/corporate/InsiderTradingDisclosureDrNachiketMor_11132014195801_1.zip,13-11-2014,620.0,635.0,618.1500244140625,623.6500244140625,598.3285522460938,1824599,0.0,0.0,20-11-2014,0
578,CIPLA,Cipla Limited,disclosure under insider trading regulation," vide its letter dated november 13, 2014 that ms. punita lal, appointed as an director holds 'nil' equity shares of the company. further, the company has submitted a copy of disclosure under regulation 13 of sebi (pit) regulations, 1992.",13-Nov-2014 19:58:00,2014-11-13 19:58:00,-,-,https://nsearchives.nseindia.com/corporate/InsiderTradingDisclosurePunitaLal_11132014195802_2.zip,13-11-2014,620.0,635.0,618.1500244140625,623.6500244140625,598.3285522460938,1824599,0.0,0.0,20-11-2014,0
579,CIPLA,Cipla Limited,outcome of board meeting," a copy of outcome of the board meeting held on november 13, 2014.",13-Nov-2014 19:33:00,2014-11-13 19:33:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_outcome_11132014193302_1.zip,13-11-2014,620.0,635.0,618.1500244140625,623.6500244140625,598.3285522460938,1824599,0.0,0.0,20-11-2014,0
580,CIPLA,Cipla Limited,press release," regarding a press release dated november 13, 2014 titled ""cipla announces q2 fy1415 unaudited consolidated financial results"" along with investor presentation.",13-Nov-2014 19:28:00,2014-11-13 19:28:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_01Press_13112014192659.zip,13-11-2014,620.0,635.0,618.1500244140625,623.6500244140625,598.3285522460938,1824599,0.0,0.0,20-11-2014,0
581,CIPLA,Cipla Limited,press release," regarding a press release dated november 13, 2014 titled ""cipla appoints ms.punita lal and dr. nachiket mor as independent directors on its board""",13-Nov-2014 19:22:00,2014-11-13 19:22:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_11132014192201_1.zip,13-11-2014,620.0,635.0,618.1500244140625,623.6500244140625,598.3285522460938,1824599,0.0,0.0,20-11-2014,0
582,CIPLA,Cipla Limited,financial result updates, the standalone & consolidated financial results for the period ended 30-sep-2014.,13-Nov-2014 18:59:02,2014-11-13 18:59:02,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_30092014_B_11132014185902_.zip,13-11-2014,620.0,635.0,618.1500244140625,623.6500244140625,598.3285522460938,1824599,0.0,0.0,20-11-2014,0
583,CIPLA,Cipla Limited,esops/esos/esps," that the nomination and remuneration committee of the board of directors of the company at its meeting held on october 31, 2014 has approved the grant of 9,22,230 stock options to employees of the company and its subsidiary companies, in terms of employee stock option scheme 2013-a (""esos 2013-a""). the said options carry the right to apply for equal number of equity shares of the company of face value of rs.2/- each.",31-Oct-2014 19:43:00,2014-10-31 19:43:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_grant_10312014194302_1.zip,31-10-2014,652.7000122070312,673.0,647.7999877929688,666.5499877929688,639.4866943359375,1185420,0.0,0.0,11-11-2014,0
584,CIPLA,Cipla Limited,press release," vide letter dated october 09, 2014 regarding a press release dated october 08, 2014, titled ""cipla medpro announces collaboration with world's largest generic pharmaceutical company"".",09-Oct-2014 09:23:00,2014-10-09 09:23:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_01_09102014092329.zip,09-10-2014,589.75,605.0,587.2000122070312,591.7000122070312,567.6757202148438,1833911,0.0,0.0,16-10-2014,0
585,CIPLA,Cipla Limited,updates," that that the company has signed a definitive agreement with its existing iranian distributor for setting up a manufacturing facility in iran. the total contribution from the company over the next 3 years will include machinery, equipment, technical know-how and is expected to be approximately inr 225 crore for a 75% stake.the proposed investment is subject to completion of certain conditions precedent and applicable regulatory approvals .",07-Oct-2014 08:24:00,2014-10-07 08:24:00,-,-,https://nsearchives.nseindia.com/corporate/DisclosureLetter_07102014082449.zip,07-10-2014,629.7000122070312,630.3499755859375,598.25,602.2000122070312,577.7494506835938,2218559,0.0,0.0,14-10-2014,0
586,CIPLA,Cipla Limited,press release,", vide letter dated september 29, 2014 regarding a press release dated september 25, 2014 titled ""cipla strengthens its presence in kenya"".",29-Sep-2014 12:28:00,2014-09-29 12:28:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_PR_29092014122833.zip,29-09-2014,612.0,622.0999755859375,608.9000244140625,616.8499755859375,591.8046264648438,1105338,0.0,0.0,09-10-2014,0
587,CIPLA,Cipla Limited,press release," regarding a press release dated september 15, 2014, titled, ""cipla enters into a licensing agreement with gilead to increase access to hepatitis c treatment"".",15-Sep-2014 17:00:00,2014-09-15 17:00:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_09152014170001_1.zip,15-09-2014,612.5999755859375,634.4000244140625,609.7999877929688,630.25,604.6605834960938,4011059,0.0,0.0,22-09-2014,0
588,CIPLA,Cipla Limited,news clarification,"the exchange had sought clarification from cipla limited with respect to a news item captioned ""indian companies to sign generic licensing deal for $1000-a-day"". the company has submitted a copy of press release dated september 15, 2014 titled ""cipla enters into a licensing agreement with gilead to increase access to hepatitis c treatment"" as response/clarification to the above news. ",15-Sep-2014 16:04:00,2014-09-15 16:04:00,-,-,https://nsearchives.nseindia.com/corporate/NEWSCLARIFICATION_CIPLA_09152014160401_1.zip,15-09-2014,612.5999755859375,634.4000244140625,609.7999877929688,630.25,604.6605834960938,4011059,0.0,0.0,22-09-2014,0
589,CIPLA,Cipla Limited,esops/esos/esps," that the nomination and remuneration committee of the board of directors of the company at its meeting held on september 08, 2014 has approved the grant of 95,248 stock options to employees of the company and its subsidiary companies, in terms of employee stock option scheme 2013-a (""esos 2013-a"").  the said options carry the right to apply for equal number of equity shares of the company of face value of rs.2/- each",08-Sep-2014 15:44:00,2014-09-08 15:44:00,-,-,https://nsearchives.nseindia.com/corporate/GrantofOptions_09082014154401_1.zip,08-09-2014,562.0,565.6500244140625,558.75,563.4500122070312,540.57275390625,2158860,0.0,0.0,15-09-2014,1
590,CIPLA,Cipla Limited,press release," regarding a press release september 08, 2014, titled, ""cipla announces a commercial collaboration with s&d pharma to enter czech republic and slovakia with affordable high quality alternatives"".",08-Sep-2014 15:28:00,2014-09-08 15:28:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_PR_09082014152802_1.zip,08-09-2014,562.0,565.6500244140625,558.75,563.4500122070312,540.57275390625,2158860,0.0,0.0,15-09-2014,1
591,CIPLA,Cipla Limited,disclosure of voting pattern - clause 35a," a copy of details of the voting results at the annual general meeting of the company held on september 03, 2014 pursuant to clause 35a of the listing agreement.",05-Sep-2014 17:28:00,2014-09-05 17:28:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_35A_09052014172802_2.zip,05-09-2014,553.2000122070312,559.9000244140625,545.6500244140625,557.5,534.8643798828125,2710206,0.0,0.0,12-09-2014,1
592,CIPLA,Cipla Limited,annual general meeting updates," regarding outcome of annual general meeting held on september 03, 2014.",05-Sep-2014 17:16:00,2014-09-05 17:16:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_2014_09052014171601_1.zip,05-09-2014,553.2000122070312,559.9000244140625,545.6500244140625,557.5,534.8643798828125,2710206,0.0,0.0,12-09-2014,1
593,CIPLA,Cipla Limited,news clarification,"the exchange sought clarification from cipla limited with respect to news item captioned ""cipla launches copy of gsk's asthama drug in germany, sweden"". the company has clarified that ""it continues to get approvals and launch products in various markets. the company has a portfolio of over 2000 products and the launch of inhaler serroflo in germany and sweden are in accordance with company's revenue guidance and in the normal course of business"".  further, the company vide its letter dated september 2, 2014 has submitted to the exchange a copy of press release dated september 1, 2014 titled ""cipla enters the respiratory market in germany and sweden with affordable high quality alternatives"". ",02-Sep-2014 17:40:00,2014-09-02 17:40:00,-,-,https://nsearchives.nseindia.com/corporate/NewsClarification_CIPLA_09022014174002_2.zip,02-09-2014,534.0,575.0,533.5,557.0499877929688,534.4326782226562,5384451,0.0,0.0,09-09-2014,0
594,CIPLA,Cipla Limited,press release," regarding the press release dated august 14, 2014 with respect to the unaudited financial results for the quarter ended june 30, 2014.",14-Aug-2014 18:16:00,2014-08-14 18:16:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_08142014181604_4.zip,14-08-2014,439.7000122070313,452.25,432.75,448.6000061035156,430.3859558105469,2478440,0.0,0.0,22-08-2014,1
595,CIPLA,Cipla Limited,financial result updates, the standalone & consolidated financial results for the period ended 30-jun-2014.,14-Aug-2014 17:35:03,2014-08-14 17:35:03,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_30JUN2014_08142014173502_.zip,14-08-2014,439.7000122070313,452.25,432.75,448.6000061035156,430.3859558105469,2478440,0.0,0.0,22-08-2014,1
596,CIPLA,Cipla Limited,disclosure under insider trading regulation,"cipla limited has informed vide its letter dated july 23, 2014 the exchange that mr. adil zainulbhai, appointed as an additional director holds  nil  equity shares of the company. further, the company has submitted a copy of disclosure under regulation 13 of sebi (pit) regulations, 1992.",24-Jul-2014 19:48:00,2014-07-24 19:48:00,-,-,https://nsearchives.nseindia.com/corporate/DisclosureunderInsiderTrading_07242014194801_1.zip,24-07-2014,441.0,444.3500061035156,437.2999877929688,439.5499877929688,419.7886962890625,674032,0.0,0.0,01-08-2014,0
597,CIPLA,Cipla Limited,appointment of director,"cipla limited has inter-alia informed the exchange that the board of directors at its meeting held on july 23, 2014 has appointed mr. adil zainulbhai as an additional director with effect from july 23, 2014 to hold office as an independent director of the company",23-Jul-2014 19:20:00,2014-07-23 19:20:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_07232014191602_.zip,23-07-2014,441.75,447.7999877929688,438.0,442.0,422.1286010742188,794876,0.0,0.0,31-07-2014,0
598,CIPLA,Cipla Limited,resignation of director," that ""mr. m.r.raghavan, director has resigned from the directorship of the company. in his letter to the board he has stated that due to increase in work load owing to various initiatives on the social front that he is associated with, he has tendered his resignation"".",23-Jul-2014 19:20:00,2014-07-23 19:20:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_07232014191603_.zip,23-07-2014,441.75,447.7999877929688,438.0,442.0,422.1286010742188,794876,0.0,0.0,31-07-2014,0
599,CIPLA,Cipla Limited,updates," that meditab specialities limited (""mspl"") a wholly owned subsidiary of the company, has acquired 75% stake in mabpharm private limited (""mabpharm"")",17-Jul-2014 16:32:00,2014-07-17 16:32:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_07172014163202_1.zip,17-07-2014,430.0,441.3999938964844,430.0,437.0499877929688,417.4010620117188,899509,0.0,0.0,24-07-2014,0
600,CIPLA,Cipla Limited,press release," regarding a press release dated july 17, 2014 titled ""the medicines patent pool signs a record seven new sub-licences to speed the availability of generic hiv medicines to developing countries"".",17-Jul-2014 14:48:00,2014-07-17 14:48:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_PR_07172014144801_1.zip,17-07-2014,430.0,441.3999938964844,430.0,437.0499877929688,417.4010620117188,899509,0.0,0.0,24-07-2014,0
601,CIPLA,Cipla Limited,updates," that the company, in collaboration with the uk government, has expressed its intention to make investments of up to pounds 100 million in its uk subsidiary over the next few years. the investments are expected to facilitate the launch of a range of products in the area of respiratory, oncology and antiretroviral medicines to further cipla's higher purpose of ""universal affordable access"". cipla also plans to invest in r&d activities, clinical trials and expand further internationally. the investment underscores the growing importance of uk in cipla's long term strategy.",07-Jul-2014 09:04:00,2014-07-07 09:04:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_07072014_07072014090401_1.zip,07-07-2014,449.0,453.7000122070313,444.7000122070313,449.6499938964844,429.43463134765625,1432449,0.0,0.0,14-07-2014,0
602,CIPLA,Cipla Limited,updates," that the company has signed a definitive agreement to acquire a 51% stake in a pharmaceuticals manufacturing and distribution business in yemen (in turn owned by a uae based parent company). given the recent preference to local manufacturing, this secures company's presence in a fast growing market. company already has a leading position in yemen with over 200 products. company will pay usd 21 million for this transaction, with additional considerations to be paid over the next 3 years on achievement of agreed milestones.closing of the transaction is subject to completion of certain conditions precedent. ",30-Jun-2014 08:56:00,2014-06-30 08:56:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_30062014_06302014085603_4.zip,30-06-2014,442.7000122070313,445.0,435.7000122070313,438.0,418.3083801269531,1645312,0.0,0.0,07-07-2014,0
603,CIPLA,Cipla Limited,updates," that cipla (mauritius) limited, a wholly owned subsidiary of the company has signed a definitive agreement with the company's existing sri lankan distributor for acquisition of 60% stake in a new company which will market the company's products in sri lanka. the consideration payable for the transaction is usd 14 million.the proposed acquisition is subject to regulatory approvals. ",17-Jun-2014 14:08:00,2014-06-17 14:08:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_17062014_06172014140802_1.zip,17-06-2014,417.0,417.0,410.6499938964844,412.9500122070313,394.3845825195313,750090,0.0,0.0,24-06-2014,0
604,CIPLA,Cipla Limited,press release," regarding a press release dated may 29, 2014 titled ""cipla announces q4 fy1314 audited consolidated financial results"".",29-May-2014 18:48:00,2014-05-29 18:48:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_press_05292014184803_1.zip,29-05-2014,380.1000061035156,382.0,370.8500061035156,372.4500122070313,355.70538330078125,2231881,0.0,0.0,05-06-2014,0
605,CIPLA,Cipla Limited,financial result updates, the standalone & consolidated financial results for the period ended 31-mar-2014.,29-May-2014 18:15:02,2014-05-29 18:15:02,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31Mar14_B_05292014181501_.zip,29-05-2014,380.1000061035156,382.0,370.8500061035156,372.4500122070313,355.70538330078125,2231881,0.0,0.0,05-06-2014,0
606,CIPLA,Cipla Limited,press release," regarding a press release dated may 12, 2014 titled ""cipla invests in chase pharmaceuticals to support alzheimer's disease drug development"".",12-May-2014 12:28:00,2014-05-12 12:28:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_PR_12052014_05122014122802_1.zip,12-05-2014,393.1000061035156,394.7999877929688,384.5,387.75,370.3174743652344,1522838,0.0,0.0,19-05-2014,0
607,CIPLA,Cipla Limited,updates," that cipla (eu) limited, uk, (""cipla"") a wholly owned subsidiary of the company has signed a definitive agreement to invest usd 1.5 million in chase pharmaceuticals corporation inc, us (""chase"") to acquire 14.6% stake in chase on a fully diluted basis. cipla will make an additional usd 4.5 million investment in chase upon achievement of certain milestones.  chase is an early stage drug development company developing novel approaches to improve treatments for alzheimer's disease.",12-May-2014 12:20:00,2014-05-12 12:20:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_12052014_05122014122002_1.zip,12-05-2014,393.1000061035156,394.7999877929688,384.5,387.75,370.3174743652344,1522838,0.0,0.0,19-05-2014,0
608,CIPLA,Cipla Limited,news clarification," clarification with reference to the news item titled ""cipla faces fresh rs. 105-cr penalty for overcharging"".",29-Apr-2014 19:08:00,2014-04-29 19:08:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_04292014190802_2.zip,29-04-2014,407.7999877929688,408.75,397.7000122070313,401.2000122070313,383.1628112792969,1115634,0.0,0.0,07-05-2014,0
609,CIPLA,Cipla Limited,disclosure under insider trading regulation," that mr. rajesh garg, appointed as an additional director and whole-time director designated as  executive director and global chief financial officer  holds  nil  equity shares of the company. further, the company has submitted a copy of disclosure under regulation 13 of sebi (pit) regulations, 1992.",02-Apr-2014 19:32:00,2014-04-02 19:32:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_04022014193202_1.zip,02-04-2014,384.7999877929688,392.0,381.5499877929688,389.25,371.7500915527344,2670463,0.0,0.0,10-04-2014,0
610,CIPLA,Cipla Limited,address change," that with effect from april 01, 2014, the registered office of the company will be shifted from mumbai central, mumbai - 400008 to the following address:  cipla house,   peninsula business park,   ganpatrao kadam marg,   lower parel, mumbai-400013 ",31-Mar-2014 20:32:00,2014-03-31 20:32:00,-,-,https://nsearchives.nseindia.com/corporate/Shiftingofregisteredoffice_03312014203201_1.zip,31-03-2014,388.2000122070313,389.75,381.7999877929688,382.7999877929688,365.5900573730469,950977,0.0,0.0,07-04-2014,0
611,CIPLA,Cipla Limited,updates," vide letter dated march 31, 2014 a copy of abstract under section 302 of the companies act, 1956 relating to the appointment of mr rajesh garg as whole-time director of the company designated as ""executive director and global chief financial officer"" for the period of five years commencing from april 01, 2014 subject to the approval of the shareholders of the comapny. ",31-Mar-2014 18:52:00,2014-03-31 18:52:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31032014_03312014185201_1.zip,31-03-2014,388.2000122070313,389.75,381.7999877929688,382.7999877929688,365.5900573730469,950977,0.0,0.0,07-04-2014,0
612,CIPLA,Cipla Limited,news clarification,"the exchange had sought clarification from cipla limited with respect to a news item captioned ""cipla to market msd's hiv drug in india"". the company has clarified that ""the company continues to evaluate such opportunities in its ordinary course of business. the company has a portfolio of over 2000 products and the revenues/profits from the sale of raltegravir are not expected to be material in the context of company's total revenues/ profits. we are enclosing the press release issued by the company on this subject and the source of the news item referred to by stock exchange is the attached press release. the attached press release is also available on company's website.""",21-Feb-2014 17:16:00,2014-02-21 17:16:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_02212014171602_2.zip,21-02-2014,374.0,374.0,367.75,369.2000122070313,352.6015319824219,2004530,0.0,0.0,03-03-2014,0
613,CIPLA,Cipla Limited,disclosure under insider trading regulation," vide letter dated february 12, 2014 a copy of disclosure under regulation 13(2), 13(2a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",13-Feb-2014 08:40:00,2014-02-13 08:40:00,-,-,https://nsearchives.nseindia.com/corporate/DisclosureunderInsiderTradiing_02132014084001_1.zip,13-02-2014,390.0,404.25,379.0,380.2999877929688,363.2024536132813,10135980,0.0,0.0,20-02-2014,0
614,CIPLA,Cipla Limited,esops/esos/esps," vide letter dated february 12, 2014 regarding grant of options under the employee stock option scheme 2013-a",12-Feb-2014 19:24:00,2014-02-12 19:24:00,-,-,https://nsearchives.nseindia.com/corporate/cipala_02122014192401_1.zip,12-02-2014,414.8999938964844,414.8999938964844,408.0,412.75,394.1935729980469,2956000,0.0,0.0,19-02-2014,-1
615,CIPLA,Cipla Limited,financial result updates, the standalone & consolidated financial results for the period ended 31-dec-2013.,12-Feb-2014 19:15:02,2014-02-12 19:15:02,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_02122014191501_.zip,12-02-2014,414.8999938964844,414.8999938964844,408.0,412.75,394.1935729980469,2956000,0.0,0.0,19-02-2014,-1
616,CIPLA,Cipla Limited,press release," regarding a press release dated february 12, 2014, titled ""cipla announces q3 fy1314 unaudited consolidated financial results"".",12-Feb-2014 19:04:00,2014-02-12 19:04:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_pr02_02122014190401_1.zip,12-02-2014,414.8999938964844,414.8999938964844,408.0,412.75,394.1935729980469,2956000,0.0,0.0,19-02-2014,-1
617,CIPLA,Cipla Limited,press release," regarding a press release dated february 12, 2014, titled ""cipla appoints dr. peter mugyenyi as an independent director on the board"".",12-Feb-2014 17:56:00,2014-02-12 17:56:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_pr_02122014175601_1.zip,12-02-2014,414.8999938964844,414.8999938964844,408.0,412.75,394.1935729980469,2956000,0.0,0.0,19-02-2014,-1
618,CIPLA,Cipla Limited,esops/esos/esps," vide letter dated december 31, 2013  regarding grant of options under the employee stock option scheme 2013-a",31-Dec-2013 15:56:00,2013-12-31 15:56:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_esop_31122013_12312013155602_1.zip,31-12-2013,402.75,404.3500061035156,399.3999938964844,400.7999877929688,382.7808227539063,550785,0.0,0.0,07-01-2014,0
619,CIPLA,Cipla Limited,updates," vide letter dated november 13 , 2013 a copy of note which is displayed on company website.",13-Nov-2013 20:12:00,2013-11-13 20:12:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_update_13112013_11132013201202_1.zip,13-11-2013,419.5499877929688,419.5499877929688,410.0499877929688,412.2999877929688,393.7637939453125,1255137,0.0,0.0,21-11-2013,-1
620,CIPLA,Cipla Limited,financial result updates, the standalone & consolidated financial results for the period ended 30-sep-2013.,13-Nov-2013 18:03:02,2013-11-13 18:03:02,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_SEP_11132013180302_.zip,13-11-2013,419.5499877929688,419.5499877929688,410.0499877929688,412.2999877929688,393.7637939453125,1255137,0.0,0.0,21-11-2013,-1
621,CIPLA,Cipla Limited,press release," regarding a press release dated november 13, 2013, titled""cipla announces q2 fy1314 unaudited consolidated financial results"".",13-Nov-2013 17:52:00,2013-11-13 17:52:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_pr_13112013_11132013175201_1.zip,13-11-2013,419.5499877929688,419.5499877929688,410.0499877929688,412.2999877929688,393.7637939453125,1255137,0.0,0.0,21-11-2013,-1
622,CIPLA,Cipla Limited,esops/esos/esps," vide letter dated october 31, 2013 regarding that grant of options under the employee stock option scheme 2013-a",31-Oct-2013 16:28:00,2013-10-31 16:28:00,-,-,https://nsearchives.nseindia.com/corporate/GrantofStockOptions_10312013162801_1.zip,31-10-2013,420.0,421.0,411.8500061035156,413.2000122070313,394.6233215332031,1884285,0.0,0.0,08-11-2013,0
623,CIPLA,Cipla Limited,disclosure under insider trading regulation," vide letter dated october 08, 2013 a copy of disclosure under regulation 13(4), 13(4a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",08-Oct-2013 12:56:00,2013-10-08 12:56:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_10082013125601_1.zip,08-10-2013,441.8999938964844,443.0,434.0,434.7000122070313,415.15673828125,546510,0.0,0.0,15-10-2013,0
624,CIPLA,Cipla Limited,disclosure under insider trading regulation,", vide letter dated october 01, 2013 a copy of disclosure under regulation 13(6) of sebi (prohibition of insider trading) regulations, 1992.",01-Oct-2013 17:44:00,2013-10-01 17:44:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_10012013174402_2.zip,01-10-2013,432.0,435.8999938964844,430.6499938964844,431.8999938964844,412.482666015625,488339,0.0,0.0,09-10-2013,0
625,CIPLA,Cipla Limited,esops/esos/esps," vide letter dated september 16, 2013 regarding ""grant of options under the employee stock option scheme 2013-b(""esos 2013-b"").",16-Sep-2013 15:52:00,2013-09-16 15:52:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_09162013155201_2.zip,16-09-2013,445.8500061035156,450.3999938964844,428.0,430.5499877929688,411.19329833984375,1248660,0.0,0.0,23-09-2013,0
626,CIPLA,Cipla Limited,disclosure of voting pattern - clause 35a," regarding the voting results at the annual general meeting of the company held on august 22, 2013 under clause 35a.",26-Aug-2013 09:12:00,2013-08-26 09:12:00,-,-,https://nsearchives.nseindia.com/corporate/DetailsofVotingResults_08262013091202_1.zip,26-08-2013,396.5,403.4500122070313,391.1000061035156,399.25,381.3005065917969,986582,0.0,0.0,02-09-2013,0
627,CIPLA,Cipla Limited,annual general meeting updates," proceedings of the annual general meeting of the company held on august 22, 2013.",23-Aug-2013 19:56:00,2013-08-23 19:56:00,-,-,https://nsearchives.nseindia.com/corporate/CIpla_OutAGM_23082013_08232013195602_1.zip,23-08-2013,402.7999877929688,404.0,392.5,396.0,378.1965942382813,1505564,0.0,0.0,30-08-2013,1
628,CIPLA,Cipla Limited,press release," regarding the press release dated august 09, 2013 in-connection with the financial results for the quarter ended june 30, 2013",12-Aug-2013 09:04:00,2013-08-12 09:04:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_08122013090401_2.zip,12-08-2013,427.0,428.9500122070313,413.6000061035156,415.5,396.8199768066406,3422954,0.0,0.0,20-08-2013,0
629,CIPLA,Cipla Limited,updates," vide letter dated august 09, 2013 a copy of note displayed on company website.",12-Aug-2013 09:04:00,2013-08-12 09:04:00,-,-,https://nsearchives.nseindia.com/corporate/NoteonWebsite_08122013090401_1.zip,12-08-2013,427.0,428.9500122070313,413.6000061035156,415.5,396.8199768066406,3422954,0.0,0.0,20-08-2013,0
630,CIPLA,Cipla Limited,financial result updates," the standalone and consolidated financial results along with the limited review report for the period ended june 30,2013.",12-Aug-2013 08:56:51,2013-08-12 08:56:51,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_30JUN2013_B_Q1.zip,12-08-2013,427.0,428.9500122070313,413.6000061035156,415.5,396.8199768066406,3422954,0.0,0.0,20-08-2013,0
631,CIPLA,Cipla Limited,disclosure under insider trading regulation,", vide letter dated july 17, 2013 a copy of disclosure under regulation 13(6) of sebi (prohibition of insider trading) regulations, 1992.",18-Jul-2013 15:52:00,2013-07-18 15:52:00,-,-,https://nsearchives.nseindia.com/corporate/DisclosureAshokSinha_07182013155201_1.zip,18-07-2013,408.2000122070313,416.5,406.6000061035156,413.2999877929688,392.7240905761719,1120322,0.0,0.0,25-07-2013,0
632,CIPLA,Cipla Limited,disclosure under insider trading regulation,", vide letter dated july 17, 2013 a copy of disclosure under regulation 13(6) of sebi (prohibition of insider trading) regulations, 1992.",18-Jul-2013 15:44:00,2013-07-18 15:44:00,-,-,https://nsearchives.nseindia.com/corporate/DisclosureSubhanuSaxena_07182013154401_1.zip,18-07-2013,408.2000122070313,416.5,406.6000061035156,413.2999877929688,392.7240905761719,1120322,0.0,0.0,25-07-2013,0
633,CIPLA,Cipla Limited,updates,", vide letter dated july 16, 2013 regarding the ""acquisition of cipla medpro south africa limited (""medpro"") by cipla limited (""company"")"".",16-Jul-2013 14:20:00,2013-07-16 14:20:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_07162013142001_1.zip,16-07-2013,402.0,408.5,399.1499938964844,402.2000122070313,382.1767272949219,572326,0.0,0.0,23-07-2013,0
634,CIPLA,Cipla Limited,outcome of board meeting," the outcome of board of directors meeting held on july 15, 2013.",15-Jul-2013 17:16:00,2013-07-15 17:16:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_07152013171202_.zip,15-07-2013,408.0,409.5499877929688,405.0,407.7000122070313,387.40283203125,671824,0.0,0.0,22-07-2013,0
635,CIPLA,Cipla Limited,updates," vide letter dated june 28, 2013 regarding update on acquisition of cipla medpro south africa limited (""medpro"") by cipla limited (""company"").",28-Jun-2013 13:04:00,2013-06-28 13:04:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_06282013130401_1.zip,28-06-2013,389.0,393.5,385.5,391.9500122070313,372.43695068359375,1568530,0.0,0.0,05-07-2013,0
636,CIPLA,Cipla Limited,updates," in connection to earlier update dated may 15, 2013 that the approvals for the scheme from south african and bostwana cometition have been received.",20-Jun-2013 16:48:00,2013-06-20 16:48:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_06202013164802_1.zip,20-06-2013,376.7999877929688,382.7999877929688,373.0499877929688,379.1000061035156,360.2267150878906,2055603,0.0,0.0,27-06-2013,0
637,CIPLA,Cipla Limited,appointment of chief financial officer, regarding appointment of mr. rajesh garg as global chief financial officer of the company and issue of stock options to him.,29-May-2013 19:16:00,2013-05-29 19:16:00,-,-,https://nsearchives.nseindia.com/corporate/AppointmentofGlobalCFO_05292013191209_.zip,29-05-2013,396.5,403.0,392.75,401.7000122070313,381.7015380859375,2492144,0.0,0.0,05-06-2013,-1
638,CIPLA,Cipla Limited,esops/esos/esps," that the board of directors of the company at its meeting held on may 29, 2013, inter alia, have decided to issue upto 84,44,528 stock options in one or more tranches, in accordance with the provisions of the securities and exchange board of india (employees stock option scheme and employees stock purchase scheme) guidelines, 1999. the said options exercisable into equity shares at a price equal to the face value of equity shares of the company will be granted to such eligible employees as may be decided by the compensation committee. the company will seek approval of shareholders to the aforesaid proposal at the ensuing annual general meeting.",29-May-2013 19:16:00,2013-05-29 19:16:00,-,-,https://nsearchives.nseindia.com/corporate/IssuanceofStockOptions_05292013191209_.zip,29-05-2013,396.5,403.0,392.75,401.7000122070313,381.7015380859375,2492144,0.0,0.0,05-06-2013,-1
639,CIPLA,Cipla Limited,press release," regarding a press release dated may 29, 2013, titled ""cipla announces q4 fy 1213 unaudited financial results"".",29-May-2013 19:00:00,2013-05-29 19:00:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_05292013190001_2.zip,29-05-2013,396.5,403.0,392.75,401.7000122070313,381.7015380859375,2492144,0.0,0.0,05-06-2013,-1
640,CIPLA,Cipla Limited,updates," vide letter dated may 29, 2013 a copy of note displayed on company website. ",29-May-2013 19:00:00,2013-05-29 19:00:00,-,-,https://nsearchives.nseindia.com/corporate/NoteOnWebsite_05292013190002_3.zip,29-05-2013,396.5,403.0,392.75,401.7000122070313,381.7015380859375,2492144,0.0,0.0,05-06-2013,-1
641,CIPLA,Cipla Limited,financial result updates," the standalone and consolidated financial results for the period ended march 31,2013.",29-May-2013 17:50:45,2013-05-29 17:50:45,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31MAR2013_B_Q4A.zip,29-05-2013,396.5,403.0,392.75,401.7000122070313,381.7015380859375,2492144,0.0,0.0,05-06-2013,-1
642,CIPLA,Cipla Limited,updates,", vide letter dated may 15, 2013 regarding an update on acquisition of cipla medro south africa limited.",15-May-2013 14:44:00,2013-05-15 14:44:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_05152013144402_2.zip,15-05-2013,398.3999938964844,412.8999938964844,397.6000061035156,411.1000061035156,390.633544921875,1604567,0.0,0.0,22-05-2013,0
643,CIPLA,Cipla Limited,disclosure of voting pattern - clause 35a, regarding the details of voting results of postal ballot/e-voting pursuant to clause 35a of the listing agreement.,10-Apr-2013 14:52:00,2013-04-10 14:52:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_04102013145201_1.zip,10-04-2013,396.7000122070313,400.5499877929688,391.5499877929688,399.0,379.135986328125,1191028,0.0,0.0,17-04-2013,0
644,CIPLA,Cipla Limited,esops/esos/esps," vide its letter dated april 09, 2013 regarding the grant of options under the employee stock option scheme 2013.",09-Apr-2013 15:28:00,2013-04-09 15:28:00,-,-,https://nsearchives.nseindia.com/corporate/GrantofOptions_04092013152802_4.zip,09-04-2013,397.3500061035156,401.0,388.8500061035156,390.8999938964844,371.439208984375,1128997,0.0,0.0,16-04-2013,0
645,CIPLA,Cipla Limited,postal ballot updates," vide letter dated april 08, 2013 regarding result of postal ballot.",09-Apr-2013 09:40:00,2013-04-09 09:40:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_rpb_09042013_04092013094002_2.zip,09-04-2013,397.3500061035156,401.0,388.8500061035156,390.8999938964844,371.439208984375,1128997,0.0,0.0,16-04-2013,0
646,CIPLA,Cipla Limited,press release," regarding a press release dated april 08, 2013, titled ""cipla announces result of postal ballot""",08-Apr-2013 18:32:00,2013-04-08 18:32:00,-,-,https://nsearchives.nseindia.com/corporate/PressRelease_04082013183202_1.zip,08-04-2013,387.4500122070313,396.8500061035156,387.0,395.0,375.3350830078125,742653,0.0,0.0,15-04-2013,0
647,CIPLA,Cipla Limited,postal ballot updates," vide letter dated april 08, 2013 regarding the result of the postal ballot.",08-Apr-2013 18:00:00,2013-04-08 18:00:00,-,-,https://nsearchives.nseindia.com/corporate/PostalBallotResults_04082013180001_1.zip,08-04-2013,387.4500122070313,396.8500061035156,387.0,395.0,375.3350830078125,742653,0.0,0.0,15-04-2013,0
648,CIPLA,Cipla Limited,postal ballot updates," a copy of notice pursuant to section 192a of the companies act, 1956 read with the companies (passing of the resolution by postal ballot) rules, 2011.",04-Mar-2013 18:12:00,2013-03-04 18:12:00,-,-,https://nsearchives.nseindia.com/corporate/PostalBallotNoticeandForm_03042013181202_2.zip,04-03-2013,370.0,373.3999938964844,363.3999938964844,371.6000061035156,353.1000366210937,1599432,0.0,0.0,11-03-2013,1
649,CIPLA,Cipla Limited,updates," regarding an update on ""joint announcement of the firm intention by cipla limited (""company"") and cipla medpro south africa limited (""medpro"") of the company's proposal in relation to an acquisition of 100% equity stake in medpro"". ",28-Feb-2013 09:04:00,2013-02-28 09:04:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_02282013090002_.zip,28-02-2013,367.0,370.2000122070313,355.75,359.8500061035156,341.9349975585937,3174611,0.0,0.0,07-03-2013,1
650,CIPLA,Cipla Limited,updates, that disclosure regarding retirement of dr. y k hamied as managing director effective 31st march 2013 and his continuation as chairman of the company in a non-executive role effective 1st april 2013,06-Feb-2013 17:16:00,2013-02-06 17:16:00,-,-,https://nsearchives.nseindia.com/corporate/LetterHamied_02062013171502_.zip,06-02-2013,408.7000122070313,409.7999877929688,401.0,405.0,384.8372802734375,4484347,0.0,0.0,13-02-2013,0
651,CIPLA,Cipla Limited,press release," regarding a press release dated february 06, 2013, titled ""cipla announces q3 fy 1213 unaudited financial results"".",06-Feb-2013 16:56:00,2013-02-06 16:56:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_PR_06022013_02062013165602_1.zip,06-02-2013,408.7000122070313,409.7999877929688,401.0,405.0,384.8372802734375,4484347,0.0,0.0,13-02-2013,0
652,CIPLA,Cipla Limited,disclosure under insider trading regulation," a copy of disclosure under regulation 13(2), 13(2a) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",05-Feb-2013 15:04:00,2013-02-05 15:04:00,-,-,https://nsearchives.nseindia.com/corporate/Disclosure_02052013150401_1.zip,05-02-2013,402.9500122070313,409.0,398.6000061035156,407.2999877929688,387.0227355957031,2468796,0.0,0.0,12-02-2013,0
653,CIPLA,Cipla Limited,disclosure under sebi takeover regulations," vide its letter dated january 09, 2013 a copy of disclosure under regulation 29(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011 along with a copy of disclosure under regulation 13(3) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",09-Jan-2013 17:15:00,2013-01-09 17:15:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_REG_09012013.zip,09-01-2013,432.8999938964844,435.0,426.25,428.3999938964844,407.0722961425781,2631466,0.0,0.0,16-01-2013,0
654,CIPLA,Cipla Limited,disclosure under sebi takeover regulations,"life insurance corporation of india has submitted to the exchange vide its letter dated january 08,2013 a copy of disclosure under regulation 29(2) of sebi (substantial acquisition of shares & takeovers) regulations, 2011 along with a copy of disclosure under regulation 13(3) and 13(6) of sebi (prohibition of insider trading) regulations, 1992.",08-Jan-2013 12:37:00,2013-01-08 12:37:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_LIC_08012013.zip,08-01-2013,426.7999877929688,431.8999938964844,423.8500061035156,429.5,408.1175842285156,3215124,0.0,0.0,15-01-2013,0
655,CIPLA,Cipla Limited,appointment of chief executive officer," regarding the appointment of mr. subhanu saxena as chief executive officer. mr. saxena has rich work experience of over 25 years, in industries as varied as fmcg, consulting, banking and pharmaceuticals. mr. saxena has been with novartis ag, where he led the global product strategy and commercialization function, a position he has held for three years.",22-Nov-2012 08:28:00,2012-11-22 08:28:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla01_appointment_22112012.zip,22-11-2012,395.5,395.5,384.1499938964844,387.25,367.970947265625,2337369,0.0,0.0,30-11-2012,1
656,CIPLA,Cipla Limited,updates," vide letter dated november 21, 2012 regarding preliminary discussions and indicative proposal in relation to the acquisition of an approximately 51% equity stake of cipla medpro south africa limited.",21-Nov-2012 14:48:00,2012-11-21 14:48:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_update_21112012.zip,21-11-2012,380.0,392.75,380.0,389.3999938964844,370.0138854980469,3367381,0.0,0.0,29-11-2012,0
657,CIPLA,Cipla Limited,updates," vide letter dated november 05, 2012 a copy of the note titled ""financial review - period ended sep 2012"".",05-Nov-2012 16:48:00,2012-11-05 16:48:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_update_05112012.zip,05-11-2012,379.3999938964844,386.0,377.2000122070313,380.2000122070313,361.2719421386719,3798873,0.0,0.0,12-11-2012,0
658,CIPLA,Cipla Limited,press release," regarding a press release dated november 05, 2012, titled ""cipla announces q2 fy 1213 unaudited financial results"".",05-Nov-2012 16:48:00,2012-11-05 16:48:00,-,-,https://nsearchives.nseindia.com/corporate/Ciplaltd_pr_05112012.zip,05-11-2012,379.3999938964844,386.0,377.2000122070313,380.2000122070313,361.2719421386719,3798873,0.0,0.0,12-11-2012,0
659,CIPLA,Cipla Limited,financial result updates," the standalone financial results along with the limited review report for the period ended september 30,2012.",05-Nov-2012 16:29:23,2012-11-05 16:29:23,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_30SEP2012_S_Q2.zip,05-11-2012,379.3999938964844,386.0,377.2000122070313,380.2000122070313,361.2719421386719,3798873,0.0,0.0,12-11-2012,0
660,CIPLA,Cipla Limited,outcome of annual general meeting," regarding the outcome of annual general meeting of the company held on august 17, 2012.",21-Aug-2012 16:22:00,2012-08-21 16:22:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_AGM_21082012.zip,21-08-2012,356.45001220703125,365.3999938964844,356.04998779296875,359.95001220703125,342.03009033203125,2452224,0.0,0.0,28-08-2012,0
661,CIPLA,Cipla Limited,disclosure of voting pattern - clause 35a," that the details of the voting results at the annual general meeting of the company held on august 17, 2012 as prescribed under the clause 35a of the listing agreement.",21-Aug-2012 08:17:00,2012-08-21 08:17:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_CL35A_21082012.zip,21-08-2012,356.45001220703125,365.3999938964844,356.04998779296875,359.95001220703125,342.03009033203125,2452224,0.0,0.0,28-08-2012,0
662,CIPLA,Cipla Limited,updates," vide letter dated july 31, 2012 a copy of the note titled ""financial review - period ended june 2012"".",31-Jul-2012 20:21:00,2012-07-31 20:21:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla01_updts_31072012.zip,31-07-2012,336.0,342.3500061035156,335.1000061035156,338.6000061035156,319.84246826171875,2641073,0.0,0.0,07-08-2012,0
663,CIPLA,Cipla Limited,press release," regarding a press release dated july 31, 2012, titled ""cipla announces q1 fy 12 13 unaudited financial results"".",31-Jul-2012 17:13:00,2012-07-31 17:13:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_PR_31072012.zip,31-07-2012,336.0,342.3500061035156,335.1000061035156,338.6000061035156,319.84246826171875,2641073,0.0,0.0,07-08-2012,0
664,CIPLA,Cipla Limited,financial result updates," the standalone financial results along with the limited review report  for the period ended june 30, 2012.",31-Jul-2012 16:28:42,2012-07-31 16:28:42,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_30JUN2012_S_Q1.zip,31-07-2012,336.0,342.3500061035156,335.1000061035156,338.6000061035156,319.84246826171875,2641073,0.0,0.0,07-08-2012,0
665,CIPLA,Cipla Limited,financial result updates," the standalone and consolidated financial results for the period ended march 31,2012.",07-Jun-2012 16:58:47,2012-06-07 16:58:47,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31MAR2012_B_AN.zip,07-06-2012,311.75,312.25,307.0,308.0,290.93768310546875,579491,0.0,0.0,14-06-2012,0
666,CIPLA,Cipla Limited,updates," vide its letter dated may 10, 2012 a copy of the note regarding financial review - period ended march 2012.",11-May-2012 08:32:00,2012-05-11 08:32:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_updates_11052012.zip,11-05-2012,328.8999938964844,331.20001220703125,316.0,318.8999938964844,301.2338562011719,1542531,0.0,0.0,18-05-2012,0
667,CIPLA,Cipla Limited,press release," regarding a press release dated may 10, 2012, titled ""financial year 2011-12 - fourth quarter unaudited results - press release"".",10-May-2012 17:01:00,2012-05-10 17:01:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA01_PR_10052012.zip,10-05-2012,326.95001220703125,331.1499938964844,320.6000061035156,326.3999938964844,308.3183898925781,2621395,0.0,0.0,17-05-2012,0
668,CIPLA,Cipla Limited,financial result updates," the standalone financial results along with limited review report for the period ended march 31,2012.",10-May-2012 16:18:19,2012-05-10 16:18:19,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31MAR2012_S_Q4.zip,10-05-2012,326.95001220703125,331.1499938964844,320.6000061035156,326.3999938964844,308.3183898925781,2621395,0.0,0.0,17-05-2012,0
669,CIPLA,Cipla Limited,financial result updates," the standalone financial results along with limited review report for the period ended december 31,2011.",13-Feb-2012 16:36:59,2012-02-13 16:36:59,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31DEC2011_S_Q3.zip,13-02-2012,353.29998779296875,353.29998779296875,339.1000061035156,342.1000061035156,323.14862060546875,1501856,0.0,0.0,21-02-2012,-1
670,CIPLA,Cipla Limited,updates," a copy of the note titled ""financial review - period ended september 2011"".",14-Nov-2011 16:42:00,2011-11-14 16:42:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_updts_14112011.zip,14-11-2011,289.45001220703125,291.0,285.5,288.1000061035156,272.14013671875,973134,0.0,0.0,21-11-2011,1
671,CIPLA,Cipla Limited,outcome of annual general meeting," regarding the outcome of the annual general meeting of the members of the company held on august 25, 2011.",26-Aug-2011 16:29:00,2011-08-26 16:29:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA01_agmproceeding_26082011.zip,26-08-2011,281.0,283.79998779296875,274.29998779296875,277.20001220703125,261.84393310546875,815774,0.0,0.0,06-09-2011,0
672,CIPLA,Cipla Limited,updates,"cipla limited has submitted the exchange a copy of abstract of audited financial results of the company for the year ended march 31, 2011 as required under clause 20 of the listing agreement.",29-Jun-2011 19:11:00,2011-06-29 19:11:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_UPDATES_29062011.zip,29-06-2011,330.79998779296875,334.5,329.3500061035156,332.20001220703125,311.7340087890625,1522486,0.0,0.0,06-07-2011,0
673,CIPLA,Cipla Limited,financial result updates," the standalone and consolidated financial results for the period ended march 31,2011.",29-Jun-2011 17:15:17,2011-06-29 17:15:17,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_31MAR2011_B_AN.zip,29-06-2011,330.79998779296875,334.5,329.3500061035156,332.20001220703125,311.7340087890625,1522486,0.0,0.0,06-07-2011,0
674,CIPLA,Cipla Limited,updates," a copy of the note titled ""financial review - period ended march 2011"".",06-May-2011 09:35:00,2011-05-06 09:35:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_Finreview_06052011.zip,06-05-2011,299.0,311.75,295.5,305.54998779296875,286.7257995605469,1998125,0.0,0.0,13-05-2011,0
675,CIPLA,Cipla Limited,demise," regarding the sad demise of mr. amar lulla, non-executive director of the company on april 22, 2011.",25-Apr-2011 12:28:00,2011-04-25 12:28:00,-,-,https://nsearchives.nseindia.com/corporate/CIPLA_DEM_25042011.zip,25-04-2011,320.0,323.95001220703125,318.75,319.75,300.0509338378906,494776,0.0,0.0,02-05-2011,0
676,CIPLA,Cipla Limited,updates," a copy of the note titled ""financial review - period ended december 2010"".",04-Feb-2011 16:37:00,2011-02-04 16:37:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_updates_04022011.zip,04-02-2011,329.3999938964844,329.3999938964844,322.0,324.29998779296875,304.3206481933594,2033304,0.0,0.0,11-02-2011,0
677,CIPLA,Cipla Limited,updates," a copy of abstract under section 302 of the companies act, 1956 relating to the appointment of mr.s.radhakrishnan as whole-time director of the company for the period of five years with effect from november 12, 2010 subject to the approval of the shareholders of the company.",02-Dec-2010 16:09:00,2010-12-02 16:09:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_Updates_02122010.zip,02-12-2010,369.5,370.7999877929688,358.25,364.9500122070313,342.46636962890625,3062176,0.0,0.0,09-12-2010,0
678,CIPLA,Cipla Limited,acquisition," that the board of director of the company at its meeting held on august 25, 2010, inter alia, has approved the acquisition of meditab specialties pvt. ltd. (""meditab"") for an aggregate consideration of rs.133.35 crores.",25-Aug-2010 15:08:00,2010-08-25 15:08:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_outcome_25082010.zip,25-08-2010,317.0,319.8999938964844,305.0,308.79998779296875,289.0163879394531,3021132,0.0,0.0,01-09-2010,0
679,CIPLA,Cipla Limited,updates," a copy of the financial performance - period ended june 30, 2010.",13-Aug-2010 16:21:00,2010-08-13 16:21:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_updates_13082010.zip,13-08-2010,314.8999938964844,318.6000061035156,313.3500061035156,314.8500061035156,294.6788024902344,926238,0.0,0.0,20-08-2010,0
680,CIPLA,Cipla Limited,updates," a copy of an abstract of audited financial results of the company for the year ended march 31, 2010 as required under clause 20 of the listing agreement.",15-Jun-2010 16:55:00,2010-06-15 16:55:00,-,-,https://nsearchives.nseindia.com/corporate/cipla_clause20_15062010.zip,15-06-2010,340.04998779296875,341.0,332.70001220703125,338.0,314.4169311523437,718333,0.0,0.0,22-06-2010,0
681,CIPLA,Cipla Limited,updates, a copy of financial performance for the period ended march 2010.,07-May-2010 16:19:00,2010-05-07 16:19:00,-,-,https://nsearchives.nseindia.com/corporate/Cipla_UP_07052010.zip,07-05-2010,343.0,353.8500061035156,339.8500061035156,342.04998779296875,318.18438720703125,2889590,0.0,0.0,14-05-2010,-1
